[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 2035
1. Thieblemont C, Gisselbrecht C: Second-line treatment paradigms for diffuse large B-cell lymphomas. Curr Oncol Rep; 2009 Sep;11(5):386-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Second-line treatment paradigms for diffuse large B-cell lymphomas.
  • Despite recent major advances in treating diffuse large B-cell lymphoma with dose-intense regimens and the addition of the anti-CD20 monoclonal antibody rituximab, a significant proportion of patients will experience early treatment failure, partial response, or relapse after initial chemotherapy.
  • For more than 10 years, the standard treatment for chemosensitive relapses has been based on salvage chemotherapy followed by high-dose therapy and autologous stem cell transplantation in selected patients.
  • What is the efficacy of rituximab in an era when R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) is accepted as standard care for frontline therapy?
  • What are the risk factors in second-line therapy?
  • What is the best treatment when high-dose therapy and autologous stem cell transplantation are not possible?
  • This article reviews all these issues and discusses new biologic therapies, with the knowledge that improvements in outcome may be achieved through a greater understanding of the biologic parameters associated with poorer prognosis.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Lymphoma, Large B-Cell, Diffuse / drug therapy. Salvage Therapy / methods
  • [MeSH-minor] Antibodies, Monoclonal, Murine-Derived. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols. Cyclophosphamide. Doxorubicin. Humans. Prednisone. Rituximab. Survival Analysis. Vincristine

  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Haematologica. 2008 Dec;93(12):1829-36 [18945747.001]
  • [Cites] Blood. 1998 Nov 15;92(10):3562-8 [9808548.001]
  • [Cites] J Clin Oncol. 2007 May 1;25(13):1741-6 [17389337.001]
  • [Cites] J Clin Oncol. 2005 Jun 20;23(18):4117-26 [15867204.001]
  • [Cites] Blood. 2004 Aug 1;104(3):634-41 [15016643.001]
  • [Cites] Eur J Haematol. 2008 Feb;80(2):127-32 [18005385.001]
  • [Cites] Cancer Biother Radiopharm. 2007 Feb;22(1):113-20 [17627419.001]
  • [Cites] Nat Rev Cancer. 2005 Apr;5(4):275-84 [15803154.001]
  • [Cites] Leuk Lymphoma. 2006 Dec;47(12):2558-66 [17169800.001]
  • [Cites] N Engl J Med. 1995 Dec 7;333(23):1540-5 [7477169.001]
  • [Cites] Ann Oncol. 2007 Aug;18(8):1363-8 [17496309.001]
  • [Cites] J Clin Oncol. 2008 Jan 1;26(1):90-5 [18025438.001]
  • [Cites] Ann Oncol. 2006 May;17 Suppl 4:iv18-24 [16702180.001]
  • [Cites] Ann Oncol. 2006 May;17 Suppl 4:iv31-2 [16702182.001]
  • [Cites] J Clin Oncol. 1998 Oct;16(10):3264-9 [9779700.001]
  • [Cites] Leuk Lymphoma. 2005 Jan;46(1):71-5 [15621783.001]
  • [Cites] J Clin Oncol. 2006 Aug 20;24(24):3880-6 [16864854.001]
  • [Cites] Bone Marrow Transplant. 2007 Dec;40(11):1007-17 [17922042.001]
  • [Cites] J Clin Oncol. 1992 Oct;10(10):1615-23 [1383435.001]
  • [Cites] Blood. 2004 May 15;103(10):3684-8 [14739217.001]
  • [Cites] Leuk Lymphoma. 2007 Apr;48(4):708-15 [17454628.001]
  • [Cites] Ann Hematol. 2007 Apr;86(4):271-6 [17216473.001]
  • [Cites] Cancer Sci. 2006 Sep;97(9):933-7 [16805825.001]
  • [Cites] Blood. 2008 Jan 15;111(2):537-43 [17971487.001]
  • [Cites] Am J Hematol. 2009 Feb;84(2):93-7 [19123458.001]
  • [Cites] Haematologica. 2006 Jan;91(1):114-20 [16434379.001]
  • [Cites] Blood. 2004 Feb 1;103(3):777-83 [12907446.001]
  • [Cites] Oncology. 2005;69(6):499-502 [16424679.001]
  • [Cites] Exp Hematol. 2007 Apr;35(4):534-40 [17379063.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):235-42 [11807147.001]
  • [Cites] Oncol Rep. 2003 Nov-Dec;10(6):1915-7 [14534718.001]
  • [Cites] J Med Chem. 2008 Nov 13;51(21):6902-15 [18841882.001]
  • [Cites] Blood. 2008 Feb 15;111(4):2230-7 [18006696.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2240-7 [15800314.001]
  • [Cites] Cancer Chemother Pharmacol. 2009 Oct;64(5):907-16 [19219604.001]
  • [Cites] Br J Haematol. 2001 Dec;115(4):786-92 [11843810.001]
  • (PMID = 19679014.001).
  • [ISSN] 1534-6269
  • [Journal-full-title] Current oncology reports
  • [ISO-abbreviation] Curr Oncol Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  • [Number-of-references] 49
  •  go-up   go-down


2. Yamashita T, Sakaura H, Oshima K, Iwasaki M, Yoshikawa H: Solitary intradural extramedullary lymphoma of the cervical spine. J Neurosurg Spine; 2010 Apr;12(4):436-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary intradural extramedullary lymphoma of the cervical spine.
  • The authors report on the case of a 64-year-old man with solitary intradural extramedullary non-Hodgkin lymphoma of the cervical spine.
  • Positron emission tomography showed increased accumulation of fluorine-18-labeled fluorodeoxyglucose only in the cervical lesion.
  • Serum levels of C-reactive protein and soluble interleukin-2 receptor were mildly elevated.
  • Based on histopathological findings, diffuse, large B-cell type non-Hodgkin lymphoma was diagnosed.
  • Postoperatively, the patient was treated with 2 courses of chemotherapy by intrathecal injection of methotrexate, cytarabine, and prednisolone and 4 courses of intravenous rituximab, an antibody binding to CD20 on the surface of B cells.
  • To the best of the authors' knowledge, this case is the first reported instance of solitary intradural extramedullary non-Hodgkin lymphoma of the cervical spine.
  • [MeSH-major] Cervical Vertebrae. Lymphoma, B-Cell / diagnosis. Lymphoma, B-Cell / surgery. Spinal Neoplasms / diagnosis. Spinal Neoplasms / surgery
  • [MeSH-minor] Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents / administration & dosage. Antineoplastic Agents, Hormonal / administration & dosage. Chemotherapy, Adjuvant. Cytarabine / administration & dosage. Fluorodeoxyglucose F18. Humans. Injections, Intravenous. Injections, Spinal. Magnetic Resonance Imaging. Male. Methotrexate / administration & dosage. Middle Aged. Positron-Emission Tomography. Prednisolone / administration & dosage. Radiopharmaceuticals. Rituximab. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Neck Injuries and Disorders.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20367381.001).
  • [ISSN] 1547-5646
  • [Journal-full-title] Journal of neurosurgery. Spine
  • [ISO-abbreviation] J Neurosurg Spine
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Hormonal; 0 / Radiopharmaceuticals; 04079A1RDZ / Cytarabine; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 4F4X42SYQ6 / Rituximab; 9PHQ9Y1OLM / Prednisolone; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


3. Tokura Y, Sugita K, Yagi H, Shimauchi T, Kabashima K, Takigawa M: Primary cutaneous anaplastic large cell lymphoma with fatal leukemic outcome in association with CLA and CCR4-negative conversion. J Am Acad Dermatol; 2007 Nov;57(5 Suppl):S92-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cutaneous anaplastic large cell lymphoma with fatal leukemic outcome in association with CLA and CCR4-negative conversion.
  • A 70-year-old Japanese male presented with a 1-year history of skin tumors, which were diagnosed as primary cutaneous anaplastic large cell lymphoma (ALCL) because of the CD3(low+), CD4(+), CD25(+), CD30(+), CD45RO(+), CD71(+), HLA-DR(+), CD8(-), CD56(-), and NPM/ALK(-) phenotype and monoclonal T-cell receptor-rearranged property of tumor cells as well as the absence of systemic involvement.
  • At this time, the tumor cell was positive for cutaneous lymphocyte-associated antigen (CLA) and TH(2) chemokine receptor CCR4.
  • The eruption had repeatedly appeared and spontaneously regressed or regressed by virtue of several therapeutic modalities, including radiotherapy, interferon-alpha and chemotherapy, until the tumor cell invaded the gastric mucosa and spread to the peripheral blood 5 years later.
  • The altered expression of skin-homing receptors might change its clinical behavior.
  • [MeSH-major] Antigens, Neoplasm / metabolism. Leukemia / etiology. Lymphoma, Large B-Cell, Diffuse / complications. Lymphoma, Large B-Cell, Diffuse / metabolism. Membrane Glycoproteins / metabolism. Receptors, Chemokine / metabolism

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17938033.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Differentiation, T-Lymphocyte; 0 / Antigens, Neoplasm; 0 / CCR4 protein, human; 0 / CTAGE1 protein, human; 0 / Membrane Glycoproteins; 0 / Receptors, CCR4; 0 / Receptors, Chemokine
  •  go-up   go-down


Advertisement
4. Imtiaz S, Muzaffar N: Ifosfamide neurotoxicty in a young female with a remarkable response to thiamine. J Pak Med Assoc; 2010 Oct;60(10):867-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ifosfamide neurotoxicty in a young female with a remarkable response to thiamine.
  • Ifosfamide induced encephalopathy develops in approximately 10-30% of patients exposed to the drug.
  • It is generally reversible after discontinuing the therapy; however cases of fatal neurotoxicity have been reported in literature.
  • We submit a case report of a young female patient with refractory diffuse large B cell lymphoma who developed severe ifosfamide neurotoxicity.
  • With the use of intravenous thiamine, encephalopathy resolved in our patient within a mean time of 30 hours (average range is 10-30 hours).
  • We found Thiamine to be safe and effective in treatment for ifosfamide induced encephalopathy.
  • [MeSH-major] Antineoplastic Agents, Alkylating / adverse effects. Ifosfamide / adverse effects. Lymphoma, Large B-Cell, Diffuse / drug therapy. Neurotoxicity Syndromes / drug therapy. Thiamine / therapeutic use. Vitamin B Complex / therapeutic use
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Central Nervous System / drug effects. Female. Humans. Treatment Outcome

  • MedlinePlus Health Information. consumer health - B Vitamins.
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. Vitamin B1 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21381624.001).
  • [ISSN] 0030-9982
  • [Journal-full-title] JPMA. The Journal of the Pakistan Medical Association
  • [ISO-abbreviation] J Pak Med Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Pakistan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 12001-76-2 / Vitamin B Complex; UM20QQM95Y / Ifosfamide; X66NSO3N35 / Thiamine
  •  go-up   go-down


5. Moskowitz CH, Zelenetz A, Schoder H: An update on the role of interim restaging FDG-PET in patients with diffuse large B-cell lymphoma and Hodgkin lymphoma. J Natl Compr Canc Netw; 2010 Mar;8(3):347-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An update on the role of interim restaging FDG-PET in patients with diffuse large B-cell lymphoma and Hodgkin lymphoma.
  • A significant amount of literature is available on treatment monitoring and response assessment in lymphoma using FDG-PET, yet confusion exists concerning the potential and limitations of FDG-PET for determining the presence of residual disease during chemotherapy (interim FDG-PET).
  • This article reviews the role of interim FDG-PET in 3 important scenarios: untreated diffuse large B-cell lymphoma, untreated Hodgkin lymphoma, and relapsed or refractory aggressive lymphoma in transplant-eligible patients, and provides recommendations on the use of this imaging modality in these settings.
  • [MeSH-major] Fluorodeoxyglucose F18. Hodgkin Disease / radionuclide imaging. Lymphoma, Large B-Cell, Diffuse / radionuclide imaging. Positron-Emission Tomography. Radiopharmaceuticals
  • [MeSH-minor] Humans. Neoplasm Staging. Prognosis. Treatment Outcome

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20202464.001).
  • [ISSN] 1540-1405
  • [Journal-full-title] Journal of the National Comprehensive Cancer Network : JNCCN
  • [ISO-abbreviation] J Natl Compr Canc Netw
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Number-of-references] 34
  •  go-up   go-down


6. Komoto D, Nishiyama Y, Yamamoto Y, Monden T, Sasakawa Y, Toyama Y, Satoh K, Ohno M, Kanenishi K, Ohkawa M: A case of non-hodgkin's lymphoma of the ovary: usefulness of 18F-FDG PET for staging and assessment of the therapeutic response. Ann Nucl Med; 2006 Feb;20(2):157-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of non-hodgkin's lymphoma of the ovary: usefulness of 18F-FDG PET for staging and assessment of the therapeutic response.
  • Primary ovarian lymphoma as the initial manifestation is rare.
  • Histological findings revealed diffuse large B-cell lymphoma.
  • The clinical stage was IV according to the Ann Arbor system.
  • International prognostic index (IPI) was 3 (high-intermediate risk).
  • Chemotherapy was administered consisting of three courses of an R-CHOP regimen, and 18F-FDG PET and CT scan revealed no signs of involvement 3 months after initiation of the chemotherapy.
  • 18F-FDG PET was a useful method for staging and assessment of the therapeutic response in primary ovarian lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Fluorodeoxyglucose F18. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / radionuclide imaging. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / radionuclide imaging. Positron-Emission Tomography / methods
  • [MeSH-minor] Adult. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Doxorubicin / analogs & derivatives. Female. Humans. Neoplasm Staging / methods. Prednisone / administration & dosage. Prognosis. Radiopharmaceuticals. Treatment Outcome. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16615426.001).
  • [ISSN] 0914-7187
  • [Journal-full-title] Annals of nuclear medicine
  • [ISO-abbreviation] Ann Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol, modified
  •  go-up   go-down


7. Dupuis J, Haioun C: [Non-Hodgkin lymphoma in the elderly]. Bull Cancer; 2008 May 28;95 FMC Onco:F79-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Non-Hodgkin lymphoma in the elderly].
  • [Transliterated title] Lymphomes non hodgkiniens du sujet âgé: lymphome à grandes cellules B et lymphome folliculaire.
  • Non-Hodgkin's lymphomas form a heterogeneous group of tumors whose incidence is rising in elderly subjects.
  • While most cases are accessible to treatment with chemotherapy, elderly patients tolerate treatments less well than younger ones.
  • Nevertheless, treatment efficacy does not seem different.
  • Two approaches can thus be proposed: the first is to give the patient a conventional treatment with a higher risk of toxicity, the second one would be to propose a "lighter", dose-adapted treatment.
  • Two examples are examined more closely: diffuse large B-cell lymphomas and follicular lymphomas.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Age Factors. Aged. Aged, 80 and over. Humans. Life Expectancy. Lymphoma, Follicular / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Prognosis

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18511372.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


8. Murase T, Yamaguchi M, Suzuki R, Okamoto M, Sato Y, Tamaru J, Kojima M, Miura I, Mori N, Yoshino T, Nakamura S: Intravascular large B-cell lymphoma (IVLBCL): a clinicopathologic study of 96 cases with special reference to the immunophenotypic heterogeneity of CD5. Blood; 2007 Jan 15;109(2):478-85
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intravascular large B-cell lymphoma (IVLBCL): a clinicopathologic study of 96 cases with special reference to the immunophenotypic heterogeneity of CD5.
  • Intravascular large B-cell lymphoma (IVLBCL) is pathologically distinct with a broad clinical spectrum and immunophenotypic heterogeneity.
  • The International Prognostic Index score was high or high-intermediate in 92%.
  • All 59 CD10- IVLBCL cases examined were nongerminal center B-cell type because they lacked the Bcl-6+MUM1- immunophenotype.
  • CD5 positivity was associated with a higher prevalence of marrow/blood involvement and thrombocytopenia and a lower frequency of neurologic abnormalities among patients with CD10-IVLBCL.
  • Compared with 97 cases of de novo CD5+CD10-diffuse LBCL, 31 cases of CD5+CD10-IVLBCL exhibited higher frequencies of poor prognostic parameters, except age.
  • [MeSH-major] Antigens, CD5 / analysis. Lymphoma, B-Cell / diagnosis. Lymphoma, B-Cell / immunology. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / immunology. Vascular Neoplasms / diagnosis. Vascular Neoplasms / immunology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Humans. Immunophenotyping. Male. Middle Aged. Multivariate Analysis. Predictive Value of Tests. Prognosis. Retrospective Studies. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16985183.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD5
  •  go-up   go-down


9. Sirohi B, Cunningham D, Norman A, Last K, Chau I, Horwich A, Oates J, Chong G, Wotherspoon A: Gemcitabine, cisplatin and methylprednisolone (GEM-P) with or without Rituximab in relapsed and refractory patients with diffuse large B cell lymphoma (DLBCL). Hematology; 2007 Apr;12(2):149-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gemcitabine, cisplatin and methylprednisolone (GEM-P) with or without Rituximab in relapsed and refractory patients with diffuse large B cell lymphoma (DLBCL).
  • This is the first report of the combination of gemcitabine, cisplatin and methylprednisolone (GEM-P) with Rituximab (GEM-PR) for diffuse large B-cell lymphoma (DLBCL).
  • Thirty-nine patients with relapsed or refractory DLBCL in this study received GEM-P with (n = 24) or without Rituximab (n = 15) 64% patients had Stage III/IV disease.
  • Patients received a median of two cycles (1-4) of treatment.
  • GEM-P is an effective second-line regimen in patients with relapsed or refractory DLBCL and the addition of Rituximab appears to further improve outcomes.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Immunotherapy. Lymphoma, Large B-Cell, Diffuse / therapy. Salvage Therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Antibodies, Monoclonal, Murine-Derived. Cisplatin / administration & dosage. Cisplatin / adverse effects. Combined Modality Therapy. Deoxycytidine / administration & dosage. Deoxycytidine / adverse effects. Deoxycytidine / analogs & derivatives. Disease-Free Survival. Drug Evaluation. Female. Humans. Kaplan-Meier Estimate. Male. Methylprednisolone / administration & dosage. Methylprednisolone / adverse effects. Middle Aged. Peripheral Blood Stem Cell Transplantation. Radiotherapy, Adjuvant. Remission Induction. Retrospective Studies. Rituximab. Survival Analysis. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. METHYLPREDNISOLONE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17454196.001).
  • [ISSN] 1607-8454
  • [Journal-full-title] Hematology (Amsterdam, Netherlands)
  • [ISO-abbreviation] Hematology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0W860991D6 / Deoxycytidine; 4F4X42SYQ6 / Rituximab; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin; X4W7ZR7023 / Methylprednisolone
  •  go-up   go-down


10. Zamkoff KW, Matulis MD, Mehta AC, Beaty MW, Hutchison RE, Gentile TC: High-dose therapy and autologous stem cell transplant does not result in long-term disease-free survival in patients with recurrent chemotherapy-sensitive ALK-negative anaplastic large-cell lymphoma. Bone Marrow Transplant; 2004 Mar;33(6):635-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose therapy and autologous stem cell transplant does not result in long-term disease-free survival in patients with recurrent chemotherapy-sensitive ALK-negative anaplastic large-cell lymphoma.
  • Primary systemic anaplastic lymphoma kinase (ALK)-negative anaplastic large-cell lymphoma (ALCL) has a poor prognosis.
  • This study sought to determine if high-dose therapy and ASCT results in long-term disease-free survival (DFS) in patients with recurrent, chemotherapy-sensitive ALK-negative ALCL.
  • All patients with non-Hodgkin's lymphoma (NHL) who underwent ASCT at Wake Forest University and Upstate Medical University from 1 January 1990 to 12 December 2002 were reviewed to determine if they had T-, B- or null-cell NHL that was CD30+/CD15-/ALK negative.
  • All 16 patients underwent ASCT at the time of first relapse and form the basis of this report.
  • International prognostic index scores in 12 patients at the time of relapse were: low 3, LI 6 and HI 3.
  • Of 15 patients, 10 have died; nine of recurrent disease.
  • In our experience, high-dose therapy and ASCT does not produce long-term DFS in patients with recurrent chemotherapy-sensitive ALK-negative ALCL.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / therapy. Protein-Tyrosine Kinases / analysis. Receptor Protein-Tyrosine Kinases / analysis. Stem Cell Transplantation / methods
  • [MeSH-minor] Disease-Free Survival. Female. Humans. Male. Recurrence. Survival Analysis. Transplantation, Autologous

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15004538.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  •  go-up   go-down


11. Visco C, Medeiros LJ, Jones D, Smith T, Rodriguez MA, McLaughlin P, Romaguera J, Cabanillas F, Sarris AH: Primary cutaneous non-Hodgkin's lymphoma with aggressive histology: inferior outcome is associated with peripheral T-cell type and elevated lactate dehydrogenase, but not extent of cutaneous involvement. Ann Oncol; 2002 Aug;13(8):1290-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cutaneous non-Hodgkin's lymphoma with aggressive histology: inferior outcome is associated with peripheral T-cell type and elevated lactate dehydrogenase, but not extent of cutaneous involvement.
  • BACKGROUND: The aim of this study was to explore the association between extent of cutaneous involvement, presenting features and progression-free survival (PFS) in patients with primary cutaneous non-Hodgkin's lymphoma (PCNHL) of aggressive histology.
  • METHODS: Previously untreated patients with localized or extensive PCNHL of aggressive histology, treated with combination chemotherapy, but excluding lymphoblastic lymphoma and mycosis fungoides and its variants, were reviewed retrospectively.
  • Median age was 52 years (range 25-81 years), and disease was localized and extensive in 37 and 16 patients, respectively.
  • Twenty-four patients had diffuse large B-cell lymphoma, nine had grade 3 follicular lymphoma, 13 had peripheral T-cell lymphoma (PTCL; not otherwise specified) and seven had anaplastic large cell lymphoma (WHO classification).
  • With a median follow-up of 101 months (range 2-237 months) for survivors, the 10-year PFS was 65 +/- 7% and overall survival was 72 +/- 8%.
  • The first failure involved the skin in 33% of B-cell and 91% of relapsing T-cell lymphomas.
  • CONCLUSIONS: PTCL and elevated serum LDH level, but not extent of cutaneous involvement are associated with inferior PFS in aggressive PCNHL treated with combination chemotherapy.

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12181254.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA-16672
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


12. Capra M, Wherrett D, Weitzman S, Dirks P, Hawkins C, Bouffet E: Pituitary stalk thickening and primary central nervous system lymphoma. J Neurooncol; 2004 Mar-Apr;67(1-2):227-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pituitary stalk thickening and primary central nervous system lymphoma.
  • We report a 14-year-old girl in whom a diagnosis of primary central nervous system lymphoma was confirmed while receiving growth hormone (GH) for GH deficiency, detected after presenting with short stature.
  • Regular MRI surveillance detected progression of the neurohypophyseal changes 13 months into GH treatment.
  • Biopsy confirmed this to be B-cell large cell lymphoma.
  • [MeSH-major] Central Nervous System Neoplasms / pathology. Growth Hormone / adverse effects. Lymphoma, B-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Pituitary Gland / pathology
  • [MeSH-minor] Child. Female. Growth Disorders / drug therapy. Humans. Magnetic Resonance Imaging

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Endocrinol Metab. 1999 Jun;84(6):1961-5 [10372694.001]
  • [Cites] J Clin Endocrinol Metab. 1997 May;82(5):1362-7 [9141516.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Jun;84(6):1954-60 [10372693.001]
  • [Cites] J Pediatr. 1997 Jul;131(1 Pt 2):S32-6 [9255225.001]
  • [Cites] Brain Tumor Pathol. 1999;16(1):29-35 [10532421.001]
  • [Cites] Med J Aust. 1992 Jul 6;157(1):27-8 [1640886.001]
  • [Cites] Hum Pathol. 2002 Oct;33(10):1044-7 [12395379.001]
  • [Cites] JAMA. 1993 Dec 15;270(23):2829-32 [8133622.001]
  • [Cites] J Pediatr Endocrinol. 1993 Jan-Mar;6(1):99-108 [8374697.001]
  • [Cites] Nature. 1987 Dec 10-16;330(6148):537-43 [2825030.001]
  • [Cites] Neurol India. 2001 Sep;49(3):314-6 [11593255.001]
  • [Cites] Clin Radiol. 1994 Oct;49(10 ):696-702 [7955832.001]
  • [Cites] Nutrition. 1995 Sep-Oct;11(5 Suppl):627-31 [8748238.001]
  • [Cites] J Clin Endocrinol Metab. 1993 Jan;76(1):49-53 [8421102.001]
  • [Cites] J Neurooncol. 2002 Aug;59(1):35-8 [12222836.001]
  • [Cites] J Pediatr Hematol Oncol. 2001 Feb;23(2):130-3 [11216706.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Jul;87(7):3136-41 [12107213.001]
  • [Cites] Med Pediatr Oncol. 2001 Mar;36(3):392-5 [11241445.001]
  • [Cites] Endocrinology. 1993 Feb;132(2):620-8 [7678796.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Mar;81(3):1278-82 [8772612.001]
  • [Cites] Cell Mol Life Sci. 1998 Oct;54(10):1057-8 [9817983.001]
  • (PMID = 15072472.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 9002-72-6 / Growth Hormone
  •  go-up   go-down


13. Bartlett NL, Johnson JL, Wagner-Johnston N, Ratain MJ, Peterson BA, Cancer and Leukemia Group B: Phase II study of 9-aminocamptothecin in previously treated lymphomas: results of Cancer and Leukemia Group B 9551. Cancer Chemother Pharmacol; 2009 Apr;63(5):793-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of 9-aminocamptothecin in previously treated lymphomas: results of Cancer and Leukemia Group B 9551.
  • PURPOSE: To evaluate the efficacy and toxicity of the topoisomerase I inhibitor, 9-aminocamptothecin (9-AC), in patients with relapsed lymphoma and to correlate 9-AC plasma concentrations with response and toxicity.
  • METHODS: Eligible patients had relapsed Hodgkin lymphoma (HL) treated with one or two prior regimens, low grade non-Hodgkin's lymphoma (NHL) treated with one or two prior regimens, or aggressive NHL treated with one prior regimen.
  • Responding patients received two cycles past best response with a minimum of six cycles.
  • RESULTS: CALGB 9551 accrued 37 patients from April 1996 through October 2000; one patient with HD, 18 patients with indolent lymphoma, and 17 patients with aggressive lymphoma.
  • Response rates were similar for both drug formulations.
  • No treatment related deaths occurred.
  • CONCLUSION: Single agent 9-AC has modest activity in aggressive non-Hodgkin's lymphomas.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Camptothecin / analogs & derivatives. Hodgkin Disease / drug therapy. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Lymphoma, Follicular / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy
  • [MeSH-minor] Adult. Aged. Drug Resistance, Neoplasm. Female. Humans. Male. Maximum Tolerated Dose. Middle Aged. Neoplasm Recurrence, Local / blood. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / drug therapy. Prognosis. Salvage Therapy. Survival Rate

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18648813.001).
  • [ISSN] 1432-0843
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA31946; United States / NCI NIH HHS / CA / CA33601
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 5MB77ICE2Q / 9-aminocamptothecin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


14. Horváth B, Demeter J, Eros N, Hársing J, Csomor J, Matolcsy A, Bottlik G, Gyori G, Marschalkó M, Kárpáti S: Intravascular large B-cell lymphoma: remission after rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisolone chemotherapy. J Am Acad Dermatol; 2009 Nov;61(5):885-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intravascular large B-cell lymphoma: remission after rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisolone chemotherapy.
  • Intravascular lymphoma is an uncommon, very aggressive extranodal non-Hodgkin lymphoma that most frequently involves the skin and central nervous system.
  • Most cases are of B-cell origin; T-cell phenotype is extremely rare.
  • Malignant cells proliferate within the lumens of capillaries, arterioles, venules, and small arteries; vascular occlusion is responsible for the clinical signs and symptoms.
  • The prognosis of this high-grade B-cell lymphoma has improved since the introduction of the anti-CD20 monoclonal antibody, rituximab.
  • We describe a case of B-cell intravascular lymphoma successfully treated with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisolone.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Large B-Cell, Diffuse / drug therapy. Skin / blood supply. Vascular Neoplasms / drug therapy
  • [MeSH-minor] Antibiotics, Antineoplastic / therapeutic use. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Agents / therapeutic use. Antineoplastic Agents, Alkylating / therapeutic use. Antineoplastic Agents, Hormonal / therapeutic use. Antineoplastic Agents, Phytogenic / therapeutic use. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Female. Humans. Middle Aged. Prednisolone / therapeutic use. Remission Induction. Rituximab. Subcutaneous Fat / blood supply. Vincristine / therapeutic use

  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19632742.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Alkylating; 0 / Antineoplastic Agents, Hormonal; 0 / Antineoplastic Agents, Phytogenic; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone
  •  go-up   go-down


15. Grosskreutz C, Troy K, Cuttner J: Primary splenic lymphoma: report of 10 cases using the REAL classification. Cancer Invest; 2002;20(5-6):749-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary splenic lymphoma: report of 10 cases using the REAL classification.
  • Primary splenic lymphoma (PSL) is rare with a reported incidence of less than 1%.
  • Diffuse large cell pathology has been reported in 22-33% of the cases and is felt to have a poor outcome.
  • Our objective was to evaluate staging (using the Ahmann and Kehoe criteria), prognosis using the International Prognostic Index (IPI), and pathology using the Revised European-American Lymphoma Classification (REAL) classification.
  • Eight of the 10 patients had diffuse large cell lymphoma (DLCL).
  • Lymph node involvement beyond the splenic hilum seen by imaging studies represents an advanced non-Hodgkin's lymphoma and should be included no longer in the staging of PSL.
  • Eight of the nine patients received chemotherapy following splenectomy.
  • Splenectomy followed by combination chemotherapy, results in excellent long-term survival in PSL.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / pathology. Splenic Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Female. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Risk Factors. Splenectomy. Survival Analysis

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12197231.001).
  • [ISSN] 0735-7907
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


16. Navarro JT, Lloveras N, Ribera JM, Oriol A, Mate JL, Feliu E: The prognosis of HIV-infected patients with diffuse large B-cell lymphoma treated with chemotherapy and highly active antiretroviral therapy is similar to that of HIV-negative patients receiving chemotherapy. Haematologica; 2005 May;90(5):704-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The prognosis of HIV-infected patients with diffuse large B-cell lymphoma treated with chemotherapy and highly active antiretroviral therapy is similar to that of HIV-negative patients receiving chemotherapy.
  • In the era of highly active antiretroviral treatment (HAART), the prognosis of AIDS-related lymphomas might be similar to that of aggressive B-cell lymphomas in human immunodeficiency (HIV)-negative patients.
  • In this study we found that HIV-infected patients with diffuse large B-cell lymphoma treated with cyclophosphamide, hydroxydoxorubicin, vincristine and prednisone (CHOP) and HAART showed a similar response rate to chemotherapy, disease-free survival and overall survival as those of HIV-negative patients receiving CHOP.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiretroviral Therapy, Highly Active. HIV Infections / mortality. Lymphoma, AIDS-Related / mortality. Lymphoma, Large B-Cell, Diffuse / mortality
  • [MeSH-minor] Adult. Cyclophosphamide / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Granulocyte Colony-Stimulating Factor / therapeutic use. HIV Seronegativity. Humans. Male. Prednisone / administration & dosage. Prognosis. Vincristine / administration & dosage


17. Guppy AE, Tebbutt NC, Norman A, Cunningham D: The role of surveillance CT scans in patients with diffuse large B-cell non-Hodgkin's lymphoma. Leuk Lymphoma; 2003 Jan;44(1):123-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of surveillance CT scans in patients with diffuse large B-cell non-Hodgkin's lymphoma.
  • The use of routine surveillance computed tomography (CT) scans in the follow-up of patients with diffuse large B-cell lymphoma may allow the detection of early asymptomatic relapse.
  • This study evaluated the effectiveness of routine surveillance CT scans performed 3 and 12 months after completion of chemotherapy in patients with diffuse large B-cell lymphoma who had achieved a complete response.
  • One hundred and seventeen patients with diffuse large B-cell lymphoma achieved complete remission at the Royal Marsden Hospital using first line combination chemotherapy between January 1992 and January 2000.
  • [MeSH-major] Lymphoma, B-Cell / radiography. Lymphoma, Large B-Cell, Diffuse / radiography. Tomography, X-Ray Computed
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Recurrence. Remission Induction. Survival Analysis

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12691151.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  •  go-up   go-down


18. Schlaberg R, Fisher JG, Flamm MJ, Murty VV, Bhagat G, Alobeid B: Chronic myeloid leukemia and HIV-infection. Leuk Lymphoma; 2008 Jun;49(6):1155-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The incidence of non-HIV-associated hematologic malignancies, including chronic myeloproliferative disorders, is increasing in HIV-infected (HIV+) patients.
  • This is thought to be due to prolonged survival in the era of highly active antiretroviral therapy (HAART).
  • Treatment was generally well tolerated, and cytogenetic response (complete in two patients) was achieved with follow-up ranging from 3 to 69 months.
  • HIV viral load remained undetectable and CD4 cell counts were stable in all three patients.
  • Concurrent treatment with imatinib and HAART can result in appropriate control of CML and HIV-infection as well as long-term survival.
  • [MeSH-major] HIV Infections / complications. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / complications. Lymphoma, Large B-Cell, Diffuse / complications
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Antiretroviral Therapy, Highly Active. Benzamides. CD4 Lymphocyte Count. Flow Cytometry. Follow-Up Studies. HIV-1 / drug effects. HIV-1 / isolation & purification. Humans. Imatinib Mesylate. Immunoenzyme Techniques. Male. Middle Aged. Piperazines / therapeutic use. Protein-Tyrosine Kinases / antagonists & inhibitors. Pyrimidines / therapeutic use. Remission Induction. Treatment Outcome. Viral Load


19. Eom DW, Huh JR, Kang YK, Lee YS, Yu E: Clinicopathological features of eight Korean cases of primary hepatic lymphoma. Pathol Int; 2004 Nov;54(11):830-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological features of eight Korean cases of primary hepatic lymphoma.
  • Primary hepatic lymphoma is very rare, accounting for less than 0.4% of extranodal lymphomas.
  • Furthermore, hepatic lymphoma, either primary or metastatic, is infrequently confirmed histopathologically in needle biopsy specimens.
  • The aim of the current study is to assess the clinicopathological characteristics of primary hepatic lymphomas in Korea, which is an endemic area of chronic B viral hepatitis.
  • In total, 17 cases with liver needle biopsy specimens with involvement of malignant lymphoma, from whom eight cases met the criteria for primary hepatic lymphoma, were selected.
  • Five of eight (62.5%) cases were T cell lymphoma, including three cases (37.5%) of hepatosplenic T cell lymphoma.
  • Three cases (37.5%) were diffuse large B cell lymphomas.
  • The partial remission was present in two of seven patients (28.6%) and five patients (71%) died of disease 25 days to 7 months after the diagnosis.
  • The data indicate that the relatively high incidence of T-cell type in Korean cases of primary hepatic lymphoma may be related to its aggressive behavior and poor prognosis despite combination chemotherapy.
  • [MeSH-major] Liver Neoplasms / pathology. Lymphoma / pathology
  • [MeSH-minor] Adult. Aged. Female. Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor. Humans. Immunohistochemistry. In Situ Hybridization. Korea. Male. Middle Aged. Polymerase Chain Reaction. Prognosis


20. Okamoto S, Kurimoto M, Hirashima Y, Hayashi N, Kuwayama N, Endo S, Okada E, Ishizawa S: [Systemic non-Hodgkin lymphoma initially presented with visual disturbance due to intrasellar lymphoma--a case report]. No Shinkei Geka; 2001 Jan;29(1):59-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Systemic non-Hodgkin lymphoma initially presented with visual disturbance due to intrasellar lymphoma--a case report].
  • A case with systemic non-Hodgkin lymphoma involving the sella turcica and kidney is reported.
  • A 69-year-old man presented with a progressive two month history of visual disturbance and headache.
  • Without extensive studies for systemic disease, the patient immediately underwent transsphenoidal surgery.
  • The histopathological examination revealed a malignant lymphoma, diffuse-large-cell type with B-cell phenotype.
  • The patient received radiation therapy and the tumor disappeared.
  • Postoperative CT examinations of the abdomen and pelvis revealed a large mass at the upper portion of the left kidney.
  • However, the patient suddenly died of acute heart failure with unknown cause just before starting chemotherapy for systemic lymphoma.
  • Patients presenting primary central nervous system lymphoma (PCNSL) may have systemic non-Hodgkin lymphoma.
  • To exclude systemic non-Hodgkin lymphoma, systemic investigation is essential for the initial management of patients presenting PCNSL.
  • [MeSH-major] Lymphoma, B-Cell / complications. Lymphoma, Large B-Cell, Diffuse / complications. Vision Disorders / etiology


21. Matoba M, Oota K, Tonami H, Masaki Y, Sakai T, Umehara H: Palliative radiotherapy with 1 x 8 Gy using conformal radiotherapy for chemotherapy-refractory, recurrent, aggressive lymphomas. Jpn J Radiol; 2010 Apr;28(3):220-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Palliative radiotherapy with 1 x 8 Gy using conformal radiotherapy for chemotherapy-refractory, recurrent, aggressive lymphomas.
  • We performed palliative radiotherapy with a single-fraction of 8 Gy using a three-dimensional conformal radiotherapy (3D-CRT) technique for patients with dyspnea due to a bulky nasooropharyngeal lesion who had chemotherapy-refractory, recurrent, aggressive lymphoma.
  • These results indicated that a single fraction of 8 Gy using 3D-CRT is an effective palliative treatment for chemotherapy-refractory, recurrent, aggressive lymphoma.
  • [MeSH-major] Head and Neck Neoplasms / radiotherapy. Lymphoma, Large B-Cell, Diffuse / radiotherapy. Lymphoma, Mantle-Cell / radiotherapy. Palliative Care. Radiotherapy, Conformal
  • [MeSH-minor] Aged. Dose Fractionation. Drug Resistance, Neoplasm. Humans. Male. Nasopharyngeal Neoplasms / pathology. Nasopharyngeal Neoplasms / radiotherapy. Neoplasm Invasiveness. Neoplasm Recurrence, Local. Radiotherapy Dosage


22. Wang SH, Yu L, Wang QS, Li HH, Zhao Y, Li F: [Clinical analysis of 23 patients with primary non-Hodgkin's lymphoma originated in bone]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Feb;16(1):200-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical analysis of 23 patients with primary non-Hodgkin's lymphoma originated in bone].
  • The purpose of this study was to investigate the clinical signs and therapy of primary non-Hodgkin's lymphoma of bone (PLB).
  • The clinical symptoms, signs, X-ray features, pathological morphology, immuno-phenotype and treatment of 23 patients with PLB were analyzed retrospectively.
  • Most of histological types were diffuse large B cell lymphoma; there were single bone involvement in 21 cases and multiple involvement in 2 cases; 3 cases had pathologic fracture.
  • The roentgenography and CT are difficult to diagnose PLB, the final diagnosis should be confirmed according to clinical features, pathological findings and immunohistochemistry assay.
  • The immunohistochemistry is helpful to diagnosis and identification of histological type for PLB.
  • The therapeutic procedure for PLB mainly includes local radiotherapy combined with chemotherapy.

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18315931.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


23. Chishima F, Hayakawa S, Ohta Y, Sugita K, Yamazaki T, Sugitani M, Yamamoto T: Ovarian Burkitt's lymphoma diagnosed by a combination of clinical features, morphology, immunophenotype, and molecular findings and successfully managed with surgery and chemotherapy. Int J Gynecol Cancer; 2006 Jan-Feb;16 Suppl 1:337-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian Burkitt's lymphoma diagnosed by a combination of clinical features, morphology, immunophenotype, and molecular findings and successfully managed with surgery and chemotherapy.
  • Ovarian involvement as an initial manifestation of lymphoma, without detectable extraovarian disease, is a rare occurrence.
  • The diagnosis of ovarian lymphoma is almost invariably unsuspected until the tumor has been examined histologically.
  • Presence of abnormal lymphoid cells in pleural effusion led to presurgical assumption that the pelvic mass noted on computerized tomography examination might be an ovarian lymphoma.
  • Clinical, histologic, and molecular examination revealed Burkitt's lymphoma of the ovary with c-myc gene rearrangement and mRNA expression of multiple cytokines.
  • She received dose-intensified combination chemotherapy.
  • She is alive and free of disease 30 months after the diagnosis.
  • Immunophenotype and molecular findings allowed reliable discrimination of Burkitt's lymphoma from diffuse large B-cell lymphoma and other lymphomas.
  • If an ovarian tumor is solid and suspected to be of lymphoid origin, we suggest that it is necessary to obtain samples for genetic examination at surgery.
  • This strategy often provides important information to establish therapeutic regimen and predict patient prognosis.
  • [MeSH-major] Burkitt Lymphoma / diagnosis. Burkitt Lymphoma / therapy. Herpesvirus 4, Human / isolation & purification. Ovarian Neoplasms / diagnosis
  • [MeSH-minor] Adult. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Cyclophosphamide / administration & dosage. Cytokines / analysis. Doxorubicin / administration & dosage. Female. Genes, myc / genetics. Gynecologic Surgical Procedures. Humans. Prednisolone / administration & dosage. Rituximab. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16515618.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Cytokines; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VAP-cyclo protocol
  •  go-up   go-down


24. Naeije G, Meert AP, Deneft F, Meuleman N, Sculier JP: B-cell lymphoma presenting with renal failure associated to spontaneous tumor lysis syndrome and urinary tract obstruction. J BUON; 2005 Jul-Sep;10(3):397-400
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] B-cell lymphoma presenting with renal failure associated to spontaneous tumor lysis syndrome and urinary tract obstruction.
  • The acute tumor lysis syndrome (ATLS) may be a dramatic complication of anticancer treatment.
  • Spontaneous tumor lysis syndrome (STLS) has been reported more frequently in Burkitt's lymphomas than in other haematological tumors, and exceptionally in solid tumors like small-cell lung carcinoma and germ-cell tumors.
  • We report on the case of a patient with a diffuse large B-cell lymphoma (DLBCL) of the urinary tract involved by acute renal failure due to STLS and complicated by obstructive uropathy subsequent to neoplastic infiltration of the bladder.
  • Hyperhydration, urine alkalinization, urate oxidase administration and continuous veno-venous haemodiafiltration (CVVHDF) permitted to control the initial renal failure and to administer chemotherapy.
  • The patient then developed chemotherapy-induced tumor lysis syndrome (TLS) controlled by urate oxidase administration, hyperhydration and urine alkalinization.
  • The treatment of TLS and the differences between ATLS and STLS are discussed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17357196.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


25. Carmichael MG: Central nervous system anaplastic large cell lymphoma in an adult: successful treatment with a combination of radiation and chemotherapy. Mil Med; 2007 Jun;172(6):673-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Central nervous system anaplastic large cell lymphoma in an adult: successful treatment with a combination of radiation and chemotherapy.
  • Anaplastic large cell lymphoma (ALCL) is 1 of 17 mature T cell neoplasms described by the World Health Organization.
  • Primary central nervous system (PCNS) ALCL represents a distinct rare form of this family of non-Hodgkin lymphoma and discussions of prognosis and management are limited to case reports and case series.
  • Therapies for this disease largely parallel that of other PCNS lymphomas.
  • We report the case of a 38-year-old male soldier who presented with a parieto-occipital mass lesion and neurological sequelae without evidence of systemic disease.
  • Pathologic evaluation of tissue from brain biopsy confirmed ALCL.
  • We elected treatment with an intensive combination of systemic and intrathecal chemotherapy with radiotherapy.
  • Our patient is in complete remission 15 months following therapy.
  • Tailored therapies for PCNS ALCL are unavailable and this regimen may be an option for patients who can tolerate intensive treatments.
  • [MeSH-major] Central Nervous System Neoplasms / drug therapy. Central Nervous System Neoplasms / radiotherapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / radiotherapy
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Dexamethasone / therapeutic use. Humans. Leucovorin / therapeutic use. Male. Methotrexate / therapeutic use. Procarbazine / therapeutic use. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17615857.001).
  • [ISSN] 0026-4075
  • [Journal-full-title] Military medicine
  • [ISO-abbreviation] Mil Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; Q573I9DVLP / Leucovorin; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


26. Halkos ME, Miller JI, Mann KP, Miller DL, Gal AA: Thoracic presentations of posttransplant lymphoproliferative disorders. Chest; 2004 Dec;126(6):2013-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Eleven cases of PTLD with a primary thoracic presentation were identified among 3,085 solid-organ transplant patients and 1,662 bone marrow transplant patients from 1990 to 2001.
  • RESULTS: There were eight men and three women with a mean age of 49 years.
  • The time to presentation ranged from 1 to 97 months (median time, 8 months).
  • Six patients developed PTLD within 1 year of undergoing transplantation.
  • Diagnosis was achieved by CT-guided transthoracic needle biopsy in eight patients, and by open biopsy in three patients.
  • Pathologic analysis revealed monomorphic PTLD (ie, diffuse large B-cell lymphoma) in seven patients, polymorphic PTLD in two patients, anaplastic large cell lymphoma in one patient, and Hodgkin lymphoma in one patient.
  • All patients were initially treated with a reduction in immunosuppression therapy, and six patients (55%) received adjuvant chemotherapy.
  • The median interval from diagnosis to death was 13 months (range, 1 to 42 months).
  • Heart and lung allograft recipients have the worst prognosis because of the mortality that accompanies rejection with subtherapeutic immunosuppression therapy.
  • Earlier diagnosis and improvements in immunosuppression and chemotherapy may improve survival for these inherently high-risk patients.
  • [MeSH-major] Lymphoproliferative Disorders / diagnosis. Thoracic Diseases / diagnosis. Transplantation / adverse effects
  • [MeSH-minor] Adult. Antibodies, Viral / analysis. Cytomegalovirus / isolation & purification. Female. Herpesvirus 4, Human / isolation & purification. Humans. Lymphoma / diagnosis. Lymphoma / etiology. Lymphoma / therapy. Lymphoma / virology. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Chest Injuries and Disorders.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15596707.001).
  • [ISSN] 0012-3692
  • [Journal-full-title] Chest
  • [ISO-abbreviation] Chest
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Viral
  •  go-up   go-down


27. Uner A, Ozet A, Arpaci F, Unsal D: Long-term clinical outcome after accidental overdose of multiple chemotherapeutic agents. Pharmacotherapy; 2005 Jul;25(7):1011-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term clinical outcome after accidental overdose of multiple chemotherapeutic agents.
  • Treatment of non-Hodgkin's lymphoma with the CHOP regimen consists of intravenous cyclophosphamide 750 mg/m2 (day 1), intravenous doxorubicin 50 mg/m2 (day 1), intravenous vincristine 1.4 mg/m2 (day 1), and oral prednisone 100 mg (days 1-5).
  • This regimen is administered in cycles of approximately 3 weeks; a total course of treatment consists of six cycles.
  • We report the case of a 23-year-old woman with diffuse large-cell lymphoma who received an accidental overdose of this chemotherapeutic regimen.
  • Unfortunately, the patient went to another hospital located in the small city where she lived, and all remaining doses of the total course of treatment were administered over the next 5 consecutive days, with no interruption in therapy.
  • She was transferred to our hospital after she developed pancytopenia, fever, and ileus.
  • With the help of intensive supportive care and symptomatic treatment, the patient recovered and was discharged home after a hospital stay of 25 days.
  • After 56 months, she was free of disease and treatment-related toxicities.
  • Only experienced clinicians should administer chemotherapy, and thorough records must be kept to document the chemotherapy administered, dosages, dates of administration, the procedure used, and the schedule of cycles administered.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / poisoning. Lymphoma, Large B-Cell, Diffuse / drug therapy
  • [MeSH-minor] Adult. Cyclophosphamide / poisoning. Cyclophosphamide / therapeutic use. Doxorubicin / poisoning. Doxorubicin / therapeutic use. Drug Overdose. Female. Humans. Prednisolone / poisoning. Prednisolone / therapeutic use. Treatment Outcome. Vincristine / poisoning. Vincristine / therapeutic use

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16006279.001).
  • [ISSN] 0277-0008
  • [Journal-full-title] Pharmacotherapy
  • [ISO-abbreviation] Pharmacotherapy
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VAP-cyclo protocol
  •  go-up   go-down


28. Warnick E, Auger D: Management of patients with primary central nervous system lymphoma treated with high-dose methotrexate. Clin J Oncol Nurs; 2009 Apr;13(2):177-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of patients with primary central nervous system lymphoma treated with high-dose methotrexate.
  • Primary central nervous system lymphoma (PCNSL) is a rare, extranodal form of non-Hodgkin lymphoma that most commonly presents with neurologic changes.
  • Comprehensive workup to diagnose PCNSL and rule out nodal non-Hodgkin lymphoma is critical to the development of an appropriate plan for therapy.
  • Past PCNSL treatments have included whole-brain radiation or steroids, but high-dose methotrexate (MTX) has emerged as initial therapy.
  • Although high-dose MTX is well tolerated, special considerations must be taken to administer the drug safely.
  • Nurses should evaluate and monitor patients closely during treatment to ensure safety and decrease drug toxicity.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Central Nervous System Neoplasms / drug therapy. Lymphoma / drug therapy. Methotrexate / therapeutic use
  • [MeSH-minor] DNA-Binding Proteins / genetics. Humans. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / genetics. Lymphoma, Large B-Cell, Diffuse / genetics

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • Hazardous Substances Data Bank. METHOTREXATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19349264.001).
  • [ISSN] 1538-067X
  • [Journal-full-title] Clinical journal of oncology nursing
  • [ISO-abbreviation] Clin J Oncol Nurs
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / BCL6 protein, human; 0 / DNA-Binding Proteins; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


29. Yang T, Belverud S, Yeh AY, Bandovic J, Farmer P, Woldenberg RF, Demopoulos A, Schulder M, Li JY: Primary CNS anaplastic diffuse large B-cell lymphoma mimicking undifferentiated metastatic tumors: a case report. J Neurooncol; 2010 Feb;96(3):433-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary CNS anaplastic diffuse large B-cell lymphoma mimicking undifferentiated metastatic tumors: a case report.
  • Primary central nervous system lymphoma (PCNSL) is a rare intracranial tumor, with an annual incidence of six per million population.
  • Anaplastic variant of primary CNS diffuse large B-cell lymphoma is less common; to our knowledge, there is only one other case report in the world literature.
  • We describe a 71 year old immunocompetent female without significant past medical history who presented with confusion and a homogeneously enhancing midline mass.
  • The patient underwent craniotomy for tumor biopsy, followed by high-dose methotrexate-based chemotherapy despite a remarkably low performance status.
  • The clinical course, diagnostic workup, pathologic correlates, and treatment outcomes are described.
  • [MeSH-major] Central Nervous System Neoplasms / diagnosis. Lymphoma, Large B-Cell, Diffuse / diagnosis


30. Luna-Ortiz K, Cervera-Ceballos E, Dominguez-Malagon H, Labardini-Mendez J, De la Garza-Salazar J, Herrera-Gomez A, Barrera-Franco JL: Primary lymphoma of bone. Rev Invest Clin; 2003 Sep-Oct;55(5):502-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary lymphoma of bone.
  • Primary lymphoma of bone (PLB) is a rare clinical-pathological entity representing less than 1% of all lymphomas.
  • This work was aimed to review the presentation characteristics of PLB at the Instituto Nacional de Cancerología including its management and evolution.
  • MATERIAL AND METHODS: Thirty cases of lymphoma of bone were diagnosed between 1972 and 1999 from a database including 577 patients with lymphoma.
  • Among them, only 8 patients (1.36% of the total lymphomas) met the criteria set out to be diagnosed as primary lymphoma of bone, stage IE.
  • In all patients, diagnosis was histopathologically made through open biopsy, and they were classified in accordance with the former criteria of the Working Formulation (WF).
  • RESULTS: Three women and five men with a mean age of 40 years (range 20-65) were identified.
  • Six patients presented clinically evident disease of the affected region.
  • Histological diagnosis was diffuse large cell lymphoma, and B immunophenotype was confirmed in 5 patients.
  • Five patients received sequential chemotherapy and radiotherapy; 1 patient received chemotherapy; and 2 patients received exclusive radiotherapy.
  • The chemotherapy regimes were based on anthracyclines.
  • Five patients presented complete response and 3 patients showed progressive disease.
  • One patient showing complete response relapse 16 years after the treatment.
  • Surgery was not therapeutic in any case.
  • CONCLUSIONS: PLB still remains a rare clinical-pathological entity, and represented 1.3% of total lymphomas in this series.
  • Sequential anthracycline-based chemotherapy and radiotherapy are the most important therapeutic choices.
  • Functional condition of patients at diagnosis and tumor localization were the most accurate prognostic factors.
  • [MeSH-major] Bone Neoplasms. Lymphoma

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14968470.001).
  • [ISSN] 0034-8376
  • [Journal-full-title] Revista de investigación clínica; organo del Hospital de Enfermedades de la Nutrición
  • [ISO-abbreviation] Rev. Invest. Clin.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


31. Okada A, Hirakawa R, Yamashita M, Aono H, Choh S, Obayashi C: [Two cases of intravascular diffuse large B-cell lymphoma diagnosed by transbronchial lung biopsy]. Nihon Kokyuki Gakkai Zasshi; 2010 Oct;48(10):779-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Two cases of intravascular diffuse large B-cell lymphoma diagnosed by transbronchial lung biopsy].
  • We encountered 2 cases of intravascular diffuse large B-cell lymphoma (IVL) diagnosed by transbronchial lung biopsy (TBLB).
  • The first patient reported fatigue and dyspnea on exertion, but chest radiography and computed tomography (CT) did not reveal any abnormalities.
  • IVL is a rare type of extranodal lymphoma characterized by the presence of lymphoma cells only in the lumenas of small vessels.
  • Major clinical symptoms such as fever, cough, dyspnea, and loss of body weight are not diagnostic, and chest radiographic findings are also nonspecific.
  • Antemortem diagnosis is relatively difficult, and the prognosis is reported to be relatively poor, but it has been reported that long-term survival may result in patients treated with combination chemotherapy.
  • Therefore, TBLB is a useful procedure for early diagnosis of IVL, and may contribute to good outcome.
  • [MeSH-major] Biopsy / methods. Lymphoma, Large B-Cell, Diffuse / pathology

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • MedlinePlus Health Information. consumer health - Biopsy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21066869.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


32. Chen HW, Sheu JC, Lin WC, Tsang YM, Liu KL: Primary liver lymphoma in a patient with chronic hepatitis C. J Formos Med Assoc; 2006 Mar;105(3):242-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary liver lymphoma in a patient with chronic hepatitis C.
  • Primary liver lymphoma is a very rare disease and is frequently overlooked as a possible diagnosis.
  • We report the case of an asymptomatic middle-aged man with chronic hepatitis C who developed primary liver lymphoma (PLL).
  • A large solitary tumor in the left lobe of the liver was incidentally detected on routine ultrasound examination.
  • Atypical hepatectomy was performed and the pathology of the hepatic tumor revealed non-Hodgkin's lymphoma.
  • There was no tumor recurrence more than 4 years after operation and chemotherapy.
  • PLL should be included in the differential diagnosis of solitary hepatic tumor in patients who are hepatitis C virus-positive, and who have atypical imaging and no known malignancy or elevated tumor marker levels.

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16520842.001).
  • [ISSN] 0929-6646
  • [Journal-full-title] Journal of the Formosan Medical Association = Taiwan yi zhi
  • [ISO-abbreviation] J. Formos. Med. Assoc.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


33. Ando T, Suguro M, Kobayashi T, Seto M, Honda H: Selection of causal gene sets for lymphoma prognostication from expression profiling and construction of prognostic fuzzy neural network models. J Biosci Bioeng; 2003;96(2):161-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Selection of causal gene sets for lymphoma prognostication from expression profiling and construction of prognostic fuzzy neural network models.
  • To assess the response of lymphomas to chemotherapy, gene expression profiling data from DNA microarrays were analyzed using the fuzzy neural network (FNN) modeling method.
  • Using these models, we were able to predict diffuse large B-cell lymphoma (DLBCL) patient outcome with 93% accuracy.
  • On Kaplan-Meier plots of overall survival, patients predicted by the FNN model to be cured survived significantly longer than those predicted to be refractory (P<0.0001), indicating that the FNN could successfully identify patients with a relatively poor prognosis among low-clinical-risk patients.

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16233502.001).
  • [ISSN] 1389-1723
  • [Journal-full-title] Journal of bioscience and bioengineering
  • [ISO-abbreviation] J. Biosci. Bioeng.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


34. Moskowitz CH, Hamlin PA, Gabrilove J, Bertino JR, Portlock CS, Straus DJ, Gencarelli AN, Nimer SD, Zelenetz AD: Maintaining the dose intensity of ICE chemotherapy with a thrombopoietic agent, PEG-rHuMGDF, may confer a survival advantage in relapsed and refractory aggressive non-Hodgkin lymphoma. Ann Oncol; 2007 Nov;18(11):1842-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Maintaining the dose intensity of ICE chemotherapy with a thrombopoietic agent, PEG-rHuMGDF, may confer a survival advantage in relapsed and refractory aggressive non-Hodgkin lymphoma.
  • INTRODUCTION: HDT/ASCT is standard for relapsed and refractory DLCL patients responding to second-line chemotherapy.
  • We incorporated a thrombopoietic agent into the ICE chemotherapy program to potentially: decrease platelet associated toxicities, augment stem cell collection and maintain dose intensity.
  • METHODS: This randomized, double-blind, placebo-controlled phase I/II trial examines PEG-rHuMGDF versus placebo with ICE chemotherapy.
  • Outcome measures included safety, hematological end-points, stem cell collection and the impact of dose-intensity on outcome.
  • RESULTS: Forty-one patients with primary refractory (16) or relapsed DLCL (25) were treated; Response rates for evaluable patients are: 75% (12/16) for placebo and 82% (18/22) for PEG-rHuMGDF.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • Hazardous Substances Data Bank. Filgrastim .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17872903.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K24CA100287
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Recombinant Proteins; 0 / polyethylene glycol-recombinant human megakaryocyte growth and development factor; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 30IQX730WE / Polyethylene Glycols; 8N3DW7272P / Cyclophosphamide; 9014-42-0 / Thrombopoietin; PVI5M0M1GW / Filgrastim; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


35. Provencio M, Sanchez A, Maximiano C, Cantos B, Méndez M, Bonilla F: A prospective study of left ventricle function after treatment with rapid-infusion rituximab in patients with non-Hodgkin lymphoma. Leuk Lymphoma; 2009 Oct;50(10):1642-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A prospective study of left ventricle function after treatment with rapid-infusion rituximab in patients with non-Hodgkin lymphoma.
  • We designed a prospective study to measure the left ventricular ejection fraction of 42 patients with non-Hodgkin lymphoma treated with Rituximab-based chemotherapy in a 1-h infusion.
  • Before treatment, basal left ventricular ejection function (LVEF) was measured and every 6 months after treatment.
  • A drop in the post-treatment ejection fraction of over 10% from the pre-treatment base figure was found in 13 patients (31% of the total of the series, 39% of those receiving adriamycin-based chemotherapy).
  • Patients with normal systolic function had LVEF with a mean of 64.09 (+/-3.86) and patients with decreased systolic function had LVEF with a mean of 59.38 (+/-5.43).
  • [MeSH-major] Antibodies, Monoclonal / pharmacology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, B-Cell / drug therapy. Stroke Volume / drug effects. Ventricular Dysfunction, Left / chemically induced
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal, Murine-Derived. Comorbidity. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Cytokines / secretion. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Female. Heart Diseases / epidemiology. Humans. Hyperlipidemias / epidemiology. Hypertension / epidemiology. Infusions, Intravenous / methods. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / physiopathology. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / physiopathology. Male. Middle Aged. Prednisone / administration & dosage. Prednisone / adverse effects. Prospective Studies. Rituximab. Smoking / epidemiology. Time Factors. Vincristine / administration & dosage. Vincristine / adverse effects

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19757315.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Cytokines; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone
  •  go-up   go-down


36. Sar A, Perizzolo M, Stewart D, Mansoor A, Difrancesco LM, Demetrick DJ: Mutation or polymorphism of the CD20 gene is not associated with the response to R-CHOP in diffuse large B cell lymphoma patients. Leuk Res; 2009 Jun;33(6):792-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mutation or polymorphism of the CD20 gene is not associated with the response to R-CHOP in diffuse large B cell lymphoma patients.
  • BACKGROUND: Rituximab, a chimeric antibody targeted to the human CD20 molecule, is a major component of the R-CHOP protocol used to treat patients with diffuse large B cell lymphoma (DLBCL).
  • It is also a very expensive drug.
  • One possible mechanism that may mediate the poor response to R-CHOP is poor binding of the drug to the CD20 molecule, perhaps due to mutations or polymorphisms of the CD20 gene that affect its structure.
  • METHODS: Eleven patients with DLBCL who exhibited a recurrence of their disease and/or died within 24 months of R-CHOP treatment were categorized as showing poor progression-free survival (poor outcomes).
  • Paraffin-embedded tissue specimens from the original tumors were evaluated for mutations or polymorphisms of the CD20 gene.
  • Furthermore, sections from these patients and as well as from matched control patients who were categorized as good outcome patients (no progression of their disease within 36 months) were stained with anti-CD20 antibody and compared for CD20 protein expression.
  • RESULTS: DNA sequence analyses revealed that no mutations were observed in DNA from the coding region of the CD20 gene in any of the initial tumors from 11 patients who showed poor outcomes with R-CHOP therapy.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antigens, CD20 / genetics. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / genetics. Mutation. Polymorphism, Genetic
  • [MeSH-minor] Aged. Aged, 80 and over. Antibodies, Monoclonal, Murine-Derived. Base Sequence. Cyclophosphamide / administration & dosage. Cyclophosphamide / therapeutic use. DNA Primers. Doxorubicin / administration & dosage. Doxorubicin / therapeutic use. Female. Humans. Immunohistochemistry. Male. Middle Aged. Polymerase Chain Reaction. Prednisone / administration & dosage. Prednisone / therapeutic use. Rituximab. Vincristine / administration & dosage. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19054557.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 0 / DNA Primers; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


37. Sehn LH, Connors JM: Treatment of aggressive non-Hodgkin's lymphoma: a north American perspective. Oncology (Williston Park); 2005 Apr;19(4 Suppl 1):26-34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of aggressive non-Hodgkin's lymphoma: a north American perspective.
  • The most common subtype of aggressive non-Hodgkin's lymphoma is diffuse large B-cell lymphoma (DLBCL).
  • Diffuse large B-cell lymphoma represents a heterogeneous entity, with 5-year overall survival rates ranging from 26% to 73%.
  • Microarray gene expression studies have confirmed that biologically distinct subgroups exist within DLBCL, and can be correlated with outcome.
  • Initial management is usually guided by stage of disease at presentation.
  • Approximately 25% of patients with DLBCL present with limited-stage disease and are treated with combined-modality therapy (brief chemotherapy and involved-field radiation).
  • Most patients present with advanced-stage disease and require treatment with an extended course of chemotherapy.
  • The CHOP (cyclophosphamide, doxorubicin HCl, vincristine [Oncovin], prednisone) chemotherapy regimen has been the mainstay of therapy since its development in the 1970s, as more intensive chemotherapy regimens failed to show additional benefit.
  • The era of monoclonal antibodies has transformed treatment practices for aggressive lymphoma and has led to a significant improvement in outcome.
  • A randomized trial comparing the use of rituximab (Rituxan), a chimeric anti-CD20 IgG1 monoclonal antibody, combined with CHOP chemotherapy vs CHOP chemotherapy alone for elderly patients with advanced-stage DLBCL demonstrated a significant benefitfor the combination approach.
  • This finding has now been confirmed in two additional randomized, controlled trials and a population-based analysis, making CHOP and rituximab the standard of care for all newly diagnosed patients with DLBCL.
  • Despite this advance, newer therapies are needed and many are under active investigation.
  • The insights gained from molecular techniques such as gene expression profiling should permit identification of additional lymphoma-specific therapeutic targets and the development of novel agents that take into account underlying biology and allow for greater tailoring of therapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, B-Cell / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Cyclophosphamide / administration & dosage. Disease Progression. Doxorubicin / administration & dosage. Humans. Neoplasm Staging. North America. Prednisone / administration & dosage. Rituximab. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15934515.001).
  • [ISSN] 0890-9091
  • [Journal-full-title] Oncology (Williston Park, N.Y.)
  • [ISO-abbreviation] Oncology (Williston Park, N.Y.)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone
  • [Number-of-references] 58
  •  go-up   go-down


38. Bertini M, Boccomini C, Calvi R: The Influence of advanced age on the treatment and prognosis of diffuse large-cell lymphoma (DLCL). Clin Lymphoma; 2001 Mar;1(4):278-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Influence of advanced age on the treatment and prognosis of diffuse large-cell lymphoma (DLCL).
  • The incidence of non-Hodgkin's lymphoma (NHL) in elderly patients has increased in recent years.
  • Approximately 36% of elderly patients with NHL are diagnosed with diffuse large-cell lymphoma (DLCL), an aggressive lymphoma subtype.
  • Some authors have suggested that lymphoma in the elderly is intrinsically different from that seen in younger patients.
  • Diffuse large-cell lymphoma, for example, is curable in about 50% of patients younger than 65 years of age but has a significantly lower cure rate in older subjects.
  • Elderly patients with DLCL represent a group that is difficult to treat because of comorbidity, diminished organ functions, altered drug metabolism, and irregular drug clearance rates.
  • These factors must be carefully considered when evaluating treatment options for older patients.
  • The quality of life (QOL) associated with various regimens should obviously be evaluated, though QOL has so far received little attention in clinical trials.
  • Analyses of the results from numerous phase II and phase III trials in patients with advanced aggressive NHL have demonstrated that overall survival is reduced when chemotherapy regimens more toxic than CHOP (cyclophosphamide/doxorubicin/ vincristine/prednisone) are employed, whereas therapeutic regimens that are less toxic are often less effective.
  • CHOP, therefore, may be regarded as the current gold standard of therapy for elderly patients with DLCL.
  • The addition of granulocyte colony-stimulating factors to CHOP chemotherapy is recommended to limit myelosuppression.
  • Intensive chemotherapy followed by autologous stem cell transplantation has recently been extended to patients older than 60 years, with encouraging results, albeit in a highly selected groups of patients.
  • Other promising lymphoma treatments with improved toxicity profiles are being developed.
  • Clinical trials are recommended to determine if these new therapies are safe and active in elderly patients with DLCL.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / drug therapy
  • [MeSH-minor] Age Factors. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Clinical Trials as Topic. Humans. Prognosis

  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11707842.001).
  • [ISSN] 1526-9655
  • [Journal-full-title] Clinical lymphoma
  • [ISO-abbreviation] Clin Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 93
  •  go-up   go-down


39. Kim SW, Oleksyn DW, Rossi RM, Jordan CT, Sanz I, Chen L, Zhao J: Protein kinase C-associated kinase is required for NF-kappaB signaling and survival in diffuse large B-cell lymphoma cells. Blood; 2008 Feb 1;111(3):1644-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Protein kinase C-associated kinase is required for NF-kappaB signaling and survival in diffuse large B-cell lymphoma cells.
  • Diffuse large B-cell lymphoma (DLBCL) is an aggressive and the most common type of non-Hodgkin lymphoma.
  • Despite recent advances in treatment, less than 50% of the patients are cured with current multiagent chemotherapy.
  • Identifying and targeting signaling molecules that control NF-kappaB activation in cancer cells may thus yield more effective therapy for DLBCL.
  • Here, we show that while overexpression of protein kinase C-associated kinase (PKK) activates NF-kappaB signaling in DLBCL cells, suppression of PKK expression inhibits NF-kappaB activity in these cells.
  • In addition, we show that NF-kappaB activation induced by B cell-activating factor of tumor necrosis factor family (BAFF) in DLBCL cells requires PKK.
  • Importantly, we show that knockdown of PKK impairs the survival of DLBCL cells in vitro and inhibits tumor growth of xenografted DLBCL cells in mice.
  • Suppression of PKK expression also sensitizes DLBCL cells to treatment with chemotherapeutic agents.
  • Together, these results indicate that PKK plays a pivotal role in the survival of human DLBCL cells and represents a potential target for DLBCL therapy.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / metabolism. Lymphoma, Large B-Cell, Diffuse / pathology. NF-kappa B / metabolism. Protein-Serine-Threonine Kinases / metabolism. Signal Transduction
  • [MeSH-minor] Animals. Antineoplastic Agents / pharmacology. B-Cell Activating Factor / genetics. B-Cell Activating Factor / metabolism. Cell Line, Tumor. Cell Survival. Gene Expression Regulation, Neoplastic. Humans. Male. Mice. Mice, SCID. Xenograft Model Antitumor Assays

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18025152.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / B-Cell Activating Factor; 0 / NF-kappa B; EC 2.7.1.- / ANKRD3 protein, human; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  •  go-up   go-down


40. Belada D, Smolej L, Hrudková M, Stepánkovd P, Slykorová A, Zák P, Bukac J, Malý J: Addition of rituximab significantly improves outcomes in patients with diffuse large B-cell lymphoma--a single-center, retrospective study. Acta Medica (Hradec Kralove); 2007;50(2):113-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Addition of rituximab significantly improves outcomes in patients with diffuse large B-cell lymphoma--a single-center, retrospective study.
  • CHOP chemotherapy has been used as a standard first-line treatment for diffuse large B-cell lymphoma since the 1970s.
  • Phase III trials have shown that the addition of rituximab (R) to CHOP chemotherapy leads to significant improvements in response rate, progression-free survival and overall survival.
  • This single-center, retrospective study was performed to evaluate the role of the addition of R to chemotherapy (CHT) in a real-world clinical setting.
  • Outcomes were assessed in 85 patients with newly diagnosed DLBCL treated with CHT alone (n=38) and R-CHT (n=47).
  • These data bring further support for rituximab-based immunochemotherapy as a standard first-line therapy for patients with DLBCL.

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18035748.001).
  • [ISSN] 1211-4286
  • [Journal-full-title] Acta medica (Hradec Kralove)
  • [ISO-abbreviation] Acta Medica (Hradec Kralove)
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Czech Republic
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone
  •  go-up   go-down


41. Meinhardt A, Burkhardt B, Zimmermann M, Borkhardt A, Kontny U, Klingebiel T, Berthold F, Janka-Schaub G, Klein C, Kabickova E, Klapper W, Attarbaschi A, Schrappe M, Reiter A, Berlin-Frankfurt-Münster group: Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin's lymphoma and Burkitt leukemia. J Clin Oncol; 2010 Jul 1;28(19):3115-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin's lymphoma and Burkitt leukemia.
  • PURPOSE: The activity of rituximab in pediatric B-cell non-Hodgkin's lymphoma (B-NHL) has not yet been determined.
  • Treatment consisted of rituximab at 375 mg/m(2) administered intravenously on day 1; concomitant therapy consisted of rasburicase, intrathecally (IT) triple drug (methotrexate, cytarabine, and prednisolone) on days 1 and 3 for CNS-positive patients and steroids only for anaphylaxis.
  • Responders had > or = 25% decrease of at least one lesion or BM or PB blasts and no disease progress at other sites.
  • Forty-nine patients were not evaluable for response because of withdrawal from the study (n = 16), IT therapy in CNS-negative patients (n = 8), corticosteroid treatment (n = 3), technical inadequacy of response evaluation (n = 21), or no evaluable lesion (n = 1).
  • Of 87 evaluable patients, 36 were responders (RR, 41.4%; 95% CI, 31% to 52%); among them, 27 of 67 with Burkitt lymphoma and seven of 15 with diffuse large B-cell lymphoma.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Burkitt Lymphoma / drug therapy. Lymphoma, B-Cell / drug therapy. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adolescent. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Child. Child, Preschool. Fatigue / chemically induced. Female. Fever / chemically induced. Humans. Infant. Infusions, Intravenous. Male. Nausea / chemically induced. Rituximab. Treatment Outcome

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2010 Jul 1;28(19):3104-6 [20516430.001]
  • (PMID = 20516455.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


42. Nasir S, DeAngelis LM: Update on the management of primary CNS lymphoma. Oncology (Williston Park); 2000 Feb;14(2):228-34; discussion 237-42, 244
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Update on the management of primary CNS lymphoma.
  • Primary central nervous system (CNS) lymphoma is a non-Hodgkin's lymphoma restricted to the nervous system.
  • The incidence of this lymphoma is rising in the immunocompetent population but may be decreasing in patients with the acquired immune deficiency syndrome (AIDS) due to the introduction of highly active antiretroviral therapy.
  • A periventricular, diffusely enhancing lesion on magnetic resonance imaging (MRI) is suggestive of primary CNS lymphoma, but a stereotactic biopsy is needed to make a definitive diagnosis.
  • Because primary CNS lymphoma is exquisitely sensitive to steroids, these drugs should be withheld until tissue is obtained for diagnosis.
  • Age and performance status are important prognostic factors, regardless of specific treatment.
  • Methotrexate in high doses is the single most effective chemotherapeutic agent for primary CNS lymphoma.
  • It substantially improves survival when combined with radiation therapy and is better than radiotherapy alone as a single agent.
  • Multimodality treatment results in delayed cognitive neurotoxicity, particularly in older patients.
  • New treatment protocols have focused on the use of chemotherapy alone.
  • [MeSH-major] Central Nervous System Neoplasms / therapy. Lymphoma, Large B-Cell, Diffuse / therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Humans. Lymphoma, AIDS-Related / diagnosis. Lymphoma, AIDS-Related / therapy. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10736810.001).
  • [ISSN] 0890-9091
  • [Journal-full-title] Oncology (Williston Park, N.Y.)
  • [ISO-abbreviation] Oncology (Williston Park, N.Y.)
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 42
  •  go-up   go-down


43. Salemis NS, Gourgiotis S, Tsiambas E, Karagkiouzis G, Nakos G, Karathanasis V: Diffuse large B cell lymphoma of the mesentery: an unusual presentation and review of the literature. J Gastrointest Cancer; 2009;40(3-4):79-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffuse large B cell lymphoma of the mesentery: an unusual presentation and review of the literature.
  • INTRODUCTION: Diffuse large B cell lymphoma is the most commonly diagnosed non-Hodgkin's lymphoma, whereas lymphoma is the most common cause of mesenteric masses.
  • We herein present a very rare case of a young male patient with a giant diffuse large B cell lymphoma of the mesentery that was incidentally diagnosed during his admission for a road traffic accident.
  • After complete surgical recection with clear margins, he recieved six cycles of CHOP chemotherapy in the pre-rituximab era.
  • RESULTS AND DISCUSSION: He remained disease-free 2 years after surgery, but unfortunately, he relapsed with disseminated disease and died 6 months later.
  • Mesenteric lymphomas may remain asymptomatic until they reach a large size.
  • The presence of a bulky mesenteric mass is a poor prognostic indicator.
  • CONCLUSION: Although chemotherapy is the treatment of choice for diffuse large B cell lymphoma, in some cases radical surgery has a role in establishing a definitive diagnosis.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Large B-Cell, Diffuse / pathology. Mesentery / pathology. Peritoneal Neoplasms / pathology
  • [MeSH-minor] Combined Modality Therapy. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Fatal Outcome. Humans. Incidental Findings. Male. Prednisone / therapeutic use. Vincristine / therapeutic use. Young Adult

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1993 Sep 30;329(14 ):987-94 [8141877.001]
  • [Cites] Lancet Oncol. 2008 May;9(5):435-44 [18400558.001]
  • [Cites] J Clin Oncol. 2005 Jun 20;23(18):4117-26 [15867204.001]
  • [Cites] Eur J Radiol. 2009 Aug;71(2):313-7 [18513906.001]
  • [Cites] Intern Med. 2006;45(5):227-8 [16595984.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Aug 1;48(1):161-8 [10924986.001]
  • [Cites] Radiology. 2003 Mar;226(3):651-2 [12616015.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5027-33 [15955905.001]
  • [Cites] Hepatogastroenterology. 2008 May-Jun;55(84):891-4 [18705290.001]
  • [Cites] J Clin Oncol. 2006 Jul 1;24(19):3121-7 [16754935.001]
  • [Cites] Br J Radiol. 2006 Jan;79(937):37-43 [16421403.001]
  • [Cites] Radiology. 2007 Feb;242(2):628-31 [17255432.001]
  • [Cites] Arch Pathol Lab Med. 2008 Jan;132(1):118-24 [18181663.001]
  • [Cites] Radiol Clin North Am. 2008 Mar;46(2):265-85, viii-ix [18619381.001]
  • [Cites] Radiology. 1980 Feb;134(2):467-73 [7352232.001]
  • [Cites] Cancer. 1990 Jul 15;66(2):267-72 [2369711.001]
  • [Cites] Leuk Lymphoma. 2008 Mar;49(3):462-9 [18297522.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):235-42 [11807147.001]
  • [Cites] Surg Today. 2008;38(1):76-80 [18085371.001]
  • [Cites] Eur J Haematol. 2006 Oct;77(4):363-4 [16856921.001]
  • [Cites] Lancet Oncol. 2006 May;7(5):379-91 [16648042.001]
  • (PMID = 19937400.001).
  • [ISSN] 1941-6636
  • [Journal-full-title] Journal of gastrointestinal cancer
  • [ISO-abbreviation] J Gastrointest Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  • [Number-of-references] 22
  •  go-up   go-down


44. Jones JA, Fayad LE, Elting LS, Rodriguez MA: Body mass index and outcomes in patients receiving chemotherapy for intermediate-grade B-cell non-Hodgkin lymphoma. Leuk Lymphoma; 2010 Sep;51(9):1649-57
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Body mass index and outcomes in patients receiving chemotherapy for intermediate-grade B-cell non-Hodgkin lymphoma.
  • We conducted a retrospective cohort study examining the influence of obesity on treatment outcome and survival among 712 patients with intermediate-grade B-cell NHL receiving frontline therapy between 1988 and 2001.
  • Logistic and Cox proportional hazards regression modeling was used to adjust for baseline patient demographic, disease, and treatment variables.
  • Risk factors were similar across groups and treatment intensity did not vary by BMI.
  • Increased BMI is associated with significantly improved survival among patients with treatment-naive, intermediate-grade B-cell NHL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Body Mass Index. Lymphoma, Follicular / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Obesity / complications


45. Hung YS, Lin TL, Kuo MC, Tang TC, Dunn P, Wang PN, Wu JH, Chang H, Kuo TT, Shih LY: Primary gastric diffuse large B-cell lymphoma. Chang Gung Med J; 2008 Mar-Apr;31(2):159-66
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary gastric diffuse large B-cell lymphoma.
  • BACKGROUND: The optimal treatment of primary gastric large-cell non-Hodgkin's lymphoma (PGL) has not been defined.
  • Recent studies have suggested that organ-preserving treatment produces the same results as surgical treatment.
  • Sixty-two patients received chemotherapy (CT), three received CT followed by radiotherapy (CT+RT), three received surgery (ST), 14 received surgery followed by CT (ST+ adjuvant CT), one patient received ST followed by radiotherapy (ST+RT), one patient received radiotherapy (RT) alone, one received eradication therapy for Helicobacter pylori only and 3 patients received no further therapy after diagnosis.
  • RESULTS: Of the 81 patients who received endoscopic biopsy of gastric lesions, the diagnosis of PGL could be made in all but one.
  • Seven patients were diagnosed by pathology after ST without preoperative pathologic diagnosis.
  • The 5-year overall survival (OS) and disease-free survival (DFS) were 50.0% and 81.6%, respectively.
  • CONCLUSION: The present data show that CT should be the primary treatment for patients with PGL if the diagnosis can be made with endoscopic biopsy.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / therapy. Stomach Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Male. Middle Aged. Retrospective Studies


46. Zodelava M, Betaneli M, Tsartsidze E, Kharabadze M: Prognostic factors in indolent and aggressive lymphomas and its influence on disease outcome. Georgian Med News; 2009 Feb;(167):32-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors in indolent and aggressive lymphomas and its influence on disease outcome.
  • The aim of the study was to determine the prognostic significance of clinical, laboratory and immunological parameters in indolent and aggressive lymphomas, and to evaluate overall survival in different risk category patients.
  • Based on our investigations patients' age, disease stage, number of extra nodal sites involved, patient performance status 2-4 by ECOG, strongly influenced overall survival in the indolent as well as in the aggressive lymphomas.
  • In indolent lymphomas in case of less than three unfavorable prognostic factors patients overall survival was high (41.04 month) in comparison with patients with three or more unfavorable prognostic factors (14.2 month).
  • Efficacy of treatment was studied in indolent lymphomas, which revealed that in case of one or two unfavorable prognostic factors treatment response is high (82-100%), in case of three factors possibility of remission decreases (56%), in regards to four or five unfavorable factors remission rate is the lowest (40%).
  • Patients overall survival rates with diagnosis in aggressive T-cell and B-cell lymphomas were studied.
  • Analysis of results showed that T-cell phenotype strongly influence the survival of patients with diagnosis of aggressive non-Hodgkin's lymphomas, patients' survival is lower in T-cell lymphomas 7.6 month compared with 17.3 month for B-cell lymphomas.
  • In patients with diagnosis of stage III or IV aggressive lymphomas, three or more unfavorable prognostic factors and T-cell phenotype detects patient which are refractory to the standard chemotherapy schedules.
  • In diffuse large B-cell lymphomas according to the CD10 expression (which was used as an unfavorable prognostic factor in high and high intermediate risk groups) and quantity of the unfavorable prognostic factors identified patients which were primary refractory to standard treatment regimens.
  • In addition we could conclude that in indolent and aggressive lymphomas clinical, laboratory and immunological parameters could be used to identify patients which are primary refractory to standard therapies of treatment.
  • [MeSH-major] Lymphoma, Non-Hodgkin / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Disease Progression. Drug Resistance, Neoplasm. Humans. Middle Aged. Neoplasm Staging. Prognosis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19276466.001).
  • [ISSN] 1512-0112
  • [Journal-full-title] Georgian medical news
  • [ISO-abbreviation] Georgian Med News
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Georgia (Republic)
  •  go-up   go-down


47. Martino R, Perea G, Caballero MD, Mateos MV, Ribera JM, de Oteyza JP, Arranz R, Terol MJ, Sierra J, San Miguel JF: Cyclophosphamide, pegylated liposomal doxorubicin (Caelyx), vincristine and prednisone (CCOP) in elderly patients with diffuse large B-cell lymphoma: results from a prospective phase II study. Haematologica; 2002 Aug;87(8):822-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyclophosphamide, pegylated liposomal doxorubicin (Caelyx), vincristine and prednisone (CCOP) in elderly patients with diffuse large B-cell lymphoma: results from a prospective phase II study.
  • BACKGROUND AND OBJECTIVES: Anthracycline-based combination chemotherapy regimens are the standard therapy for patients with diffuse large B-cell lymphoma (DLBCL), but such regimens may be poorly tolerated in elderly patients.
  • DESIGN AND METHODS: In a prospective phase II study we analyzed the feasibility of a regimen (CCOP) that includes pegylated liposomal doxorubicin (Caelyx ) plus vincristine, cyclophosphamide and prednisone in patients with DLBCL above the age of 60 years.
  • RESULTS: Thirty-three patients, with a median age of 74 years, were enrolled in the study.
  • INTERPRETATION AND CONCLUSIONS: These results suggest that CCOP appears to be an acceptable alternative for elderly patients with DLBCL, and randomized trials against a conventional doxorubicin-containing regimen are justified.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Large B-Cell, Diffuse / drug therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Anemia / chemically induced. Disease-Free Survival. Drug Eruptions / etiology. Drug Eruptions / prevention & control. Female. Granulocyte Colony-Stimulating Factor / therapeutic use. Humans. Male. Nausea / chemically induced. Nausea / drug therapy. Neutropenia / chemically induced. Neutropenia / prevention & control. Prospective Studies. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12161358.001).
  • [ISSN] 0390-6078
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 143011-72-7 / Granulocyte Colony-Stimulating Factor
  •  go-up   go-down


48. Mohammad RM, Al-Katib A, Aboukameel A, Doerge DR, Sarkar F, Kucuk O: Genistein sensitizes diffuse large cell lymphoma to CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy. Mol Cancer Ther; 2003 Dec;2(12):1361-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genistein sensitizes diffuse large cell lymphoma to CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy.
  • The incidence of non-Hodgkin's lymphoma (NHL) has been increasing and is now the leading cause of death in males aged 15-54.
  • Diffuse large cell lymphoma (DLCL) is the most common subtype of NHL.
  • These cells are notable for the high expression of the transcription factor nuclear factor kappa beta (NF-kappaB), raising the possibility that constitutive activation of the NF-kappaB pathway may contribute to the poor prognosis of DLCL patients.
  • The combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) remains the standard therapy for DLCL with a cure rate of approximately 40%.
  • The WSU-DLCL(2) cell line and its severe combined immunodeficient (SCID) xenograft have constitutively active NF-kappaB which provides us with an excellent model in which to study NF-kappaB modulation and CHOP sensitization by genistein.
  • The antitumor activity of CHOP with or without a genistein was evaluated in our WSU-DLCL(2) model.
  • In vivo, WSU-DLCL(2)-bearing SCID mice received genistein alone (800 micro g kg(-1) day(-1), p.o. as gavages for 5 days), CHOP alone ("C", 40 mg/kg, i.v.
  • To begin elucidating the mechanism of genistein-induced sensitization of WSU-DLCL(2) cells to CHOP chemotherapy in this xenograft mouse model, we studied the in vitro effect of genistein on WSU-DLCL(2) growth inhibition, cell cycle, Bax:Bcl-2 ratio, NF-kappaB DNA binding, and apoptosis in vitro.
  • Our results show that genistein has growth modulatory effects on WSU-DLCL(2) cells and enhances the antitumor activity of CHOP.
  • Because soy isoflavone genistein is a widely available nutritional supplement, its use in combination with CHOP chemotherapy should be further explored in a clinical trial in patients with NHL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Genistein / pharmacology. Lymphoma, Large B-Cell, Diffuse / drug therapy
  • [MeSH-minor] Animals. Apoptosis / drug effects. Cell Line, Tumor. Cyclophosphamide / administration & dosage. DNA, Neoplasm / metabolism. Doxorubicin / administration & dosage. G2 Phase / drug effects. Humans. Mice. Mice, SCID. Mitosis / drug effects. NF-kappa B / metabolism. Prednisone / administration & dosage. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. GENISTEIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14707277.001).
  • [ISSN] 1535-7163
  • [Journal-full-title] Molecular cancer therapeutics
  • [ISO-abbreviation] Mol. Cancer Ther.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA33453-20
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / NF-kappa B; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; DH2M523P0H / Genistein; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


49. Moleti ML, Testi AM, Giona F, Malandruccolo L, Pescarmona E, Martino P, Paoloni F, Barberi W, Palumbo G, Mandelli F, Foa R: CODOX-M/IVAC (NCI 89-C-41) in children and adolescents with Burkitt's leukemia/lymphoma and large B-cell lymphomas: a 15-year monocentric experience. Leuk Lymphoma; 2007 Mar;48(3):551-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CODOX-M/IVAC (NCI 89-C-41) in children and adolescents with Burkitt's leukemia/lymphoma and large B-cell lymphomas: a 15-year monocentric experience.
  • During the last 15 years, we have used the National Cancer Institute (NCI) 89-C-41 protocol in patients aged younger than 21 years with Burkitt's leukemia/lymphoma (BLL) and diffuse large B-cell lymphoma (DLBCL).
  • Low-risk received three cycles of the CODOX-M regimen; high-risk patients received four alternating cycles with the CODOX-M and IVAC regimens.
  • Thirty-five patients entered the study: 32 (91%) achieved complete remission (CR); three were non-responders and died and one patient died in CR.
  • Two responders relapsed after 2 months and one presented early B acute lymphoblastic leukemia 33 months from the end of therapy.
  • In our experience with a median follow-up of 11 years, the NCI 89-C-41 protocol has confirmed its high cure rate in BLL and DLBCL children and adolescents.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy. Leukemia / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Cyclophosphamide / therapeutic use. Cytarabine / therapeutic use. Doxorubicin / therapeutic use. Etoposide / therapeutic use. Female. Humans. Ifosfamide / therapeutic use. Male. Methotrexate / therapeutic use. Neoplasm Recurrence, Local / drug therapy. Neoplasm Staging. Prognosis. Risk Factors. Survival Rate. Treatment Outcome. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17454598.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; UM20QQM95Y / Ifosfamide; YL5FZ2Y5U1 / Methotrexate; ANAVACYM protocol; IVAC protocol
  •  go-up   go-down


50. Pallure V, Dandurand M, Stoebner PE, Habib F, Colonna G, Meunier L: [Intravascular B-cell lymphoma with febrile inflammatory lymphoedema of the lower limbs and lower back]. Ann Dermatol Venereol; 2008 Apr;135(4):299-303
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Intravascular B-cell lymphoma with febrile inflammatory lymphoedema of the lower limbs and lower back].
  • [Transliterated title] Lymphome B intravasculaire à type de lymphoedème inflammatoire fébrile des membres inférieurs et des lombes.
  • BACKGROUND: Intravascular lymphomas are diffuse large-cell lymphomas belonging to a group of high-grade non-Hodgkin's lymphomas and are generally of phenotype B.
  • Clinical polymorphism is dominated by neurological and cutaneous involvement.
  • PATIENTS AND METHODS: We report the case of an 80-year-old woman with cutaneous intravascular B-cell lymphoma as revealed by an isolated episode of febrile bilateral inflammatory lymphoedema.
  • Following combined chemotherapy with rituximab and mini-CHOP (cyclophosphamide, adriamycin, oncovin and prednisone), complete remission was obtained rapidly, with no relapse at two years.
  • DISCUSSION: Diagnosis of these tumours is rendered difficult by the clinical polymorphism and multifocal nature of lymphocytic proliferations.
  • In the present case, diagnosis was based on histology results since presentation of the disease in the form of bilateral inflammatory oedema of the lower limbs is not sufficient to establish lymphoma.
  • [MeSH-major] Lymphedema / complications. Lymphedema / pathology. Lymphoma, B-Cell / complications

  • MedlinePlus Health Information. consumer health - Lymphedema.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18420078.001).
  • [ISSN] 0151-9638
  • [Journal-full-title] Annales de dermatologie et de vénéréologie
  • [ISO-abbreviation] Ann Dermatol Venereol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


51. Kamel S, O'Connor S, Lee N, Filshie R, Nandurkar H, Tam CS: High incidence of Pneumocystis jirovecii pneumonia in patients receiving biweekly rituximab and cyclophosphamide, adriamycin, vincristine, and prednisone. Leuk Lymphoma; 2010 May;51(5):797-801
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The risk of infection with Pneumocystis jirovecii pneumonia (PCP) in patients undergoing chemotherapy is closely related to the intensity of corticosteroid exposure.
  • Among 47 consecutive patients treated with R-CHOP-14 at our institution, five (11%) developed microbiologically proven PCP, with a further two (4%) having classical clinical and radiological features of PCP, but without microbiological confirmation.
  • Our experience suggests that PCP prophylaxis should be considered in institutions using R-CHOP-14 for the treatment of patients with aggressive lymphomas.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Lymphoma, Large B-Cell, Diffuse / drug therapy. Neoplasm Recurrence, Local / therapy. Pneumocystis jirovecii / isolation & purification. Pneumonia, Pneumocystis / chemically induced
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Cohort Studies. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Humans. Male. Middle Aged. Prednisone / administration & dosage. Retrospective Studies. Rituximab. Survival Rate. Treatment Outcome. Vincristine / administration & dosage

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Lymphoma. 2010 May;51(5):737-8 [20367567.001]
  • (PMID = 20367135.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone
  •  go-up   go-down


52. Ohsawa M, Ikura Y, Fukushima H, Shirai N, Sugama Y, Suekane T, Hirayama M, Hino M, Ueda M: Immunohistochemical expression of multidrug resistance proteins as a predictor of poor response to chemotherapy and prognosis in patients with nodal diffuse large B-cell lymphoma. Oncology; 2005;68(4-6):422-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical expression of multidrug resistance proteins as a predictor of poor response to chemotherapy and prognosis in patients with nodal diffuse large B-cell lymphoma.
  • BACKGROUND/AIMS: The aim of this study was to determine whether expression of P-glycoprotein (P-gp), multidrug-resistance-related protein 1 (MRP1), and lung resistance protein (LRP) was related to the response to induction chemotherapy and prognosis in untreated diffuse large B-cell lymphoma (DLBCL).
  • METHODS: We assessed immunohistochemical expression of P-gp, MRP1 and LRP, using formalin-fixed and paraffin-embedded specimens of lymph node in 41 patients with DLBCL.
  • Association between expression of these three proteins and their impact on clinical outcome and prognosis was statistically evaluated.
  • CONCLUSIONS: These findings suggest that the three MDR proteins are important predictive factors for the clinical outcome and prognosis in patients with DLBCL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / metabolism. Lymphoma, Large B-Cell, Diffuse / metabolism. Neoplasm Proteins / metabolism. P-Glycoprotein / metabolism. Vault Ribonucleoprotein Particles / metabolism
  • [MeSH-minor] Adult. Aged. Drug Resistance, Multiple. Drug Resistance, Neoplasm. Female. Humans. Lymph Nodes / pathology. Male. Middle Aged. Predictive Value of Tests. Prognosis. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16020972.001).
  • [ISSN] 0030-2414
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / P-Glycoprotein; 0 / Vault Ribonucleoprotein Particles; 0 / major vault protein
  •  go-up   go-down


53. Khan F, Bauer F, Gazi G, Bilgrami S: Regression of large B-cell non-Hodgkin's lymphoma of stomach with HAART: case report and review. Leuk Lymphoma; 2006 Apr;47(4):750-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regression of large B-cell non-Hodgkin's lymphoma of stomach with HAART: case report and review.
  • [MeSH-major] Antiretroviral Therapy, Highly Active. Lymphoma, AIDS-Related / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Non-Hodgkin / drug therapy. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Acquired Immunodeficiency Syndrome / complications. Acquired Immunodeficiency Syndrome / drug therapy. Adult. Fatal Outcome. Female. Hepatitis C / complications. Humans


54. Avilés A, Nambo MJ, Cleto S, Neri N, Huerta-Guzmán J: Rituximab and dose-dense chemotherapy in primary testicular lymphoma. Clin Lymphoma Myeloma; 2009 Oct;9(5):386-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rituximab and dose-dense chemotherapy in primary testicular lymphoma.
  • BACKGROUND: Treatment of primary testicular lymphoma (PTL) remains unsatisfactory even in patients with good prognosis, as < 30% of patients are alive at 3 years.
  • PATIENTS AND METHODS: We began a phase II study to assess efficacy and toxicity of a dose-dense cyclophosphamide/epirubicin/vincristine/prednisone (CEOP14) regimen with rituximab (CEOP14R) in 38 previously untreated patients with PTL with early-stage (I or II) and low-risk disease, followed by adjuvant radiation therapy and central nervous system prophylaxis.
  • CONCLUSION: The addition of rituximab to dose-dense chemotherapy improves outcome in this setting of patients who previously had been considered to have the poorest prognosis.
  • It is important that these findings will be validated in multicentric, controlled clinical trials.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Large B-Cell, Diffuse / drug therapy. Testicular Neoplasms / drug therapy
  • [MeSH-minor] Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Cyclophosphamide / administration & dosage. Disease-Free Survival. Epirubicin / administration & dosage. Humans. Longitudinal Studies. Male. Middle Aged. Prednisone / administration & dosage. Rituximab. Survival Rate. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19858059.001).
  • [ISSN] 1938-0712
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 3Z8479ZZ5X / Epirubicin; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone
  •  go-up   go-down


55. Webb TR, Slavish J, George RE, Look AT, Xue L, Jiang Q, Cui X, Rentrop WB, Morris SW: Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy. Expert Rev Anticancer Ther; 2009 Mar;9(3):331-56
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy.
  • Anaplastic lymphoma kinase (ALK), a receptor tyrosine kinase in the insulin receptor superfamily, was initially identified in constitutively activated oncogenic fusion forms - the most common being nucleophosmin-ALK - in anaplastic large-cell lymphomas, and subsequent studies have identified ALK fusions in diffuse large B-cell lymphomas, systemic histiocytosis, inflammatory myofibroblastic tumors, esophageal squamous cell carcinomas and non-small-cell lung carcinomas.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Crit Rev Oncol Hematol. 2006 Dec;60(3):216-26 [16860997.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Dec 29;351(4):839-46 [17094947.001]
  • [Cites] Am J Surg Pathol. 2006 Dec;30(12):1502-12 [17122505.001]
  • [Cites] World J Gastroenterol. 2006 Nov 28;12(44):7104-12 [17131471.001]
  • [Cites] J Clin Invest. 2006 Dec;116(12):3171-82 [17111047.001]
  • [Cites] Ann Oncol. 2000 Jan;11(1):53-8 [10690387.001]
  • [Cites] Cancer Res. 2000 Feb 15;60(4):793-8 [10706082.001]
  • [Cites] Blood. 2000 Mar 15;95(6):2144-9 [10706887.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Mar 14;97(6):2603-8 [10706604.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Apr 21;270(3):936-41 [10772929.001]
  • [Cites] Am J Pathol. 2000 May;156(5):1711-21 [10793082.001]
  • [Cites] Br J Haematol. 2000 Jun;109(3):584-91 [10886208.001]
  • [Cites] Am J Pathol. 2000 Aug;157(2):377-84 [10934142.001]
  • [Cites] Science. 2000 Sep 15;289(5486):1938-42 [10988075.001]
  • [Cites] Curr Oncol Rep. 2002 Jul;4(4):317-24 [12044241.001]
  • [Cites] Br J Haematol. 2002 Jun;117(4):812-20 [12060115.001]
  • [Cites] Genes Chromosomes Cancer. 2002 Aug;34(4):354-62 [12112524.001]
  • [Cites] Int J Cancer. 2002 Jul 1;100(1):49-56 [12115586.001]
  • [Cites] Genes Chromosomes Cancer. 2001 May;31(1):85-90 [11284039.001]
  • [Cites] Lab Invest. 2001 Mar;81(3):419-26 [11310834.001]
  • [Cites] Blood. 1999 Nov 15;94(10):3509-15 [10552961.001]
  • [Cites] Blood. 1997 Mar 1;89(5):1483-90 [9057627.001]
  • [Cites] Mol Cell Biol. 1997 Apr;17(4):2312-25 [9121481.001]
  • [Cites] J Biol Chem. 1997 Apr 4;272(14):9410-6 [9083079.001]
  • [Cites] Cancer Res. 1997 May 1;57(9):1814-9 [9135027.001]
  • [Cites] Cell. 2000 Oct 13;103(2):211-25 [11057895.001]
  • [Cites] Neuron. 2000 Dec;28(3):819-33 [11163269.001]
  • [Cites] Bull Cancer. 2000 Dec;87(12):873-6 [11174115.001]
  • [Cites] Ann Diagn Pathol. 2001 Feb;5(1):10-4 [11172201.001]
  • [Cites] Blood. 1994 Oct 15;84(8):2467-71 [7919366.001]
  • [Cites] J Biochem. 1994 Jun;115(6):1088-96 [7982887.001]
  • [Cites] Cancer Res. 1995 Apr 15;55(8):1792-7 [7712489.001]
  • [Cites] Cytogenet Cell Genet. 1995;70(1-2):143-4 [7736780.001]
  • [Cites] Ann N Y Acad Sci. 1995 Sep 7;766:442-58 [7486690.001]
  • [Cites] Cancer Res. 1996 Jan 1;56(1):100-4 [8548747.001]
  • [Cites] Nat Med. 1996 May;2(5):561-6 [8616716.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Apr 30;93(9):4181-6 [8633037.001]
  • [Cites] Cancer Res. 1996 Jun 1;56(11):2515-8 [8653688.001]
  • [Cites] J Biol Chem. 1996 Aug 30;271(35):21446-52 [8702927.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Dec 10;93(25):14753-8 [8962127.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Dec 10;93(25):14759-64 [8962128.001]
  • [Cites] Oncogene. 1997 Jan 30;14(4):439-49 [9053841.001]
  • [Cites] Blood. 1997 Feb 15;89(4):1394-404 [9028963.001]
  • [Cites] Cell Signal. 2007 Apr;19(4):740-7 [17110082.001]
  • [Cites] PLoS One. 2007;2(2):e255 [17327916.001]
  • [Cites] Mod Pathol. 2007 Mar;20(3):310-9 [17277765.001]
  • [Cites] Cell. 2007 Mar 9;128(5):961-75 [17350579.001]
  • [Cites] Oncogene. 1997 May 8;14(18):2175-88 [9174053.001]
  • [Cites] Biochim Biophys Acta. 1997 Dec 9;1333(3):F217-48 [9426205.001]
  • [Cites] Blood. 1998 Mar 15;91(6):2076-84 [9490693.001]
  • [Cites] Cancer Res. 1998 Mar 1;58(5):1057-62 [9500471.001]
  • [Cites] Leuk Lymphoma. 1998 Apr;29(3-4):249-56 [9684923.001]
  • [Cites] Am J Pathol. 1998 Sep;153(3):875-86 [9736036.001]
  • [Cites] Blood. 1998 Nov 15;92(10):3591-8 [9808552.001]
  • [Cites] Mol Cell Biol. 1998 Dec;18(12):6951-61 [9819383.001]
  • [Cites] Am J Clin Pathol. 1999 Jan;111(1 Suppl 1):S56-67 [9894470.001]
  • [Cites] Blood. 1999 Apr 15;93(8):2697-706 [10194450.001]
  • [Cites] J Biol Chem. 1999 Apr 30;274(18):12474-9 [10212223.001]
  • [Cites] Blood. 1999 Jun 1;93(11):3913-21 [10339500.001]
  • [Cites] Am J Pathol. 1999 Jun;154(6):1657-63 [10362790.001]
  • [Cites] Cancer Res. 1999 Jun 15;59(12):2776-80 [10383129.001]
  • [Cites] Blood. 1999 Jul 1;94(1):362-4 [10381534.001]
  • [Cites] N Engl J Med. 1999 Oct 14;341(16):1165-73 [10519894.001]
  • [Cites] J Med Chem. 2004 Dec 30;47(27):6658-61 [15615512.001]
  • [Cites] Clin Lung Cancer. 2004 Dec;6 Suppl 1:S20-3 [15638953.001]
  • [Cites] Cancer Sci. 2005 Jan;96(1):54-6 [15649256.001]
  • [Cites] Eur J Neurosci. 2005 Jan;21(2):513-21 [15673450.001]
  • [Cites] J Clin Pharmacol. 2005 Apr;45(4):394-403 [15778420.001]
  • [Cites] Oncogene. 2005 Apr 28;24(19):3206-15 [15735675.001]
  • [Cites] Cancer Lett. 2005 Jul 8;225(1):1-26 [15922853.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Jul 15;332(4):1146-52 [15949466.001]
  • [Cites] Am J Pathol. 2005 Jul;167(1):213-22 [15972965.001]
  • [Cites] Haematologica. 2005 Jul;90(7):988-90 [15996942.001]
  • [Cites] Methods Mol Med. 2005;115:271-94 [15998974.001]
  • [Cites] J Biol Chem. 2005 Jul 15;280(28):26039-48 [15886198.001]
  • [Cites] J Biol Chem. 2005 Jul 22;280(29):26953-64 [15908427.001]
  • [Cites] Pediatr Blood Cancer. 2005 Nov;45(6):796-801 [15602716.001]
  • [Cites] Semin Cancer Biol. 2005 Dec;15(6):506-14 [16154360.001]
  • [Cites] J Pediatr Surg. 2005 Oct;40(10):1581-6 [16226988.001]
  • [Cites] Int J Cancer. 2005 Dec 20;117(6):942-51 [15986444.001]
  • [Cites] Curr Mol Med. 2005 Nov;5(7):625-42 [16305489.001]
  • [Cites] Dev Genes Evol. 2006 Jan;216(1):10-8 [16220264.001]
  • [Cites] Int J Cancer. 2006 Mar 1;118(5):1181-6 [16161041.001]
  • [Cites] J Comp Neurol. 2006 Mar 10;495(2):202-12 [16435287.001]
  • [Cites] J Med Chem. 2006 Feb 9;49(3):1006-15 [16451066.001]
  • [Cites] Blood. 2006 Feb 15;107(4):1617-23 [16254137.001]
  • [Cites] Cancer Lett. 2006 Feb 20;233(1):16-20 [15878231.001]
  • [Cites] Oncogene. 2006 May 25;25(22):3150-9 [16501609.001]
  • [Cites] Gene Expr Patterns. 2006 Jun;6(5):448-61 [16458083.001]
  • [Cites] J Med Chem. 2006 Sep 21;49(19):5759-68 [16970400.001]
  • [Cites] J Neural Transm (Vienna). 2006 Oct;113(10):1569-73 [16604305.001]
  • [Cites] J Biol Chem. 2006 Oct 13;281(41):30857-64 [16901907.001]
  • [Cites] Lancet. 2006 Oct 14;368(9544):1303-4 [17046443.001]
  • [Cites] Med Res Rev. 2008 May;28(3):372-412 [17694547.001]
  • [Cites] Exp Hematol. 2006 Dec;34(12):1670-9 [17157164.001]
  • [Cites] Hum Pathol. 2001 Apr;32(4):428-33 [11331960.001]
  • [Cites] Nature. 2001 May 17;411(6835):355-65 [11357143.001]
  • [Cites] J Biol Chem. 2001 May 18;276(20):16772-9 [11278720.001]
  • [Cites] Br J Haematol. 2001 May;113(2):275-95 [11380391.001]
  • [Cites] Am J Surg Pathol. 2001 Jun;25(6):761-8 [11395553.001]
  • [Cites] Mod Pathol. 2001 Jun;14(6):569-76 [11406658.001]
  • [Cites] Genes Cells. 2001 Jun;6(6):531-44 [11442633.001]
  • [Cites] Am J Pathol. 2001 Aug;159(2):411-5 [11485898.001]
  • [Cites] Am J Surg Pathol. 2001 Nov;25(11):1364-71 [11684952.001]
  • [Cites] Cell. 2001 Nov 2;107(3):387-98 [11701128.001]
  • [Cites] Lancet. 2001 Oct 27;358(9291):1421-3 [11705489.001]
  • [Cites] Clin Cancer Res. 2002 Jan;8(1):240-5 [11801565.001]
  • [Cites] N Engl J Med. 2002 Feb 28;346(9):645-52 [11870241.001]
  • [Cites] Blood. 2002 Mar 15;99(6):1928-37 [11877262.001]
  • [Cites] J Biol Chem. 2002 Apr 19;277(16):14153-8 [11809760.001]
  • [Cites] Oncogene. 2002 May 13;21(21):3314-33 [12032772.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10700-5 [12149456.001]
  • [Cites] Oncogene. 2002 Aug 29;21(38):5823-34 [12185581.001]
  • [Cites] J Biol Chem. 2002 Aug 30;277(35):32071-7 [12070152.001]
  • [Cites] J Biochem. 2002 Sep;132(3):359-71 [12204104.001]
  • [Cites] Mod Pathol. 2002 Sep;15(9):931-8 [12218210.001]
  • [Cites] J Biol Chem. 2002 Sep 27;277(39):35862-8 [12107166.001]
  • [Cites] J Biol Chem. 2002 Sep 27;277(39):35990-8 [12122009.001]
  • [Cites] Histopathology. 2002 Nov;41(5):461-7 [12405914.001]
  • [Cites] Ai Zheng. 2002 Jan;21(1):58-62 [12500399.001]
  • [Cites] Genes Chromosomes Cancer. 2003 May;37(1):98-105 [12661011.001]
  • [Cites] Pathol Oncol Res. 2003;9(1):13-9 [12704441.001]
  • [Cites] Br J Cancer. 2003 May 19;88(10):1522-6 [12771916.001]
  • [Cites] Eur J Neurosci. 2003 May;17(10):2127-34 [12786979.001]
  • [Cites] Science. 2003 Aug 8;301(5634):805-9 [12907793.001]
  • [Cites] Mod Pathol. 2003 Aug;16(8):828-32 [12920229.001]
  • [Cites] EMBO Rep. 2003 Aug;4(8):781-6 [12855999.001]
  • [Cites] Blood. 2003 Oct 1;102(7):2638-41 [12750159.001]
  • [Cites] Blood. 2003 Oct 1;102(7):2568-73 [12763927.001]
  • [Cites] Blood. 2003 Oct 1;102(7):2642-4 [12816858.001]
  • [Cites] J Pediatr Surg. 2003 Sep;38(9):1296-304 [14523809.001]
  • [Cites] Nature. 2003 Oct 2;425(6957):507-12 [14523446.001]
  • [Cites] Nature. 2003 Oct 2;425(6957):512-6 [14523447.001]
  • [Cites] Cancer Res. 2003 Nov 1;63(21):7345-55 [14612533.001]
  • [Cites] Science. 2003 Dec 5;302(5651):1760-5 [14615545.001]
  • [Cites] Nature. 2003 Dec 18;426(6968):789-96 [14685227.001]
  • [Cites] Cancer Lett. 2004 Feb 20;204(2):127-43 [15013213.001]
  • [Cites] Cancer Res. 2004 May 1;64(9):3256-64 [15126367.001]
  • [Cites] Hum Pathol. 2004 Jun;35(6):711-21 [15188137.001]
  • [Cites] Nature. 2004 Jul 15;430(6997):345-50 [15208641.001]
  • [Cites] Science. 2004 Jul 16;305(5682):399-401 [15256671.001]
  • [Cites] Brain Res Dev Brain Res. 2004 Sep 17;152(2):189-97 [15351507.001]
  • [Cites] J Cell Sci. 2004 Oct 15;117(Pt 22):5405-15 [15466886.001]
  • [Cites] Br J Haematol. 1989 Jan;71(1):31-6 [2917127.001]
  • [Cites] Blood. 1989 Feb 15;73(3):806-13 [2537120.001]
  • [Cites] Leukemia. 1989 Dec;3(12):866-70 [2555633.001]
  • [Cites] J Cell Biol. 1990 Mar;110(3):607-16 [1689730.001]
  • [Cites] Br J Haematol. 1990 Feb;74(2):161-8 [2156548.001]
  • [Cites] Am J Surg Pathol. 1990 Apr;14(4):305-16 [2157342.001]
  • [Cites] Science. 1990 Dec 21;250(4988):1690-4 [2270483.001]
  • [Cites] J Biol Chem. 1992 Feb 5;267(4):2582-7 [1733956.001]
  • [Cites] J Biol Chem. 1992 Jun 5;267(16):11408-16 [1597470.001]
  • [Cites] J Biol Chem. 1992 Dec 25;267(36):25889-97 [1464602.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Jan 15;90(2):679-82 [8421705.001]
  • [Cites] Science. 1994 Mar 4;263(5151):1281-4 [8122112.001]
  • [Cites] J Biol Chem. 1994 Apr 29;269(17):12999-3004 [8175719.001]
  • [Cites] Oncogene. 1994 Jun;9(6):1567-74 [8183550.001]
  • [Cites] Cancer Res. 2008 May 1;68(9):3389-95 [18451166.001]
  • [Cites] Br J Cancer. 2008 May 6;98(9):1536-9 [18414414.001]
  • [Cites] Curr Opin Genet Dev. 2008 Feb;18(1):87-96 [18406132.001]
  • [Cites] Cancer Sci. 2008 Jul;99(7):1319-25 [18452557.001]
  • [Cites] Hum Pathol. 2008 Jun;39(6):846-56 [18400254.001]
  • [Cites] Biochem Biophys Res Commun. 2008 Jul 25;372(2):351-5 [18501703.001]
  • [Cites] Blood. 2008 Jun 15;111(12):5496-504 [18385450.001]
  • [Cites] Cancer Res. 2008 Jul 1;68(13):4971-6 [18593892.001]
  • [Cites] Clin Cancer Res. 2008 Jul 1;14(13):4275-83 [18594010.001]
  • [Cites] Lung Cancer. 2008 Aug;61(2):163-9 [18242762.001]
  • [Cites] J Biol Chem. 2008 Sep 5;283(36):25036-45 [18599487.001]
  • [Cites] Blood. 2008 Oct 1;112(7):2965-8 [18660380.001]
  • [Cites] Nature. 2008 Oct 16;455(7215):930-5 [18724359.001]
  • [Cites] Nature. 2008 Oct 16;455(7215):967-70 [18923523.001]
  • [Cites] Nature. 2008 Oct 16;455(7215):971-4 [18923524.001]
  • [Cites] Nature. 2008 Oct 16;455(7215):975-8 [18923525.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Dec 16;105(50):19893-7 [19064915.001]
  • [Cites] Oncogene. 2008 Apr 24;27(19):2728-36 [17998938.001]
  • [Cites] Semin Radiat Oncol. 2007 Jan;17(1):62-9 [17185199.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jan 2;104(1):270-5 [17185414.001]
  • [Cites] J Neurochem. 2006 Dec;99(6):1470-9 [17230638.001]
  • [Cites] FEBS Lett. 2007 Feb 20;581(4):727-34 [17274988.001]
  • [Cites] Cancer Control. 2007 Apr;14(2):124-32 [17387297.001]
  • [Cites] Am J Surg Pathol. 2007 Apr;31(4):509-20 [17414097.001]
  • [Cites] Am J Clin Pathol. 2007 May;127(5):670-86 [17439828.001]
  • [Cites] Cancer Res. 2007 Apr 15;67(8):3529-34 [17440059.001]
  • [Cites] Nat Rev Cancer. 2007 May;7(5):345-56 [17457302.001]
  • [Cites] Cancer Res. 2007 May 1;67(9):4278-86 [17483340.001]
  • [Cites] Cancer Res. 2007 May 1;67(9):4408-17 [17483355.001]
  • [Cites] Leuk Lymphoma. 2007 May;48(5):1053-6 [17487757.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Jun 29;358(2):399-403 [17490616.001]
  • [Cites] Oncology (Williston Park). 2007 May;21(6):689-96; discussion 699-700, [17564326.001]
  • [Cites] Int J Biochem Cell Biol. 2007;39(7-8):1349-57 [17537667.001]
  • [Cites] J Mol Med (Berl). 2007 Aug;85(8):863-75 [17318615.001]
  • [Cites] Exp Hematol. 2007 Aug;35(8):1240-8 [17560012.001]
  • [Cites] Nature. 2007 Aug 2;448(7153):561-6 [17625570.001]
  • [Cites] Oncogene. 2007 Aug 16;26(38):5606-14 [17353907.001]
  • [Cites] Blood. 2007 Sep 1;110(5):1621-30 [17416736.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Oct 12;362(1):5-10 [17706593.001]
  • [Cites] Ann Oncol. 2007 Sep;18 Suppl 10:x25-31 [17761720.001]
  • [Cites] Blood. 2007 Oct 1;110(7):2600-9 [17537995.001]
  • [Cites] J Biol Chem. 2007 Sep 28;282(39):28683-90 [17681947.001]
  • [Cites] Nat Rev Drug Discov. 2007 Oct;6(10):834-48 [17853901.001]
  • [Cites] Cell Signal. 2007 Dec;19(12):2434-43 [17904822.001]
  • [Cites] Blood. 2007 Nov 1;110(9):3374-83 [17690253.001]
  • [Cites] Nat Med. 2007 Nov;13(11):1341-8 [17922009.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Dec 11;104(50):19936-41 [18077425.001]
  • [Cites] Cell. 2007 Dec 14;131(6):1190-203 [18083107.001]
  • [Cites] Mol Cancer Ther. 2007 Dec;6(12 Pt 1):3314-22 [18089725.001]
  • [Cites] Nat Rev Cancer. 2008 Jan;8(1):11-23 [18097461.001]
  • [Cites] J Thorac Oncol. 2008 Jan;3(1):13-7 [18166835.001]
  • [Cites] Nat Biotechnol. 2008 Jan;26(1):127-32 [18183025.001]
  • [Cites] Neuropsychopharmacology. 2008 Feb;33(3):685-700 [17487225.001]
  • [Cites] Recent Pat Anticancer Drug Discov. 2007 Jun;2(2):175-86 [18221061.001]
  • [Cites] Pediatr Clin North Am. 2008 Feb;55(1):97-120, x [18242317.001]
  • [Cites] Oncology (Williston Park). 2007 Dec;21(14):1696-706; discussion 1706-9, 1712, 1715 [18247017.001]
  • [Cites] Hum Pathol. 2008 Mar;39(3):410-9 [18261625.001]
  • [Cites] J Biol Chem. 2008 Feb 15;283(7):3743-50 [18070884.001]
  • [Cites] Curr Opin Oncol. 2008 Mar;20(2):162-75 [18300766.001]
  • [Cites] Leuk Res. 2008 Mar;32(3):383-93 [17720243.001]
  • [Cites] Neoplasia. 2008 Mar;10(3):298-302 [18320074.001]
  • [Cites] J Clin Oncol. 2008 Apr 1;26(10):1742-51 [18375904.001]
  • [Cites] J Clin Pathol. 2008 Apr;61(4):428-37 [17938159.001]
  • [Cites] Curr Opin Hematol. 2008 May;15(3):210-4 [18391787.001]
  • (PMID = 19275511.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA069129-10; United States / NCI NIH HHS / CA / R01 CA69129; United States / NCI NIH HHS / CA / R01 CA069129; United States / NCI NIH HHS / CA / CA21765; United States / NCI NIH HHS / CA / P30 CA021765; United States / NCI NIH HHS / CA / R01 CA069129-10
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Carrier Proteins; 0 / Cytokines; 0 / Enzyme Inhibitors; 0 / Nuclear Proteins; 117896-08-9 / nucleophosmin; 134034-50-7 / pleiotrophin; 137497-38-2 / midkine; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  • [Number-of-references] 304
  • [Other-IDs] NLM/ NIHMS105118; NLM/ PMC2780428
  •  go-up   go-down


56. Johnson NA, Leach S, Woolcock B, deLeeuw RJ, Bashashati A, Sehn LH, Connors JM, Chhanabhai M, Brooks-Wilson A, Gascoyne RD: CD20 mutations involving the rituximab epitope are rare in diffuse large B-cell lymphomas and are not a significant cause of R-CHOP failure. Haematologica; 2009 Mar;94(3):423-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD20 mutations involving the rituximab epitope are rare in diffuse large B-cell lymphomas and are not a significant cause of R-CHOP failure.
  • We sequenced this region and correlated the presence of mutations with CD20 protein expression and response to R-CHOP in patients with diffuse large B-cell lymphoma: 264 diagnostic biopsies and 15 biopsies taken at the time of relapse were successfully sequenced.
  • CD20 mutations involving the rituximab epitope were detected in only 1/264 (0.4%) and 1/15 (6%) of the biopsies taken at diagnosis and relapse, respectively.
  • Three patients had malignant cells that were CD20 protein-positive at diagnosis but CD20-negative at relapse.
  • Thus, CD20 mutations involving the rituximab epitope are rare in both de novo and relapsed diffuse large B-cell lymphoma, and do not represent a significant cause of R-CHOP resistance.
  • CD20 protein-negative relapses occur after R-CHOP therapy but their clinical relevance is unknown.
  • [MeSH-major] Antibodies, Monoclonal / metabolism. Antigens, CD20 / genetics. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Large B-Cell, Diffuse / drug therapy. Mutation
  • [MeSH-minor] Amino Acid Sequence. Antibodies, Monoclonal, Murine-Derived. Binding Sites, Antibody / genetics. Cyclophosphamide / administration & dosage. DNA Mutational Analysis. Doxorubicin / administration & dosage. Drug Resistance, Neoplasm / genetics. Epitopes / genetics. Female. Humans. Immunohistochemistry. Male. Middle Aged. Molecular Sequence Data. Neoplasm Recurrence, Local. Prednisone / administration & dosage. Rituximab. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cytometry. 2001 Apr 15;46(2):98-104 [11309819.001]
  • [Cites] Clin Cancer Res. 2008 Mar 1;14(5):1561-70 [18316581.001]
  • [Cites] Br J Haematol. 2002 Nov;119(2):412-6 [12406079.001]
  • [Cites] Eur J Haematol. 2003 May;70(5):330-2 [12694172.001]
  • [Cites] Oncogene. 2003 Oct 20;22(47):7359-68 [14576843.001]
  • [Cites] J Med Genet. 2004 Jul;41(7):508-17 [15235021.001]
  • [Cites] Clin Exp Immunol. 1984 Oct;58(1):183-92 [6332692.001]
  • [Cites] EMBO J. 1988 Mar;7(3):711-7 [2456210.001]
  • [Cites] Am J Pathol. 1990 Jun;136(6):1215-22 [1694056.001]
  • [Cites] Blood. 1994 Oct 15;84(8):2457-66 [7522629.001]
  • [Cites] Nucleic Acids Res. 1997 Jul 15;25(14):2745-51 [9207020.001]
  • [Cites] J Biol Chem. 1998 Jan 2;273(1):344-8 [9417086.001]
  • [Cites] Genome Res. 1998 Mar;8(3):195-202 [9521923.001]
  • [Cites] J Immunol. 1998 Oct 1;161(7):3242-8 [9759838.001]
  • [Cites] Clin Cancer Res. 1999 Mar;5(3):611-5 [10100713.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5027-33 [15955905.001]
  • [Cites] Biochemistry. 2005 Nov 22;44(46):15150-8 [16285718.001]
  • [Cites] Blood. 2006 Mar 15;107(6):2477-85 [16317097.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2006 Mar;14(1):18-23 [16540725.001]
  • [Cites] Blood. 2006 Sep 15;108(6):1975-8 [16705086.001]
  • [Cites] J Biol Chem. 2007 May 18;282(20):15073-80 [17395584.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):235-42 [11807147.001]
  • (PMID = 19211644.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 0 / Epitopes; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone
  • [Other-IDs] NLM/ PMC2649361
  •  go-up   go-down


57. Leonard JP, Coleman M, Ketas JC, Chadburn A, Furman R, Schuster MW, Feldman EJ, Ashe M, Schuster SJ, Wegener WA, Hansen HJ, Ziccardi H, Eschenberg M, Gayko U, Fields SZ, Cesano A, Goldenberg DM: Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results. Clin Cancer Res; 2004 Aug 15;10(16):5327-34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results.
  • PURPOSE: We conducted a single-center, dose-escalation study evaluating the safety, pharmacokinetics, and efficacy of epratuzumab, an anti-CD22 humanized monoclonal antibody, in patients with aggressive non-Hodgkin's lymphoma.
  • EXPERIMENTAL DESIGN: Epratuzumab was administered once weekly for 4 weeks at 120-1000-mg/m2 doses to 56 patients [most (n = 35) with diffuse large B-cell lymphoma].
  • RESULTS: Patients were heavily pretreated (median, 4 prior therapies), 25% received prior high-dose chemotherapy with stem cell transplant, and 84% had bulky disease (> or =5 cm).
  • In patients with diffuse large B-cell lymphoma, 15% had ORs.
  • Median duration of OR was 26.3 weeks, and median time to progression for responders was 35 weeks.
  • CONCLUSIONS: These data demonstrate that epratuzumab has a good safety profile and exerts antitumor activity in aggressive non-Hodgkin's lymphoma at doses of > or =240 mg/m2, thus warranting further evaluation in this clinical setting.
  • [MeSH-major] Antibodies, Monoclonal / toxicity. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal, Humanized. Antigens, CD / immunology. Antigens, Differentiation, B-Lymphocyte / immunology. Antineoplastic Agents / pharmacokinetics. Antineoplastic Agents / therapeutic use. Antineoplastic Agents / toxicity. Cell Adhesion Molecules / immunology. Combined Modality Therapy. Dose-Response Relationship, Drug. Female. Follow-Up Studies. Half-Life. Humans. Infusions, Intravenous. Lectins / immunology. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / pathology. Male. Middle Aged. Neoplasm Staging. Safety. Sialic Acid Binding Ig-like Lectin 2. Time Factors

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Cancer Res. 2004 Aug 15;10(16):5297-8 [15328164.001]
  • (PMID = 15328168.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / K23 RR16814-02
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antigens, CD; 0 / Antigens, Differentiation, B-Lymphocyte; 0 / Antineoplastic Agents; 0 / CD22 protein, human; 0 / Cell Adhesion Molecules; 0 / Lectins; 0 / Sialic Acid Binding Ig-like Lectin 2; 0 / epratuzumab
  •  go-up   go-down


58. Mey UJ, Olivieri A, Orlopp KS, Rabe C, Strehl JW, Gorschlueter M, Hensel M, Flieger D, Glasmacher AG, Schmidt-Wolf IG: DHAP in combination with rituximab vs DHAP alone as salvage treatment for patients with relapsed or refractory diffuse large B-cell lymphoma: a matched-pair analysis. Leuk Lymphoma; 2006 Dec;47(12):2558-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] DHAP in combination with rituximab vs DHAP alone as salvage treatment for patients with relapsed or refractory diffuse large B-cell lymphoma: a matched-pair analysis.
  • The addition of rituximab to chemotherapy in patients with diffuse large B-cell lymphoma (DLBCL) has been shown to improve outcome in first-line therapy.
  • However, in patients with relapsed or refractory disease, the value of adding rituximab to salvage chemotherapy is less clearly defined.
  • This study performed a matched-pair analysis of patients with relapsed or refractory DLBCL by comparing the combination of dexamethasone, high-dose cytarabine and cisplatin (DHAP) with rituximab to DHAP alone.
  • Sixty-seven patients with relapsed or refractory DLBCL were collected from two prospective phase II trials from Germany and Italy.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, B-Cell / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Salvage Therapy

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Lymphoma. 2006 Dec;47(12):2437-9 [17169786.001]
  • (PMID = 17169800.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 04079A1RDZ / Cytarabine; 4F4X42SYQ6 / Rituximab; 7S5I7G3JQL / Dexamethasone; Q20Q21Q62J / Cisplatin; DHAP protocol
  •  go-up   go-down


59. Cillessen SA, Reed JC, Welsh K, Pinilla C, Houghten R, Hooijberg E, Deurhof J, Castricum KC, Kortman P, Hess CJ, Ossenkoppele GJ, Meijer CJ, Oudejans JJ: Small-molecule XIAP antagonist restores caspase-9 mediated apoptosis in XIAP-positive diffuse large B-cell lymphoma cells. Blood; 2008 Jan 1;111(1):369-75
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small-molecule XIAP antagonist restores caspase-9 mediated apoptosis in XIAP-positive diffuse large B-cell lymphoma cells.
  • Clinical outcome in patients with primary nodal diffuse large B-cell lymphomas (DLBCLs) is correlated with expression of inhibitors of the intrinsic apoptosis pathway, including X-linked inhibitor of apoptosis protein (XIAP).
  • In this study, we investigated to see if the small-molecule XIAP antagonist 1396-12 induces cell death in cultured lymphoma cells of patients with DLBCL.
  • Treatment with this XIAP antagonist resulted in relief of caspase-3 inhibition and in induction of apoptosis in 16 of 20 tested DLBCL samples.
  • Sensitivity to the XIAP antagonist was observed in both chemotherapy-refractory and -responsive DLBCL, but did not affect peripheral blood mononuclear cells and tonsil germinal-center B cells from healthy donors.
  • These data indicate that the small-molecule XIAP antagonist can induce apoptosis in cultured DLBCL cells and therefore should be considered for possible development as a therapy for these patients.
  • In vitro sensitivity to the XIAP antagonist can be predicted based on biological markers, suggesting the possibility of predefining patients most likely to benefit from XIAP antagonist therapy.

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2000 May;6(5):1796-803 [10815900.001]
  • [Cites] Clin Cancer Res. 2007 Dec 1;13(23):7012-21 [18056177.001]
  • [Cites] Nat Med. 2000 Sep;6(9):1029-35 [10973324.001]
  • [Cites] J Biol Chem. 2000 Oct 20;275(42):32438-43 [10961984.001]
  • [Cites] Blood Cells Mol Dis. 2001 Jan-Feb;27(1):206-16 [11358381.001]
  • [Cites] Clin Cancer Res. 2001 Aug;7(8):2468-74 [11489828.001]
  • [Cites] Mol Pharmacol. 2001 Dec;60(6):1268-79 [11723234.001]
  • [Cites] J Pathol. 2002 Mar;196(3):307-15 [11857494.001]
  • [Cites] Cell Death Differ. 2003 Jul;10(7):853-5 [12815469.001]
  • [Cites] Int J Mol Med. 2003 Nov;12(5):705-8 [14532997.001]
  • [Cites] Leukemia. 2003 Nov;17(11):2081-9 [12970762.001]
  • [Cites] Blood. 2004 Jan 1;103(1):275-82 [14504078.001]
  • [Cites] Cancer Cell. 2004 Jan;5(1):25-35 [14749124.001]
  • [Cites] Blood. 1993 Jan 1;81(1):151-7 [8417786.001]
  • [Cites] J Virol. 1993 Apr;67(4):2168-74 [8445726.001]
  • [Cites] Science. 1994 Nov 4;266(5186):807-10 [7973635.001]
  • [Cites] Nature. 1996 Jan 25;379(6563):349-53 [8552191.001]
  • [Cites] EMBO J. 1996 Jun 3;15(11):2685-94 [8654366.001]
  • [Cites] Blood. 1997 Jun 1;89(11):3909-18 [9166827.001]
  • [Cites] Blood. 1997 Jul 1;90(1):244-51 [9207459.001]
  • [Cites] Nature. 1997 Jul 17;388(6639):300-4 [9230442.001]
  • [Cites] J Biol Chem. 1998 Apr 3;273(14):7787-90 [9525868.001]
  • [Cites] EMBO J. 1998 Apr 15;17(8):2215-23 [9545235.001]
  • [Cites] Blood. 1998 Nov 1;92(9):3152-62 [9787151.001]
  • [Cites] Cancer Res. 1999 Jul 1;59(13):3077-83 [10397248.001]
  • [Cites] J Immunol. 1999 Sep 1;163(5):2478-82 [10452983.001]
  • [Cites] EMBO J. 1999 Oct 1;18(19):5242-51 [10508158.001]
  • [Cites] J Biol Chem. 2004 Nov 12;279(46):48168-76 [15337764.001]
  • [Cites] Leukemia. 2004 Dec;18(12):1981-8 [15470488.001]
  • [Cites] Blood. 2005 Apr 1;105(7):2916-23 [15576477.001]
  • [Cites] Blood. 2005 May 15;105(10):4043-50 [15687241.001]
  • [Cites] J Clin Oncol. 2005 Jun 20;23(18):4117-26 [15867204.001]
  • [Cites] Blood. 2005 Sep 1;106(5):1742-8 [15914559.001]
  • [Cites] J Clin Oncol. 2005 Sep 10;23(26):6387-93 [16155024.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2005;:215-9 [16304383.001]
  • [Cites] J Pathol. 2006 Apr;208(5):714-23 [16400625.001]
  • [Cites] Br J Haematol. 2006 Aug;134(3):283-93 [16848771.001]
  • [Cites] Br J Haematol. 2007 Jan;136(1):38-47 [17062006.001]
  • [Cites] Exp Cell Res. 2000 Jul 10;258(1):223-35 [10912804.001]
  • (PMID = 17916749.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA081534; United States / NCI NIH HHS / CA / CA -113318; United States / NCI NIH HHS / CA / P01 CA-081534
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aniline Compounds; 0 / Antineoplastic Agents, Phytogenic; 0 / N-(6-((anilinocarbonyl)amino)-5-((anilinocarbonyl)((1-(4-cyclohexylbutyl)pyrrolidin-2-yl)methyl)amino)hexyl)-N-methyl-N'-phenylurea; 0 / Phenylurea Compounds; 0 / X-Linked Inhibitor of Apoptosis Protein; 0 / XIAP protein, human; 6PLQ3CP4P3 / Etoposide; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspase 7; EC 3.4.22.- / Caspase 9
  • [Other-IDs] NLM/ PMC2200818
  •  go-up   go-down


60. Winter JN: Prognostic markers in diffuse large B-cell lymphoma: Keys to the underlying biology. Curr Hematol Malig Rep; 2007 Oct;2(4):235-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic markers in diffuse large B-cell lymphoma: Keys to the underlying biology.
  • Prognostic markers identify subgroups of patients with similar risk profiles, helping to guide clinical care.
  • The addition of rituximab to conventional anthracycline-based chemotherapy has improved clinical outcomes for patients with diffuse large B-cell lymphoma (DLBCL).
  • Studies suggest that rituximab eliminates or modulates the significance of some markers (eg, BCL6 or BCL2), whereas other previously unimportant markers may emerge as significant prognostic indicators in the setting of treatment that now includes rituximab.
  • These changes in the prognostic profile are likely to reflect the impact of rituximab on survival pathways important to some groups of patients with DLBCL but not to other groups, and thereby may provide clues to the underlying biology of the disease.
  • They also identify subgroups of patients likely to benefit most from rituximab therapy and those who seem to garner no advantage from its inclusion in their treatment.
  • Studies of prognostic indicators in the context of modern therapy have the potential to identify new, rational therapeutic targets for this biologically diverse disease.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Biomarkers, Tumor / blood. DNA-Binding Proteins / blood. Immunologic Factors / therapeutic use. Lymphoma, Large B-Cell, Diffuse / mortality. Neoplasm Proteins / blood. Proto-Oncogene Proteins c-bcl-2 / blood. Tumor Suppressor Protein p53 / blood
  • [MeSH-minor] Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Cyclin-Dependent Kinase Inhibitor p21 / blood. Cyclin-Dependent Kinase Inhibitor p21 / physiology. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Genes, bcl-2. Genes, p53. Humans. Immunotherapy. L-Lactate Dehydrogenase / blood. Multicenter Studies as Topic. Prednisone / administration & dosage. Prognosis. Proto-Oncogene Proteins c-bcl-6. Randomized Controlled Trials as Topic. Retrospective Studies. Rituximab. Survival Analysis. Vincristine / administration & dosage. beta 2-Microglobulin / analysis

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1993 Sep 30;329(14 ):987-94 [8141877.001]
  • [Cites] Blood. 2004 Jan 1;103(1):275-82 [14504078.001]
  • [Cites] Blood. 2003 Dec 1;102(12):3871-9 [12933571.001]
  • [Cites] Nature. 2004 Dec 2;432(7017):635-9 [15577913.001]
  • [Cites] N Engl J Med. 1993 Apr 8;328(14):1002-6 [7680764.001]
  • [Cites] J Clin Oncol. 2005 Jun 20;23(18):4117-26 [15867204.001]
  • [Cites] Blood. 2005 Mar 1;105(5):1851-61 [15550490.001]
  • [Cites] J Exp Med. 2003 Sep 15;198(6):851-62 [12975453.001]
  • [Cites] Blood. 2007 Jun 1;109(11):4930-5 [17299093.001]
  • [Cites] J Clin Oncol. 2006 Feb 20;24(6):961-8 [16418494.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3207-12 [17360630.001]
  • [Cites] Cancer Res. 2005 Jan 1;65(1):264-76 [15665303.001]
  • [Cites] Blood. 1997 Jul 1;90(1):244-51 [9207459.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):7117-26 [15466208.001]
  • [Cites] Blood. 2003 Jun 1;101(11):4279-84 [12576316.001]
  • [Cites] Blood. 2006 Feb 15;107(4):1599-607 [16249378.001]
  • [Cites] Blood. 1996 Jan 1;87(1):265-72 [8547651.001]
  • [Cites] N Engl J Med. 2004 Apr 29;350(18):1828-37 [15115829.001]
  • [Cites] Blood. 2004 Nov 1;104(9):2635-42 [15226177.001]
  • [Cites] Nat Med. 2004 Dec;10 (12 ):1329-35 [15531890.001]
  • [Cites] Blood. 2008 Oct 15;112(8):3088-98 [18559976.001]
  • [Cites] Blood. 1996 Aug 1;88(3):1046-51 [8704213.001]
  • [Cites] Blood. 2007 May 1;109(9):3922-8 [17255358.001]
  • [Cites] Haematologica. 2006 May;91(5):715-6 [16670080.001]
  • [Cites] J Clin Oncol. 2006 Jul 1;24(19):3121-7 [16754935.001]
  • [Cites] Blood. 1998 Nov 1;92(9):3152-62 [9787151.001]
  • [Cites] Nature. 2000 Feb 3;403(6769):503-11 [10676951.001]
  • [Cites] J Clin Oncol. 1989 Oct;7(10):1518-27 [2674337.001]
  • [Cites] J Clin Oncol. 2007 Mar 1;25(7):805-12 [17327602.001]
  • [Cites] J Clin Oncol. 2006 Feb 20;24(6):995-1007 [16418498.001]
  • [Cites] Nat Immunol. 2005 Oct;6(10):1054-60 [16142238.001]
  • [Cites] Diagn Mol Pathol. 2007 Jun;16(2):61-72 [17525674.001]
  • [Cites] Blood. 2006 Nov 15;108(10):3514-9 [16868254.001]
  • [Cites] Blood. 2007 Mar 1;109(5):1857-61 [17105812.001]
  • [Cites] Am J Med. 1989 Aug;87(2):167-72 [2757057.001]
  • [Cites] Blood. 2007 Jul 1;110(1):339-44 [17379744.001]
  • [Cites] Haematologica. 2006 May;91(5):687-90 [16670073.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):235-42 [11807147.001]
  • [Cites] Blood. 2002 Feb 15;99(4):1136-43 [11830458.001]
  • [Cites] Blood. 2006 Jun 1;107(11):4207-13 [16449523.001]
  • [Cites] N Engl J Med. 2002 Jun 20;346(25):1937-47 [12075054.001]
  • [Cites] Blood. 2007 Apr 15;109(8):3409-16 [17179223.001]
  • [Cites] N Engl J Med. 1997 Aug 21;337(8):529-34 [9262496.001]
  • [Cites] Lancet Oncol. 2006 May;7(5):379-91 [16648042.001]
  • [Cites] Blood. 2001 Aug 15;98(4):945-51 [11493437.001]
  • (PMID = 20425375.001).
  • [ISSN] 1558-822X
  • [Journal-full-title] Current hematologic malignancy reports
  • [ISO-abbreviation] Curr Hematol Malig Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / BCL6 protein, human; 0 / Biomarkers, Tumor; 0 / CDKN1A protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / DNA-Binding Proteins; 0 / Immunologic Factors; 0 / Neoplasm Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Proto-Oncogene Proteins c-bcl-6; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53; 0 / beta 2-Microglobulin; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; EC 1.1.1.27 / L-Lactate Dehydrogenase; VB0R961HZT / Prednisone; CHOP protocol
  • [Number-of-references] 51
  •  go-up   go-down


61. Liu JK, Kan P, Schmidt MH: Diffuse large B-cell lymphoma presenting as a sacral tumor. Report of two cases. Neurosurg Focus; 2003 Aug 15;15(2):E10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffuse large B-cell lymphoma presenting as a sacral tumor. Report of two cases.
  • Primary lymphomas of the sacrum are rare tumors, reported only in a few cases in the literature.
  • The authors describe two patients with diffuse large B-cell lymphomas presenting as a sacral tumor.
  • In the first case a 52-year-old man presented with progressive back pain, bilateral radicular pain, and saddle block anesthesia secondary to a lytic, expansile soft-tissue mass.
  • In the second case a 64-year-old man presented with left-sided radicular pain, paresthesias, and progressive weakness due to a lytic soft-tissue mass in the left sacral ala extending into the left L-5 and S-1 foramina.
  • In both cases, an open biopsy procedure was performed after nondiagnostic examination of needle biopsy samples.
  • Histopathological examination showed evidence consistent with diffuse large B-cell lymphoma in both patients.
  • In the first case the disease was classified as Stage IAE, and the patient subsequently underwent four cycles of cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP)- and rituximab-based chemotherapy followed by consolidation radiotherapy.
  • In the second case the disease was also classified as Stage IAE, and the patient underwent CHOP-based chemotherapy and consolidation radiotherapy.
  • In both cases radiography demonstrated a decrease in size of the sacral lymphomas.
  • The authors review the clinical, radiological, and histological features of sacral lymphomas.
  • Lymphoma should be considered in the differential diagnosis of sacral tumors.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Large B-Cell, Diffuse / pathology. Sacrum / pathology. Spinal Neoplasms / pathology
  • [MeSH-minor] Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Biopsy. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Diagnosis, Differential. Doxorubicin / administration & dosage. Humans. Laminectomy. Low Back Pain / etiology. Magnetic Resonance Imaging. Male. Melanoma. Middle Aged. Neoplasm, Residual. Neoplasms, Multiple Primary. Prednisone / administration & dosage. Radiotherapy, Adjuvant. Reflex, Abnormal. Rituximab. Tomography, X-Ray Computed. Urinary Retention / etiology. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15350041.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


62. Avilés A, Neri N, Cuadra I, Alvarado I, Fernández R, Calva A, Huerta-Guzmán J: Lack of prognostic factors in follicular lymphoma. Leuk Lymphoma; 2003 Jan;44(1):143-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lack of prognostic factors in follicular lymphoma.
  • We performed a retrospective analysis of prognostic factors in patients with stage III and IV and high-tumor burden follicular lymphoma (FL) treated with uniform schedules and with a long term follow-up.
  • Eight-hundred and ten patients treated with intensive, anthracycline-based, chemotherapy and adjuvant radiotherapy to sites of initial bulky nodal disease were the basis of this analysis.
  • Age >60 years, presence of B symptoms, bulky disease, >2 extranodal sites involved, high levels of LDH and the presence of serous effusions all identified as worse prognostic factors in univariate analysis were subject to multivariate analysis.
  • Three factors remained significant: age >60 years old, presence of B symptoms and >2 extranodal sites involved and these were found to influence overall survival (OS) and progression-free survival (PFS).
  • We developed a score system and only two groups (score 0 and 1 and score 2 and 3) showed statistical significance in OS.
  • When the International Prognostic Index was applied to these patients, no statistical differences were observed in OS and PFS between the four groups.
  • Comparison of our results with multiple previous studies showed a lack of uniform prognostic factors and adequate prognostic classification could not be performed.
  • In conclusion, it is mandatory for multicentric international clinical analysis to define prognostic factors and search for a clinical classification, as in diffuse large B cell lymphoma, so as to define groups of FL for more aggressive or conservative therapy.
  • [MeSH-major] Lymphoma, Follicular / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Risk Assessment. Severity of Illness Index. Survival Analysis. Survival Rate

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12691155.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


63. Huang MQ, Pickup S, Nelson DS, Qiao H, Xu HN, Li LZ, Zhou R, Delikatny EJ, Poptani H, Glickson JD: Monitoring response to chemotherapy of non-Hodgkin's lymphoma xenografts by T(2)-weighted and diffusion-weighted MRI. NMR Biomed; 2008 Nov;21(10):1021-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Monitoring response to chemotherapy of non-Hodgkin's lymphoma xenografts by T(2)-weighted and diffusion-weighted MRI.
  • An effective method for in vivo detection of early therapeutic response of patients with non-Hodgkin's lymphoma would enable personalized clinical management of cancer therapy and facilitate the design of optimal treatment regimens.
  • This study evaluates the feasibility of T(2)-weighted MRI (T2WI) and diffusion-weighted MRI (DWI) for in vivo detection of response of human diffuse large B-cell lymphoma xenografts in severe combined immunodeficient mice to chemotherapy.
  • Each cycle of combination chemotherapy with cyclophosphamide, hydroxydoxorubicin, Oncovin, prednisone, and bryostatin 1 (CHOPB) was administered to tumor-carrying mice weekly for up to four cycles.
  • Both MRI methods produced high-resolution (0.1 x 0.1 x 1.0 mm(3)) maps of regional therapeutic response in the treated tumors based on local apparent diffusion coefficient and T(2).
  • The therapeutic response of the treated tumors detected by MRI was accompanied by changes in tumor cell density, proliferation and apoptosis revealed by histological studies performed upon completion of the longitudinal study.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Diffusion Magnetic Resonance Imaging / methods. Image Interpretation, Computer-Assisted / methods. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Animals. Cell Line, Tumor. Feasibility Studies. Humans. Mice. Prognosis. Reproducibility of Results. Sensitivity and Specificity. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2008 John Wiley & Sons, Ltd.
  • (PMID = 18988250.001).
  • [ISSN] 0952-3480
  • [Journal-full-title] NMR in biomedicine
  • [ISO-abbreviation] NMR Biomed
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01-CA101700
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  •  go-up   go-down


64. Sissolak G, Juritz J, Sissolak D, Wood L, Jacobs P: Lymphoma--emerging realities in sub-Saharan Africa. Transfus Apher Sci; 2010 Apr;42(2):141-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphoma--emerging realities in sub-Saharan Africa.
  • Substantial geographical differences exist for Hodgkin and other lymphoproliferative disorders with these having previously been documented in a report from the lymphoma reclassification project.
  • Median age was 55.2 years 61% were males, 10% had Hodgkin lymphoma and, overall, constitutional symptoms were present in 20%.
  • Prior to referral 19% had received chemotherapy and a further 20% some form of irradiation.
  • Median survival in hairy cell leukaemia (n=14), chronic lymphocytic leukaemia-small lymphocytic lymphoma (n=103), Hodgkin (n=41) and follicular lymphoma (n=59) was not reached at the time of analysis and exceeded 36 months.
  • This was followed by 32 months for those with mantle cell (n=7), splenic (n=2) and extranodal marginal cell (n=11), 24 months for T-cell lymphomas (n=24), 20 months for diffuse large B-cell variants (n=88) but only 12 months for the aggressive tumours exemplified by Burkitt (n=7) and lymphoblastic subtypes (n=6).
  • Adverse factors were constitutional symptoms, prior treatment with chemotherapy, intermediate or high-risk scores as defined by the international prognostic index, histologic grading and certain anatomical sites of primary tumour.
  • In contrast gender, staging by Rye or Rai classification, retroviral infection and prior treatment with radiotherapy were without effect.
  • Overall survival at 3 years in each category was compared to the curve for the entire cohort and was 100% in hairy cell leukaemia receiving two chlorodeoxyadenosine and greater than 88% in Hodgkin lymphoma treated according to the German study group protocols (p=0.0004).
  • Corresponding figures for chronic lymphocytic leukaemia-small lymphocytic lymphoma were 82% (p=0.0006), follicular lymphoma 71% (p=0.060), peripheral T-cell lymphoma 43% (p=0.0156), diffuse large B-cell lymphoma 39% (p<0.0001), aggressive tumours 25% (p=0.0002) and for the indolent categories including mantle cell, splenic and extra nodal marginal cell lymphomas 22% (p=0.2023).
  • Outcome argues in favour of patient management by a multidisciplinary team implicit in which are standardised protocols for diagnosis, staging and treatment.
  • [MeSH-major] Lymphoma

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010. Published by Elsevier Ltd.
  • (PMID = 20149748.001).
  • [ISSN] 1473-0502
  • [Journal-full-title] Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
  • [ISO-abbreviation] Transfus. Apher. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


65. Mafune KI, Tanaka Y, Suda Y, Izumo T: Outcome of patients with non-Hodgkin's lymphoma of the stomach after gastrectomy: clinicopathologic study and reclassification according to the revised European-American lymphoma classification. Gastric Cancer; 2001;4(3):137-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of patients with non-Hodgkin's lymphoma of the stomach after gastrectomy: clinicopathologic study and reclassification according to the revised European-American lymphoma classification.
  • BACKGROUND: The best treatment for patients with non-Hodgkin's lymphoma (NHL) of the stomach is still uncertain.
  • The revised European-American lymphoma (REAL) classification has helped to define new, potentially more appropriate classification schemes for gastric lymphomas.
  • METHODS: Fifty-one resected gastric lymphomas were reclassified according to the REAL classification, and the efficacy of multimodal treatment was examined retrospectively.
  • The principal treatment plan consisted of:.
  • (1) surgical resection of the stomach with lymph node dissection, followed by (2) systemic chemotherapy, mainly using the cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) regimen.
  • RESULTS: According to the Ann Arbor classification, 27 patients had stage IE, 19 had stage IIE, and 5 had stage IV NHL.
  • Using the REAL classification, we diagnosed diffuse large B-cell lymphoma (DLBL) in 23 patients, marginal zone B-cell (low-grade mucosa-associated lymphoid tissue [MALT]-type) lymphoma in 22, follicle center lymphoma in 4, mantle cell lymphoma in 1, and peripheral T-cell lymphoma in 1 patient.
  • Nine of the 51 patients relapsed, and 8 patients with DLBL died of cancer.
  • Univariate analysis indicated that the tumor histology (according to the REAL classification), depth of invasion, degree of nodal involvement, Ann Arbor staging, and chemotherapy had an impact on patient outcome (P = 0.0018; P = 0.0002; P = 0.0308; P = 0.0016, and P = 0.0118, respectively).
  • CONCLUSIONS: These data reveal that gastric NHL, especially of the low-grade MALT-type, often remains localized and has a good prognosis after surgery.
  • The REAL classification was useful for classifying new categories of NHL, including the MALT-type, in the clinical setting, and for determining the optimal treatment modality for gastric NHL.
  • [MeSH-major] Lymphoma, Non-Hodgkin / pathology. Neoplasm Staging / methods. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11760079.001).
  • [ISSN] 1436-3291
  • [Journal-full-title] Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  • [ISO-abbreviation] Gastric Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


66. Babu RD, Damodaran D: Primary malignant intestinal lymphoma. Trop Gastroenterol; 2001 Apr-Jun;22(2):113-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary malignant intestinal lymphoma.
  • BACKGROUND: Primary malignant intestinal lymphoma is an uncommon gut malignancy.
  • METHODS: Our experience of seven patients with a diagnosis of primary intestinal lymphoma over a period of 22 months is presented here.
  • Imaging modalities revealed abnormality in all the cases but were rarely diagnostic.
  • Most patients presented at an early stage when the disease was confined to the bowel.
  • The commonest site was the large intestine (42.6%) especially the caecum.
  • Diffuse large cell, high grade tumour were found to be the commonest histological type.
  • Surgery followed by adjuvant chemotherapy gave good results.
  • [MeSH-major] Intestinal Neoplasms / diagnosis. Lymphoma, Non-Hodgkin / diagnosis
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / therapeutic use. Barium Sulfate. Colectomy / methods. Combined Modality Therapy. Endoscopy, Gastrointestinal. Enema. Female. Humans. Image Enhancement / methods. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Primary malignant lymphoma.
  • Hazardous Substances Data Bank. Barium sulfate .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11552483.001).
  • [ISSN] 0250-636X
  • [Journal-full-title] Tropical gastroenterology : official journal of the Digestive Diseases Foundation
  • [ISO-abbreviation] Trop Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 25BB7EKE2E / Barium Sulfate
  •  go-up   go-down


67. Nagai H, Yano T, Watanabe T, Uike N, Okamura S, Hanada S, Kawano F, Sunami K, Inoue N, Sawamura M, Nishiura T, Hotta T, Horibe K: Remission induction therapy containing rituximab markedly improved the outcome of untreated mature B cell lymphoma. Br J Haematol; 2008 Dec;143(5):672-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Remission induction therapy containing rituximab markedly improved the outcome of untreated mature B cell lymphoma.
  • Many controlled clinical trials have proven that rituximab improves the clinical outcome of patients with mature B cell lymphoma.
  • This study was conducted to assess the contribution of rituximab in the actual clinical practice.
  • Patients with newly diagnosed mature B cell lymphoma treated at 20 National Hospital Organization hospitals from January 2000 to December 2004 were consecutively registered.
  • Rituximab was approved in September 2002 for indolent B cell lymphoma and in September 2003 for aggressive B cell lymphoma in Japan.
  • The patients were divided into two groups depending on whether they received induction therapy containing rituximab.
  • Of these, 762 were diagnosed as diffuse large B cell lymphoma (DLBCL) and 215 as follicular lymphoma (FL).
  • PFS and OS were markedly improved in the rituximab group compared with the non-rituximab group in patients with DLBCL (both P < 0.001) and in patients with FL (P < 0.001 and P = 0.003 respectively).
  • Rituximab, when used for remission induction therapy, significantly improved the clinical outcome of the mature B cell lymphoma patient in actual clinical practice.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, B-Cell / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal, Murine-Derived. Disease-Free Survival. Female. Humans. Kaplan-Meier Estimate. Lymphoma, Follicular / drug therapy. Lymphoma, Follicular / mortality. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / mortality. Male. Middle Aged. Proportional Hazards Models. Remission Induction / methods. Retrospective Studies. Rituximab. Survival Rate. Treatment Outcome. Young Adult

  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18950459.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


68. Decaudin D, Marszak FB, Couturier J, Mathiot C, Martin A, Némati F, Lantz O, Santo Jd, Arnaud P, Bordier V, Vincent-Salomon A, Poupon MF: High efficacy of combined rituximab and gemcitabine on Epstein-Barr virus-associated human B-cell lymphoma obtained after Hodgkin's xenograft in immunodeficient mice. Anticancer Drugs; 2006 Jul;17(6):685-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High efficacy of combined rituximab and gemcitabine on Epstein-Barr virus-associated human B-cell lymphoma obtained after Hodgkin's xenograft in immunodeficient mice.
  • The objectives were to characterize an Epstein-Barr virus-associated human B-cell lymphoma obtained from Hodgkin's xenograft, and to evaluate the in-vivo combination of rituximab and/or gemcitabine.
  • A lymph node biopsy sample from a patient with Hodgkin's disease was xenografted into Rag gamma(c)(-/-) mice.
  • Histologic features of the patient's biopsy concluded on classical CD15/CD30-positive Hodgkin's disease without expression of Epstein-Barr virus proteins.
  • In contrast, morphologic and immunophenotypic examination of the xenograft showed diffuse proliferation of large B cells with high Epstein-Barr virus protein expression.
  • Comparative genomic hybridization showed a normal pattern in the first case and a gain of chromosomal 12 in the xenografted tumor.
  • Altogether, these results indicate that the xenograft grew from the patient's Epstein-Barr virus-infected B-lymphoid cells and could be assimilated to posttransplant lymphoproliferative disease.
  • In-vivo treatments of xenografted tumors showed significant tumor growth inhibition induced either by rituximab or gemcitabine alone and an impressive efficacy of combined treatment.
  • This result therefore indicates that combined rituximab and gemcitabine could be an alternative approach in patients with posttransplant lymphoproliferative disease.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Epstein-Barr Virus Infections / drug therapy. Herpesvirus 4, Human / pathogenicity. Hodgkin Disease / drug therapy. Lymphoma, B-Cell / drug therapy
  • [MeSH-minor] Adult. Animals. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Biopsy. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Female. Homeodomain Proteins / genetics. Homeodomain Proteins / physiology. Humans. Immunoglobulin Heavy Chains / genetics. Immunoglobulin Heavy Chains / metabolism. Lymph Nodes / pathology. Lymph Nodes / transplantation. Lymph Nodes / virology. Lymphoma, Large B-Cell, Diffuse / complications. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / virology. Male. Mice. Mice, Knockout. Mice, SCID. Nucleic Acid Hybridization. Rituximab. Sialic Acid Binding Ig-like Lectin 2 / metabolism. Transplantation, Heterologous. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16917214.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Homeodomain Proteins; 0 / Immunoglobulin Heavy Chains; 0 / Sialic Acid Binding Ig-like Lectin 2; 0W860991D6 / Deoxycytidine; 128559-51-3 / RAG-1 protein; 4F4X42SYQ6 / Rituximab; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


69. Hong J, Kim AJ, Park JS, Lee SH, Lee KC, Park J, Sym SJ, Cho EK, Shin DB, Lee JH: Additional rituximab-CHOP (R-CHOP) versus involved-field radiotherapy after a brief course of R-CHOP in limited, non-bulky diffuse large B-cell lymphoma: a retrospective analysis. Korean J Hematol; 2010 Dec;45(4):253-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Additional rituximab-CHOP (R-CHOP) versus involved-field radiotherapy after a brief course of R-CHOP in limited, non-bulky diffuse large B-cell lymphoma: a retrospective analysis.
  • BACKGROUND: Standard treatment for stage I or non-bulky stage II diffuse large B-cell lymphoma (DLBCL) has been either a brief course of chemotherapy plus involved-field radiotherapy (IFRT) or prolonged cycles of chemotherapy.
  • The introduction of rituximab has necessitated re-evaluation of the treatment for limited disease (LD) DLBCL.
  • METHODS: Thirty-nine LD DLBCL patients (median age, 52 years; range, 24-85) treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) were retrospectively analyzed.
  • Treatment outcomes were evaluated, and toxicity, event-free survival (EFS), and overall survival (OS) were compared according to the treatment and risk factors.
  • Severe neutropenia and neutropenic fever were more frequent in patients treated with R-CHOP alone, with 1 treatment-related mortality.
  • CONCLUSION: The difference in outcomes between the 2 treatment options was not significant.
  • Analysis of treatment outcomes suggested that baseline characteristics and expected toxicities should be considered in LD DLBCL treatment.
  • Further studies are needed to define the optimal treatment in the rituximab era.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2008 May 10;26(14):2258-63 [18413640.001]
  • [Cites] J Clin Oncol. 2007 Mar 1;25(7):787-92 [17228021.001]
  • [Cites] J Clin Oncol. 1989 Sep;7(9):1295-302 [2788716.001]
  • [Cites] Ann Intern Med. 1987 Jul;107(1):25-30 [3296898.001]
  • [Cites] Radiother Oncol. 1985 Nov;4(3):211-23 [3909240.001]
  • [Cites] Cancer. 1983 Jul 1;52(1):1-7 [6406037.001]
  • [Cites] N Engl J Med. 1998 Jul 2;339(1):21-6 [9647875.001]
  • [Cites] Ann Oncol. 1998 Jul;9(7):717-20 [9739436.001]
  • [Cites] Cancer. 1980 Dec 1;46(11):2356-9 [7002279.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] J Clin Oncol. 2002 Jan 1;20(1):197-204 [11773170.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):235-42 [11807147.001]
  • [Cites] Blood. 2003 Jul 1;102(1):324-7 [12649152.001]
  • [Cites] J Clin Oncol. 2004 Aug 1;22(15):2982-4 [15210737.001]
  • [Cites] J Clin Oncol. 2004 Aug 1;22(15):3032-8 [15210738.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2004;:221-36 [15561685.001]
  • [Cites] N Engl J Med. 2005 Mar 24;352(12):1197-205 [15788496.001]
  • [Cites] Lancet Oncol. 2006 May;7(5):379-91 [16648042.001]
  • [Cites] BMC Cancer. 2010;10:321 [20569446.001]
  • (PMID = 21253427.001).
  • [ISSN] 2092-9129
  • [Journal-full-title] The Korean journal of hematology
  • [ISO-abbreviation] Korean J Hematol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC3023051
  • [Keywords] NOTNLM ; Diffuse large B-cell lymphoma / Radiotherapy / Rituximab
  •  go-up   go-down


70. Foran JM: Antibody-based therapy of non-Hodgkin's lymphoma. Best Pract Res Clin Haematol; 2002 Sep;15(3):449-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antibody-based therapy of non-Hodgkin's lymphoma.
  • Monoclonal antibodies (mAb) have dramatically advanced our ability to treat non-Hodgkin's lymphoma (NHL), and there has been a virtual explosion of clinical data regarding their use.
  • Rituximab is a humanized anti-CD20 mAb and has significant single agent activity in follicular lymphoma, and to a lesser extent in mantle-cell and diffuse large B-cell lymphoma (DLCL).
  • Rituximab appears to have synergistic activity with cytotoxic chemotherapy and the combination has recently demonstrated improved rates of complete remission (CR) and overall survival in older patients with DLCL.
  • Alemtuzumab (Campath-1H) is a humanized mAb targeting CD52 and has recently been approved in the USA for the treatment of fludarabine-refractory B-cell chronic lymphocytic leukaemia.
  • Impressive activity has also been demonstrated in T-cell prolymphocytic leukaemia and mycosis fungoides.
  • The radioconjugated anti-CD20 mAbs ibritumomab tiuxetan and I131-tositumomab also have impressive clinical activity in low-grade B-cell NHL, and the former has demonstrated superior CR rates to rituximab.
  • Myelosuppression is more significant however, and their place in the treatment algorithm remains to be clearly defined.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Antibodies, Monoclonal, Humanized. Antibodies, Monoclonal, Murine-Derived. Antibodies, Neoplasm / adverse effects. Antibodies, Neoplasm / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Humans. Immunoconjugates / adverse effects. Immunoconjugates / therapeutic use. Rituximab. Treatment Outcome

  • Hazardous Substances Data Bank. RITUXIMAB .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12468399.001).
  • [ISSN] 1521-6926
  • [Journal-full-title] Best practice & research. Clinical haematology
  • [ISO-abbreviation] Best Pract Res Clin Haematol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antibodies, Neoplasm; 0 / Immunoconjugates; 3A189DH42V / alemtuzumab; 4F4X42SYQ6 / Rituximab
  • [Number-of-references] 86
  •  go-up   go-down


71. Ramadan KM, Shenkier T, Sehn LH, Gascoyne RD, Connors JM: A clinicopathological retrospective study of 131 patients with primary bone lymphoma: a population-based study of successively treated cohorts from the British Columbia Cancer Agency. Ann Oncol; 2007 Jan;18(1):129-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A clinicopathological retrospective study of 131 patients with primary bone lymphoma: a population-based study of successively treated cohorts from the British Columbia Cancer Agency.
  • BACKGROUND: Primary bone lymphoma (PBL) is a distinct clinicopathological entity.
  • Although PBL has been reviewed in several small studies, few reflect recent improvements in primary treatment.
  • METHODS: We used the British Columbia Cancer Agency Lymphoid Cancer Database to identify all patients with PBL (1983-2005).
  • RESULTS: We identified 131 patients with a median age of 63 years (18-87).
  • One third had disease in long bones and another one third had disease in the spine, of which half presented with spinal cord compression.
  • Patients with diffuse large-cell lymphoma (DLCL) (n=103, 79%) had 5- and 10-year overall survivals (OS) of 62% and 41%, respectively.
  • Multivariate analysis identified three prognostic groups: age<60 with International Prognostic Index (IPI) 1-3 (n=43), age>or=60 with IPI 0-3 (n=23) and age>or=60 with IPI 4-5 (n=33), with markedly different 5-year OS of 90%, 61% and 25%, respectively (P<0.0001).
  • The 3-year progression-free survival in patients who received rituximab plus combination chemotherapy with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOPR) chemotherapy was 88% compared with 52% in those who received CHOP-like chemotherapy without rituximab (P=0.005).
  • The 10-year OS for those with advanced-stage disease who received irradiation plus chemotherapy was 25% versus 56% for those who received chemotherapy alone (P=0.025).
  • Patients received irradiation if spinal cord compression was present or residual disease at the end of chemotherapy was thought to require it.
  • CONCLUSIONS: PBL is usually of DLCL type and has an improved outcome with CHOPR.

  • Genetic Alliance. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17018705.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone
  •  go-up   go-down


72. Saito T, Tamaru J, Kayao J, Kuzuu Y, Wakita H, Mikata A: Cytomorphologic diagnosis of malignant lymphoma arising in the heart: a case report. Acta Cytol; 2001 Nov-Dec;45(6):1043-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytomorphologic diagnosis of malignant lymphoma arising in the heart: a case report.
  • BACKGROUND: Primary malignant lymphoma of the heart is extremely rare.
  • Because its clinical signs and symptoms are typically nonspecific, it is often very difficult to detect cardiac involvement while the patient is alive.
  • We describe a case of malignant lymphoma involving predominantly the heart and pericardium and diagnosed by pericardiac effusion cytology antemortem.
  • Diagnosis of diffuse large B-cell lymphoma was made by cytomorphologic examination and flow cytometry of the tumor cells obtained from the effusion.
  • Although chemotherapy was instituted immediately, the patient died of progressive heart failure.
  • Diffuse large B-cell lymphoma predominantly involving the intracardiovascular region was confirmed at autopsy.
  • CONCLUSION: From the experience in this case, we conclude that cytopathologic examination of sonographically guided aspiration of the cardiovascular region is very useful for antemortem diagnosis of primary malignant lymphoma of the heart.
  • [MeSH-major] Heart Neoplasms / diagnosis. Lymphoma, B-Cell / diagnosis. Lymphoma, Large B-Cell, Diffuse / diagnosis
  • [MeSH-minor] Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Drug Therapy, Combination. Echocardiography. Fatal Outcome. Female. Flow Cytometry. Heart Failure / etiology. Heart Failure / pathology. Humans. Immunophenotyping. Pericardial Effusion / diagnosis. Prednisone / administration & dosage. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11726101.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone
  •  go-up   go-down


73. Ang MK, Hee SW, Quek R, Yap SP, Loong S, Tan L, Tao M, Lim ST: Presence of a high-grade component in gastric mucosa-associated lymphoid tissue (MALT) lymphoma is not associated with an adverse prognosis. Ann Hematol; 2009 May;88(5):417-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Presence of a high-grade component in gastric mucosa-associated lymphoid tissue (MALT) lymphoma is not associated with an adverse prognosis.
  • Gastric mucosa-associated lymphoid tissue (MALT) lymphoma and diffuse large B cell lymphoma (DLBCL) show a spectrum of disease characterized by varying proportions of low-grade and high-grade components.
  • While the natural history and optimum treatment for low-grade gastric MALT lymphoma and DLBCL is well established, the prognosis and optimal treatment of patients with both low- and high-grade components is not well established.
  • The purpose of our study was to evaluate the clinical characteristics, survival outcomes, and prognostic factors of patients with gastric MALT lymphoma and gastric DLBCL.
  • A retrospective review of patients with gastric MALT lymphoma, gastric DLBCL, or MALT lymphoma with a high-grade component treated at our centers from 1994 to 2006 was performed.
  • Patients were divided into three categories: "pure MALT lymphoma," "MALT lymphoma with high-grade component" (mixed), and "pure DLBCL."
  • Seventy-six patients were included in our study-26 with pure MALT, 22 with MALT with high-grade component ("mixed"), and 28 with pure DLBCL.
  • Pure MALT lymphoma and mixed lymphoma patients had similar clinical characteristics, whereas pure DLBCL patients had less favorable disease characteristics with significantly poorer performance status, higher number of extranodal sites of disease, higher stage, and larger proportion of bone marrow involvement and international prognostic index (IPI) scores compared with mixed lymphoma.
  • The majority of mixed lymphoma (72.7%) and DLBCL patients (71.4%) were treated with chemotherapy.
  • Of patients receiving chemotherapy, a higher proportion of mixed lymphoma and DLBCL patients received anthracycline-based combination chemotherapy regimens compared with MALT lymphoma (73% vs 71% vs 8%) whereas the proportion of mixed lymphoma and DLBCL patients was similar (p = 0.919).
  • The 5-year overall survival was 78% for MALT lymphoma, 84% for mixed lymphoma, and 45% for DLBCL.
  • On univariate analysis, DLBCL histology, age, performance status, serum albumin, lactate dehydrogenase, bone marrow, number of extranodal sites, stage, and IPI score were prognostic for inferior survival.
  • On multivariate analysis, DLBCL histology remained significantly prognostic for inferior survival, independent of chemotherapy regimen (hazard ratio (HR) 6.66, 95% confidence interval (CI) 2.01-21.41, p = 0.001).
  • Other factors prognostic for inferior survival were serum albumin <37 g/L (HR 3.22, 95% CI 1.11-13.22, p = 0.034) and treatment with non-cyclophosphamide, doxorubicin, vincristine, and prednisolone chemotherapy (HR 4.89, 95% CI 1.67-14.36, p = 0.004).
  • In conclusion, the clinical characteristics of mixed histology MALT lymphoma are similar to low-grade MALT lymphoma and significantly different from pure DLBCL.
  • The prognosis of mixed histology MALT lymphoma is significantly better than pure DLBCL, independent of IPI and chemotherapy regimen, and pure DLBCL histology is independently prognostic of inferior survival outcome.
  • [MeSH-major] Lymphoma, B-Cell, Marginal Zone / diagnosis
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers / blood. Bone Marrow Neoplasms. Follow-Up Studies. Histological Techniques. Humans. L-Lactate Dehydrogenase / analysis. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / mortality. Middle Aged. Predictive Value of Tests. Prognosis. Retrospective Studies. Serum Albumin / analysis. Survival Analysis

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18777110.001).
  • [ISSN] 1432-0584
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Serum Albumin; EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


74. Saif MW, Khubchandani S, Walczak M: Secondary pancreatic involvement by a diffuse large B-cell lymphoma presenting as acute pancreatitis. World J Gastroenterol; 2007 Sep 28;13(36):4909-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secondary pancreatic involvement by a diffuse large B-cell lymphoma presenting as acute pancreatitis.
  • Diffuse large B-cell lymphoma is the most common type of non-Hodgkin's lymphoma.
  • More than 50% of patients have some site of extra-nodal involvement at diagnosis, including the gastrointestinal tract and bone marrow.
  • However, a diffuse large B-cell lymphoma presenting as acute pancreatitis is rare.
  • A 57-year-old female presented with abdominal pain and matted lymph nodes in her axilla.
  • She was admitted with a diagnosis of acute pancreatitis.
  • Abdominal computed tomography (CT) scan showed diffusely enlarged pancreas due to infiltrative neoplasm and peripancreatic lymphadenopathy.
  • Biopsy of the axillary mass revealed a large B-cell lymphoma.
  • The patient was classified as stage IV, based on the Ann Arbor Classification, and as having a high-risk lymphoma, based on the International Prognostic Index.
  • She was started on chemotherapy with CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone).
  • Within a week after chemotherapy, the patient's abdominal pain resolved.
  • A literature search revealed only seven cases of primary involvement of the pancreas in B-cell lymphoma presenting as acute pancreatitis.
  • However, only one case of secondary pancreatic involvement by B-cell lymphoma presenting as acute pancreatitis has been published.
  • Both cases responded well to chemotherapy.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / diagnosis. Pancreatic Neoplasms / diagnosis. Pancreatitis / etiology


75. Woehrer S, Hejna M, Skrabs C, Drach J, Zielinski CC, Jaeger U, Raderer M: Rituximab, Ara-C, dexamethasone and oxaliplatin is safe and active in heavily pretreated patients with diffuse large B-cell lymphoma. Oncology; 2005;69(6):499-502
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rituximab, Ara-C, dexamethasone and oxaliplatin is safe and active in heavily pretreated patients with diffuse large B-cell lymphoma.
  • OBJECTIVE: Patients with relapsed diffuse large B-cell lymphoma (DLBCL) who are either not suitable for stem cell transplantation or suffer from relapsed disease after standard second-line chemotherapy face a dismal prognosis.
  • Most of them have a reduced performance status and do not tolerate intensive chemotherapy.
  • METHODS: Twenty patients with relapsed DLBCL were given rituximab 375 mg/m(2) intravenously on day 1, Ara-C 2 x 1,000 mg intravenously on day 2, dexamethasone 40 mg intravenously on days 1-4, and oxaliplatin 130 mg/m(2) intravenously over 2 h on day 3 (R-ADOx).
  • RESULTS: Five patients (25%) achieved a complete remission, 9 (45%) had a partial response , 2 (10%) had stable disease with improvement in performance status, while 4 patients (20%) progressed.
  • In addition, it displays impressive therapeutic activity given the highly unfavorable patient characteristics and should be further investigated for treatment of DLBCL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, B-Cell / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Antimetabolites, Antineoplastic / administration & dosage. Cytarabine / administration & dosage. Dexamethasone / administration & dosage. Female. Humans. Male. Middle Aged. Organoplatinum Compounds / administration & dosage. Retrospective Studies. Rituximab. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16424679.001).
  • [ISSN] 0030-2414
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antimetabolites, Antineoplastic; 0 / Organoplatinum Compounds; 04079A1RDZ / Cytarabine; 04ZR38536J / oxaliplatin; 4F4X42SYQ6 / Rituximab; 7S5I7G3JQL / Dexamethasone
  •  go-up   go-down


76. Fisher RI: Diffuse large-cell lymphoma. Ann Oncol; 2000;11 Suppl 1:29-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffuse large-cell lymphoma.
  • BACKGROUND: New treatments are desperately needed to improve the results obtained using CHOP chemotherapy for patients with diffuse large cell lymphoma.
  • In order to develop successful new strategies we need to understand why prior promising therapies have failed and to develop new testable hypotheses based on our current knowledge.
  • PATIENTS AND METHODS: The International Non-Hodgkin's Lymphoma Prognostic Factors Index has provided us with a methodology to compare the expected prognosis of patients on different clinical trials.
  • Many prior, apparent improvements in treatment outcome can now be attributed to the inclusion of patients with better prognoses.
  • 1) the identification of new active drugs for the treatment of lymphoma, 2) the use of colony stimulating factors to allow dose escalation of the active myelotoxic drugs, 3) the use of strategies which may overcome the problem of resistance to chemotherapy, 4) the combination of monoclonal antibodies with combination chemotherapy and 5) ablative chemotherapy with autologous stem-cell support.
  • CONCLUSIONS: Based on all of the available data, the North American Lymphoma Intergroup has developed the hypothesis that high-intermediate and high risk patients with aggressive lymphoma who receive full course standard induction therapy will benefit form the addition of high dose therapy and has antedated a clinical trial testing that hypothesis.

  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10707775.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 21
  •  go-up   go-down


77. Bollen P, Bourgain C, Van Berlaer G, Duville L, Vandenplas Y: Non-Hodgkin lymphoma presenting as a solitary rectal polyp. J Pediatr Gastroenterol Nutr; 2000 Aug;31(2):193-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin lymphoma presenting as a solitary rectal polyp.
  • [MeSH-major] Intestinal Polyps / pathology. Lymphoma, Non-Hodgkin / diagnosis. Rectum / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Child. Colonoscopy. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Gastrointestinal Hemorrhage. Humans. Hydrocortisone / administration & dosage. Immunophenotyping. Intestinal Mucosa / pathology. Leucovorin / administration & dosage. Lymphoma, B-Cell / diagnosis. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / pathology. Male. Methotrexate / administration & dosage. Methylprednisolone / administration & dosage. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • Hazardous Substances Data Bank. METHYLPREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10941976.001).
  • [ISSN] 0277-2116
  • [Journal-full-title] Journal of pediatric gastroenterology and nutrition
  • [ISO-abbreviation] J. Pediatr. Gastroenterol. Nutr.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q573I9DVLP / Leucovorin; WI4X0X7BPJ / Hydrocortisone; X4W7ZR7023 / Methylprednisolone; YL5FZ2Y5U1 / Methotrexate; COPADEM protocol
  •  go-up   go-down


78. Ganjoo K, Advani R, Mariappan MR, McMillan A, Horning S: Non-Hodgkin lymphoma of the breast. Cancer; 2007 Jul 1;110(1):25-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin lymphoma of the breast.
  • BACKGROUND: Primary lymphoma of the breast has been reported to have a high local and central nervous system recurrence (CNS) rate, suggesting the need for consolidation radiotherapy and CNS prophylaxis.
  • METHODS: In all, 37 patients with lymphoma involving the breast at initial diagnosis and managed at Stanford University from 1981-2005 were included.
  • Diagnostic tissue biopsies were obtained either from the breast mass or an involved lymph node.
  • Treatment and response data, patterns of recurrence, and outcomes were reviewed.
  • RESULTS: Diffuse large B cell lymphoma (DLBCL) was the most common histologic subtype seen in 18 of 37 (49%) patients.
  • Four (11%) patients presented with bilateral breast involvement, with only 1 patient presenting with CNS disease.
  • DLBCL patients received doxorubicin-based chemotherapy, with 70% receiving involved field radiotherapy and a single patient receiving intrathecal therapy.
  • No recurrences occurred in the involved breast and a single parenchymal CNS recurrence was recorded.
  • Among the DLBCL patients, the 5-year progression-free survival (PFS) was 61%, with a median follow-up of 3.8 years (range, 5 months to 19 years) and the 5-year overall survival (OS) was estimated at 82%.
  • Patients with indolent lymphoma had an estimated 5-year PFS of 76% and an OS of 92%.
  • CONCLUSIONS: DLBCL of the breast was successfully treated with doxorubicin-based chemotherapy alone or with involved field radiotherapy in an estimated 61% of patients at 5 years.
  • A single CNS recurrence was observed in our series of patients, most of whom presented with limited disease.
  • [MeSH-major] Breast Neoplasms / pathology. Lymphoma, Non-Hodgkin / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antibiotics, Antineoplastic / therapeutic use. Antigens, CD20 / analysis. Central Nervous System / pathology. Doxorubicin / therapeutic use. Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Ki-67 Antigen / analysis. Lymphoma, B-Cell / metabolism. Lymphoma, B-Cell / pathology. Lymphoma, B-Cell / therapy. Lymphoma, Large B-Cell, Diffuse / metabolism. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Large B-Cell, Diffuse / therapy. Middle Aged. Neoplasm Recurrence, Local. Radiotherapy / methods. Retrospective Studies

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2007 American Cancer Society.
  • (PMID = 17541937.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antigens, CD20; 0 / Ki-67 Antigen; 80168379AG / Doxorubicin
  •  go-up   go-down


79. Mian M, Rass C, Hutarew G, Kofler B, Fiegl M, Greil R: Extensive organizing pneumonia during chemo-immunotherapy containing rituximab and G-CSF in a patient with diffuse large B-cell lymphoma: case report and review of the literature. Leuk Lymphoma; 2006 Aug;47(8):1683-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extensive organizing pneumonia during chemo-immunotherapy containing rituximab and G-CSF in a patient with diffuse large B-cell lymphoma: case report and review of the literature.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Large B-Cell, Diffuse / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Murine-Derived. Granulocyte Colony-Stimulating Factor / therapeutic use. Humans. Immunotherapy. Lymphoma, B-Cell / drug therapy. Male. Middle Aged. Pneumonia. Rituximab

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16966286.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Letter; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 4F4X42SYQ6 / Rituximab
  • [Number-of-references] 15
  •  go-up   go-down


80. Hirose A, Yamane T, Nakajima Y, Manabe M, Kanashima H, Hagihara K, Sakamoto E, Nakamae M, Terada Y, Kosaka S, Aoyama Y, Sakamoto C, Kumura T, Koh KR, Hirai M, Ohta K, Nakao Y, Mugitani A, Teshima H, Hino M: [Autologous hematopoietic stem cell transplantation for aggressive B-cell non-Hodgkin's lymphoma]. Gan To Kagaku Ryoho; 2005 Dec;32(13):2059-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Autologous hematopoietic stem cell transplantation for aggressive B-cell non-Hodgkin's lymphoma].
  • To evaluate the results of high-dose chemotherapy (HDT) and autologous hematopoietic stem cell transplantation (ASCT) in patients with diffuse B-cell aggressive non-Hodgkin's lymphoma(NHL).
  • Between 1991 and 2004, 25 patients who did not achieve complete remission and 26 in complete remission from conventional chemotherapy received HDC-ASCT.
  • Of 25 patients with refractory NHL,14 were chemotherapy-sensitive before HDT-ASCT and 11 were chemotherapy-resistant.
  • CR was achieved after HDC-ASCT in 50% of 14 chemotherapy sensitive patients and in none of 11 chemotherapy-resistant patients.
  • The 5-year probability of event-free survival for chemotherapy-sensitive and chemotherapy-resistant patients was 51.3% and 20.8%, respectively (p<0.05, log-rank test).
  • Moreover, the 5-year probability of event-free survival for patients in the low-risk group with International Prognostic Index (IPI) and in the high-risk group with IPI was 75.0% and 16.3%, respectively (p<0.05, log-rank test).
  • HDT-ASCT should be considered for patients with refractory aggressive NHL who are chemotherapy-sensitive rather than chemotherapy-resistant.
  • Twenty-six patients in complete remission received consolidation therapy with HDT-ASCT.
  • The 5-year probability of disease-free survival for patients in the low-risk group and in the high-risk group was 68.8% and 60.0%,respectively (p = 0.9 6).
  • HDT-ASCT should be considered for patients at high risk who achieve complete remission after induction treatment.
  • In future, HDT-ASCT combined with rituximab as induction therapy or as consolidation therapy is needed for patients with aggressive NHL in the high-risk group.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Lymphoma, B-Cell / therapy. Lymphoma, Large B-Cell, Diffuse / therapy. Transplantation, Autologous
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Disease-Free Survival. Drug Administration Schedule. Etoposide / administration & dosage. Female. Humans. Male. Middle Aged. Nitrosourea Compounds / administration & dosage. Remission Induction. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16352929.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Nitrosourea Compounds; 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin; RYH2T97J77 / ranimustine
  •  go-up   go-down


81. Hiraga J, Tomita A, Sugimoto T, Shimada K, Ito M, Nakamura S, Kiyoi H, Kinoshita T, Naoe T: Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance. Blood; 2009 May 14;113(20):4885-93
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance.
  • Although rituximab is a key molecular targeting drug for CD20-positive B-cell lymphomas, resistance to rituximab has recently been recognized as a considerable problem.
  • Here, we report that a CD20-negative phenotypic change after chemotherapies with rituximab occurs in a certain number of CD20-positive B-cell lymphoma patients.
  • For 5 years, 124 patients with B-cell malignancies were treated with rituximab-containing chemotherapies in Nagoya University Hospital.
  • Relapse or progression was confirmed in 36 patients (29.0%), and a rebiopsy was performed in 19 patients.
  • Of those 19, 5 (26.3%; diffuse large B-cell lymphoma [DLBCL], 3 cases; DLBCL transformed from follicular lymphoma, 2 cases) indicated CD20 protein-negative transformation.
  • Interestingly, when CD20-negative cells were treated with 5-aza-2'-deoxycytidine in vitro, the expression of CD20 mRNA was stimulated within 3 days, resulting in the restoration of both cell surface expression of the CD20 protein and rituximab sensitivity.
  • These findings suggest that some epigenetic mechanisms may be partly related to the down-regulation of CD20 expression after rituximab treatment.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antigens, CD20 / genetics. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal, Murine-Derived. Down-Regulation / drug effects. Epigenesis, Genetic / drug effects. Epigenesis, Genetic / physiology. Follow-Up Studies. Gene Expression Regulation, Neoplastic / drug effects. Humans. Middle Aged. Mutation. Phenotype. Prognosis. RNA, Messenger / metabolism. Rituximab. Young Adult


82. Lagmay J, Termuhlen A, Fung B, Ranalli M: Primary testicular presentation of ALK-1-negative anaplastic large cell lymphoma in a pediatric patient. J Pediatr Hematol Oncol; 2009 May;31(5):330-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary testicular presentation of ALK-1-negative anaplastic large cell lymphoma in a pediatric patient.
  • Anaplastic large cell lymphoma is a heterogeneous group of malignant non-Hodgkin lymphomas that occurs in up to 15% of all pediatric non-Hodgkin lymphomas.
  • It is characterized by B-symptoms and involvement of extranodal sites such as skin, bone, and soft tissue.
  • This brief report describes first reported case of pediatric primary testicular anaplastic large cell lymphoma in a 14-year-old boy.
  • After chemotherapy and unilateral radical orchiectomy, patient continues in complete remission.
  • [MeSH-major] Activin Receptors, Type II / metabolism. Lymphoma, Large B-Cell, Diffuse / metabolism. Lymphoma, Large B-Cell, Diffuse / pathology. Testicular Neoplasms / metabolism. Testicular Neoplasms / pathology
  • [MeSH-minor] Adolescent. Antigens, CD30 / metabolism. Biomarkers, Tumor / metabolism. Biopsy. Cell Nucleus / metabolism. Cell Nucleus / pathology. Golgi Apparatus / metabolism. Golgi Apparatus / pathology. Humans. Male. Orchiectomy. Testis / pathology. Testis / surgery

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19415011.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD30; 0 / Biomarkers, Tumor; EC 2.7.11.30 / ACVRL1 protein, human; EC 2.7.11.30 / Activin Receptors, Type II
  •  go-up   go-down


83. Kyllönen H, Pasanen AK, Kuittinen O, Haapasaari KM, Turpeenniemi-Hujanen T: Lack of prognostic value of MMP-9 expression and immunohistochemically defined germinal center phenotype in patients with diffuse large B-cell lymphoma treated with modern chemotherapy with or without CD20 antibody. Leuk Lymphoma; 2009 Aug;50(8):1301-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lack of prognostic value of MMP-9 expression and immunohistochemically defined germinal center phenotype in patients with diffuse large B-cell lymphoma treated with modern chemotherapy with or without CD20 antibody.
  • Diffuse large B-cell lymphomas (DLBCLs) are a heterogeneous group of lymphomas, with no accepted biological prognostic markers in routine clinical practice.
  • Previously, matrix metalloproteinase (MMP-9), tissue inhibitors of matrix metalloproteinase (TIMP)- 1 and non-germinal center (GC) phenotype have been shown to associate with poor prognosis in DLBCL patients.
  • The aim of this study was to find out whether tissue expression of gelatinases (MMP-2 and MMP-9) or their tissue inhibitors (TIMP-1 and TIMP-2) or immunohistochemically defined GC phenotype could act as prognostic markers in patients treated with modern treatments.
  • GC phenotype and tissue expression of MMP-2, MMP-9, TIMP-1 and TIMP-2 were analyzed by immunohistochemistry in tissue samples from 114 DLBCL patients.
  • In this study, in patients treated with modern lymphoma treatments (5-year cause-specific survival 69.8%) MMP-2, MMP-9, TIMP-1 or TIMP-2 expression or GC phenotype did not correlate with survival.
  • International Prognostic Index (IPI) and stage were the only factors, which retained their prognostic significance in this patient material.
  • Prognostic markers are dependent on the lymphoma treatments used.
  • In DLBCL patients treated with modern chemotherapy with or without rituximab, MMP-9, TIMP-1 and GC phenotype seem to have lost their prognostic value.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Germinal Center / pathology. Lymphoma, Large B-Cell, Diffuse / mortality. Matrix Metalloproteinase 9 / analysis. Neoplasm Proteins / analysis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Female. Hematopoietic Stem Cell Transplantation. Humans. Male. Matrix Metalloproteinase 2 / analysis. Middle Aged. Neoplasm Staging. Prednisolone / administration & dosage. Prednisone / administration & dosage. Prognosis. Rituximab. Survival Rate. Tissue Inhibitor of Metalloproteinase-1 / analysis. Tissue Inhibitor of Metalloproteinase-2 / analysis. Vincristine / administration & dosage. Young Adult

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19811332.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Neoplasm Proteins; 0 / Tissue Inhibitor of Metalloproteinase-1; 127497-59-0 / Tissue Inhibitor of Metalloproteinase-2; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9; VB0R961HZT / Prednisone; CHOEP protocol; CHOP protocol
  •  go-up   go-down


84. Dölken MT, Schüler F, Hirt C, Lorenz G, Hosten N, Dölken G: Multiple osteolytic lesions and testicular involvement at first relapse of follicular lymphoma grade 1 in transformation. Leuk Lymphoma; 2006 Feb;47(2):369-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple osteolytic lesions and testicular involvement at first relapse of follicular lymphoma grade 1 in transformation.
  • A 62-year-old man was initially diagnosed with stage IA follicular lymphoma grade 1 of the left tonsil.
  • Shortly after radiotherapy he rapidly developed multiple painful acroosteolytic lesions and testicular involvement.
  • The histological examination revealed a transformed lymphoma in the testis (DLCL) and follicular lymphoma in the acroosteolytic lesions.
  • The clonal identity of lymphoma cells within the primary biopsy as well as in the two sites at relapse was shown by PCR and nucleotide sequence analysis of the lymphoma clone specific B-cell receptor rearrangement.
  • Chemotherapy with six cycles of CHOP followed by high dose chemotherapy and autologous blood stem cell transplantation led to a complete clinical remission with disappearance of all osteolytic lesions.
  • [MeSH-major] Bone Neoplasms / diagnosis. Lymphoma, Follicular / diagnosis. Testicular Neoplasms / diagnosis
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Humans. Male. Middle Aged. Neoplasm Staging. Osteolysis / etiology. Peripheral Blood Stem Cell Transplantation. Recurrence. Remission Induction. Transplantation, Autologous. Treatment Outcome


85. Kim JG, Sohn SK, Kim DH, Baek JH, Park TI, Lee KB: Phase II study of cyclophosphamide,epirubicin, vincristine, prednisone, and etoposide (CEOP-E) for aggressive non-Hodgkin 's lymphoma. J Korean Med Sci; 2004 Dec;19(6):820-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of cyclophosphamide,epirubicin, vincristine, prednisone, and etoposide (CEOP-E) for aggressive non-Hodgkin 's lymphoma.
  • The main objectives of the current study were to evaluate the efficacy and safety of a CEOP-E regimen for patients with aggressive non-Hodgkin's lymphoma (NHL).
  • Diffuse large B cell lymphoma (68.8%) was the most common histological subtype.
  • Thirty patients (58.8%) had Ann Arbor stage III or IV diseases at diagnosis.
  • One course of chemotherapy consisted of an intravenous combination of cyclophosphamide 750 mg/m(2), epirubicin 50 mg/(2), vincristine 2 mg, etoposide 80 mg/(2) on day 1 and oral administration of 100 mg prednisone on days 1 to 5 (CEOP-E).
  • With a median follow-up of 16.3 months, 26 events including relapse and death were observed.
  • The estimated 2-yr survival rate for all patients and disease free survival rate for patients achieving complete response was 58.9% and 57.1%, respectively.
  • Transient episodes of ECG abnormality (1st degree AV block) were observed in 2 patients.
  • The current regimen seemed to minimize the cardiac toxicity due to an accumulated dose of anthracycline in the treatment of aggressive NHL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Cyclophosphamide / administration & dosage. Epirubicin / administration & dosage. Etoposide / administration & dosage. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / mortality. Prednisone / administration & dosage. Risk Assessment / methods. Vincristine / administration & dosage
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Agents / administration & dosage. Female. Humans. Male. Middle Aged. Risk Factors. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] Hematol Oncol. 1998 Sep;16(3):117-23 [10235070.001]
  • [Cites] Am J Clin Oncol. 2001 Dec;24(6):570-5 [11801756.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):235-42 [11807147.001]
  • [Cites] J Clin Oncol. 1984 Aug;2(8):898-902 [6379123.001]
  • [Cites] J Clin Oncol. 1985 Sep;3(9):1188-95 [3897470.001]
  • [Cites] Cancer Res. 1987 Dec 1;47(23):6393-6 [3479245.001]
  • [Cites] Med Oncol Tumor Pharmacother. 1989;6(2):163-9 [2473364.001]
  • [Cites] Br J Cancer. 1989 Jul;60(1):79-82 [2679846.001]
  • [Cites] J Clin Oncol. 1990 Jan;8(1):84-93 [1688615.001]
  • [Cites] J Clin Oncol. 1991 Jan;9(1):25-38 [1702144.001]
  • [Cites] N Engl J Med. 1992 Nov 5;327(19):1342-9 [1383819.001]
  • [Cites] N Engl J Med. 1993 Apr 8;328(14):1002-6 [7680764.001]
  • [Cites] N Engl J Med. 1993 Sep 30;329(14):987-94 [8141877.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Haematologica. 1995 Jul-Aug;80(4):318-24 [7590500.001]
  • [Cites] Leuk Lymphoma. 1996 Dec;24(1-2):121-9 [9049968.001]
  • [Cites] Blood. 1997 Jun 15;89(12):4514-20 [9192775.001]
  • [Cites] Cancer. 1998 Jun 1;82(11):2282-8 [9610711.001]
  • [Cites] J Clin Oncol. 1998 Jun;16(6):2070-9 [9626206.001]
  • [Cites] N Engl J Med. 1998 Jul 2;339(1):21-6 [9647875.001]
  • [Cites] Blood. 1998 Jul 1;92(1):76-82 [9639502.001]
  • [Cites] Anticancer Res. 1999 Jul-Aug;19(4C):3393-7 [10629625.001]
  • (PMID = 15608392.001).
  • [ISSN] 1011-8934
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 3Z8479ZZ5X / Epirubicin; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CEOP protocol 1
  • [Other-IDs] NLM/ PMC2816291
  •  go-up   go-down


86. Dilhuydy MS, Lamy T, Foussard C, Gressin R, Casassus P, Deconninck E, Le Maignan C, Damotte D, Milpied N, Groupe Ouest-Est des Leucémies et Autres Maladies du Sang (GOELAMS): Front-line high-dose chemotherapy with rituximab showed excellent long-term survival in adults with aggressive large b-cell lymphoma: final results of a Phase II GOELAMS Study. Biol Blood Marrow Transplant; 2010 May;16(5):672-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Front-line high-dose chemotherapy with rituximab showed excellent long-term survival in adults with aggressive large b-cell lymphoma: final results of a Phase II GOELAMS Study.
  • To evaluate the effect of rituximab in poor-prognosis patients with diffuse large B-cell lymphoma (DLBCL), a multicenter phase II trial combining rituximab with chemotherapy followed by high-dose therapy (HDT) with autologous stem cell transplant was conducted by the Groupe Ouest-Est des Leucémies et des Autres Maladies du Sang (GOELAMS).
  • Patients were aged 18 to 60 years, with newly diagnosed CD20-expressing DLBCL, and at least 2 adverse risk factors as defined by the age-adjusted International Prognostic Index (aa-IPI).
  • The treatment consisted of 2 courses of high-dose CHOP-like regimen on day 1 and 15 and 1 course of methotrexate and cytarabine on day 36.
  • For patients who achieved at least a partial remission (PR), HDT followed by autologous stem cell transplant was performed on day 66.
  • Thirty-eight patients (90%) completed the treatment.
  • Treatment-related mortality was 7% and no toxic death was related to rituximab.
  • Complete response rate after the end of the full treatment was 67%.
  • With a median follow-up of 66 months, event-free survival and overall survival rates were 55% and 74%, respectively.
  • First-line HDT with rituximab offers promising results for young adults with intermediate high or high aa-IPI high-grade lymphoma.
  • This treatment is being randomly compared prospectively with CHOP-14-rituximab in young adults with DLBCL (GOELAMS 075 trial).
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Hematopoietic Stem Cell Transplantation / methods. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / mortality
  • [MeSH-minor] Adolescent. Adult. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cytarabine / administration & dosage. Disease-Free Survival. Drug Administration Schedule. Female. Follow-Up Studies. Humans. Male. Methotrexate / administration & dosage. Middle Aged. Remission Induction. Risk Factors. Rituximab. Survival Rate. Transplantation, Autologous

  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20045738.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 04079A1RDZ / Cytarabine; 4F4X42SYQ6 / Rituximab; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


87. Mohammad RM, Wall NR, Dutcher JA, Al-Katib AM: The addition of bryostatin 1 to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy improves response in a CHOP-resistant human diffuse large cell lymphoma xenograft model. Clin Cancer Res; 2000 Dec;6(12):4950-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The addition of bryostatin 1 to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy improves response in a CHOP-resistant human diffuse large cell lymphoma xenograft model.
  • The incidence of non-Hodgkin's lymphoma has been increasing at a rate of 4% per year since 1950; more than 62,000 cases will be diagnosed in the United States in 2000.
  • Diffuse large cell lymphoma (DLCL) is the prototype of curable non-Hodgkin's lymphoma.
  • Empirically designed chemotherapy regimens did not increase the cure rate of 30-40% achieved by the original four-drug regimen introduced in the 1970s [cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP)].
  • We studied the antitumor effects of the CHOP regimen alone or in combination with a unique protein kinase C activator, bryostatin 1, on a xenograft model for resistant DLCL in mice with severe combined immune deficiency (WSU-DLCL2-SCID).
  • In this model, the efficacy of bryostatin 1 given at 75 microg/kg, i.p., alone for 1 or 2 days [B(1x) and B(2x)]was compared with the efficacy of CHOP alone, bryostatin 1 + CHOP (B+CHOP) given concurrently, bryostatin 1 for 1 day followed by CHOP on day 2 [B(1x)-CHOP], and bryostatin 1 for 2 days followed by CHOP on day 3 [B(2x)-CHOP].
  • Tumor growth inhibition (T/C), tumor growth delay (T-C), and log10 kill for B(1x), B(2x), CHOP, B+CHOP, B(1x)-CHOP and B(2x)-CHOP were 49%, 39%, 25.8%, 15.1%, 14.6%, and 12%; 6, 7, 16, 25, 12, and 15 days; and 0.6, 0.5, 2.2, 3.6, 1.7, and 2.0, respectively.
  • Bax protein increased in a time-dependent manner without any measurable change in Bcl-2 expression.
  • The use of this combination should be further explored clinically in the treatment of lymphoma.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Lactones / administration & dosage. Lymphoma, Large B-Cell, Diffuse / drug therapy. Prednisolone / administration & dosage. Vincristine / administration & dosage
  • [MeSH-minor] Animals. Apoptosis / drug effects. Blotting, Western. Bryostatins. Enzyme Activation. Flow Cytometry. Humans. Macrolides. Mice. Mice, SCID. Neoplasm Transplantation. Poly(ADP-ribose) Polymerases / biosynthesis. Protein Kinase C / metabolism. Proto-Oncogene Proteins / biosynthesis. Proto-Oncogene Proteins c-bcl-2 / biosynthesis. Time Factors. Tumor Cells, Cultured. bcl-2-Associated X Protein

  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11156256.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA79837; United States / NCI NIH HHS / CA / P30 CA22453-20
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / BAX protein, human; 0 / Bax protein, mouse; 0 / Bryostatins; 0 / Lactones; 0 / Macrolides; 0 / Proto-Oncogene Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / bcl-2-Associated X Protein; 37O2X55Y9E / bryostatin 1; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; EC 2.4.2.30 / Poly(ADP-ribose) Polymerases; EC 2.7.11.13 / Protein Kinase C; VAP-cyclo protocol
  •  go-up   go-down


88. Martínez-Jaramillo G, Avilés A, Neri N, Huerta J, Madrigal-Velazquez M, Flores-Guzmán P, Mayani H: In vitro proliferation and expansion of hematopoietic progenitors from patients with diffuse large B-cell lymphoma before and after chemotherapy. Leuk Lymphoma; 2004 Jun;45(6):1247-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vitro proliferation and expansion of hematopoietic progenitors from patients with diffuse large B-cell lymphoma before and after chemotherapy.
  • We have previously demonstrated that when cultured in Dexter-type Long-Term Marrow Cultures (LTMC), hematopoietic progenitor cells (HPC) from patients with Diffuse Large B-Cell Lymphoma (DLBCL) show a defective proliferation, as compared to HPC from normal marrow.
  • In that study it was also demonstrated that functional alterations were present in the hematopoietic microenvironment developed in culture; thus, it was not clear whether such a defective proliferation in vitro was due to an intrinsic defect in the HPC compartment of DLBCL patients, or to an altered microenvironment, or both.
  • In order to address this question, in the present study we have assessed the proliferation and expansion potentials of HPC present in bone marrow from patients with DLBCL, in cytokine-supplemented liquid cultures initiated with a cell population enriched for CD34+ Lin- cells, in the absence of stromal cells and in the presence of reduced numbers of accessory cells.
  • Our results demonstrated that bone marrow-derived HPC from patients with DLBCL, both before and right after chemotherapy, possessed reduced proliferation and expansion potentials in vitro, as compared to their normal counterparts.
  • Interestingly, in patients analyzed 18 months after treatment the proliferation and expansion levels were similar to those of normal HPC, indicating a complete restoration of the hematopoietic function.
  • Although the reason for these observations is not clear, our results suggest the possibility that primitive CD34+ progenitor cells present in bone marrow, which show deficient proliferation and expansion potentials in vitro, are involved in the origin/progression of DLBCL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow / pathology. Hematopoietic Stem Cells / pathology. Lymphoma, B-Cell / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15360008.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD34
  •  go-up   go-down


89. Li JM, Wang L, Shen Y, Xia ZG, Chen Y, Chen QS, Chen Y, Zeng XY, You JH, Qian Y, Shen ZX: Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in Chinese patients. Ann Hematol; 2007 Sep;86(9):639-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in Chinese patients.
  • The objective of this study is to evaluate the long-term efficacy and safety of rituximab combined with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in Chinese patients with newly diagnosed diffuse large B cell lymphoma (DLBCL).
  • Patients received four to six infusions of rituximab (375 mg/m(2) per dose) on day 1 of each cycle of CHOP chemotherapy.
  • A total of 82 patients with a median age of 45 years (range 18-76 years) was included.
  • Patients with International Prognostic Index (IPI) scores < or = 2 had significantly higher OR, CR, PFS, and OS rates (p = 0.01, p = 0.02, p = 0.01, p < 0.001, respectively) compared with patients with IPI scores >2.
  • Five patients with a history of chronic hepatitis B experienced a reactivation of viral hepatitis.
  • The rituximab-CHOP combination was effective and well tolerated in Chinese patients with newly diagnosed DLBCL.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Lymphoma, Large B-Cell, Diffuse / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Antibodies, Monoclonal, Murine-Derived. China. Cyclophosphamide / administration & dosage. Cyclophosphamide / toxicity. Doxorubicin / administration & dosage. Doxorubicin / toxicity. Hepatitis B virus. Humans. Middle Aged. Prednisone / administration & dosage. Prednisone / toxicity. Retrospective Studies. Rituximab. Survival Analysis. Vincristine / administration & dosage. Vincristine / toxicity. Virus Activation / drug effects

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17572895.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


90. Levine AM, Seneviratne L, Espina BM, Wohl AR, Tulpule A, Nathwani BN, Gill PS: Evolving characteristics of AIDS-related lymphoma. Blood; 2000 Dec 15;96(13):4084-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evolving characteristics of AIDS-related lymphoma.
  • Over time, the epidemiologic and demographic characteristics of AIDS have changed in the United States, while the use of highly active antiretroviral therapy has changed the natural history of the disease.
  • The goal of the study was to ascertain any changes in the epidemiologic, immunologic, pathologic, or clinical characteristics of AIDS-related lymphoma (ARL) over the course of the AIDS epidemic.
  • Significant changes in the demographic profile of patients with newly diagnosed ARL have occurred, with the later time intervals associated with a higher prevalence in women (P =.25), in Latino/Hispanic individuals (P <.0001), and in those who acquired human immunodeficiency virus (HIV) heterosexually (P =.01).
  • The median CD4(+) lymphocyte count at lymphoma diagnosis has decreased significantly over the years, from 177/dL in the earliest time period (1982-1986), to 53/dL in the last time period from 1995 to 1998 (P =.0006).
  • The pathologic spectrum of disease has also changed, with a decrease in the prevalence of small noncleaved lymphoma (P =.0005) and an increase in diffuse large cell lymphoma (P <.0001).
  • Despite changes in the use of antiretroviral or chemotherapy regimens, the median survival has not significantly changed.
  • [MeSH-major] Lymphoma, AIDS-Related / epidemiology
  • [MeSH-minor] AIDS-Related Opportunistic Infections / epidemiology. Adult. Anti-HIV Agents / therapeutic use. Antiretroviral Therapy, Highly Active. Central Nervous System Neoplasms / drug therapy. Central Nervous System Neoplasms / epidemiology. Central Nervous System Neoplasms / immunology. Central Nervous System Neoplasms / mortality. Central Nervous System Neoplasms / pathology. Comorbidity. Ethnic Groups. Female. HIV Infections / drug therapy. Humans. Life Tables. Los Angeles / epidemiology. Male. Mortality / trends. Retrospective Studies. Risk Factors. Sarcoma, Kaposi / epidemiology. Survival Analysis

  • Genetic Alliance. consumer health - AIDS-HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11110677.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Grant] United States / SAMHSA HHS / OA / N0A-A1-62540; United States / NCI NIH HHS / CA / R01-CA-55510; United States / NCI NIH HHS / CA / R01-CA50850; etc
  • [Publication-type] Comparative Study; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Anti-HIV Agents
  •  go-up   go-down


91. Shiratori S, Tsutsumi Y, Kawamura T, Kudo K, Shimoyama N, Masauzi N, Tanaka J, Asaka M, Imamura M: HCV non-structural protein 3 and HCV RNA genome in non-Hodgkin lymphoma and transition of the serum HCV RNA level: a retrospective analysis in one institution. Int J Hematol; 2008 Apr;87(3):298-302
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HCV non-structural protein 3 and HCV RNA genome in non-Hodgkin lymphoma and transition of the serum HCV RNA level: a retrospective analysis in one institution.
  • There have been various reports on the association of hepatitis C virus (HCV) infection with B lymphocyte proliferative disorders, such as non-Hodgkin lymphoma (NHL).
  • We experienced a case (Case 1) of anti-HCV antibody (HCV-Ab)-positive NHL in which HCV nonstructural protein 3 (NS3) expression was observed in lymphoma tissue at the time of recurrence and in which the serum HCV RNA level exhibited a transient increase prior to recurrence.
  • We investigated the HCV RNA genome in lymphoma tissue in Case 1, and it could be detected at recurrence.
  • We also investigated HCV NS3 protein expression in lymphoma tissue and changes in serum HCV RNA level during the clinical course in four other cases of HCV-Ab-positive NHL treated in our hospital.
  • We examined lymphoma tissues for HCV NS3 protein expression in four of the five cases, but it was not identified except for in Case 1 at recurrence.
  • In three cases with no recurrence, serum HCV RNA levels showed a tendency to decrease after completion of chemotherapy and became stable thereafter.
  • [MeSH-major] Hepacivirus. Lymphoma, Large B-Cell, Diffuse / virology. Neoplasm Recurrence, Local / virology. RNA, Viral / blood. Viral Nonstructural Proteins / metabolism

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hematol J. 2004;5(6):530-3 [15570298.001]
  • [Cites] Ann Oncol. 2003 Sep;14(9):1341-5 [12954572.001]
  • [Cites] Am J Med. 1999 May;106(5):556-60 [10335728.001]
  • [Cites] J Clin Oncol. 2005 Jan 20;23 (3):468-73 [15659492.001]
  • [Cites] Am J Gastroenterol. 2002 Jul;97(7):1802-6 [12135039.001]
  • [Cites] Am J Hematol. 2001 Jul;67(3):168-71 [11391713.001]
  • [Cites] Hum Pathol. 2005 Aug;36(8):878-85 [16112004.001]
  • [Cites] Int J Cancer. 2004 Aug 10;111(1):81-5 [15185347.001]
  • [Cites] Int J Cancer. 2004 Jun 20;110(3):380-5 [15095303.001]
  • [Cites] Leuk Lymphoma. 2003 Jul;44(7):1113-20 [12916862.001]
  • [Cites] N Engl J Med. 2002 Jul 11;347(2):89-94 [12110736.001]
  • [Cites] Am J Hematol. 2000 Jun;64(2):95-100 [10814987.001]
  • [Cites] Leukemia. 2004 Oct;18(10):1711-6 [15284859.001]
  • [Cites] Blood. 2003 Aug 1;102(3):996-9 [12714514.001]
  • [Cites] Am J Clin Pathol. 2000 Mar;113(3):391-8 [10705820.001]
  • [Cites] Gastroenterology. 1999 Mar;116(3):636-42 [10029622.001]
  • [Cites] Histopathology. 2006 Jan;48(2):189-98 [16405668.001]
  • [Cites] Blood. 2001 Dec 15;98(13):3745-9 [11739181.001]
  • [Cites] Int J Cancer. 2004 Aug 10;111(1):76-80 [15185346.001]
  • [Cites] Am J Hematol. 2004 Jul;76(3):252-7 [15224361.001]
  • [Cites] Med Oncol. 2003;20(2):165-8 [12835519.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18544-9 [16339892.001]
  • (PMID = 18320139.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Hepatitis C Antibodies; 0 / NS3 protein, hepatitis C virus; 0 / RNA, Viral; 0 / Viral Nonstructural Proteins
  •  go-up   go-down


92. Kim B, Oh SY, Lee S, Kwon HC, Kim SH, Hong SH, Kim SS, Kim HJ: Unusual presentation of large B cell lymphoma- bone and stomach- treated with autologous transplantation. Cancer Res Treat; 2007 Dec;39(4):181-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual presentation of large B cell lymphoma- bone and stomach- treated with autologous transplantation.
  • Extranodal presentation of diffuse large B cell lymphoma (DLBL) is frequently observed in the gastrointestinal tract, CNS, bone, testes and liver.
  • However, the simultaneous detection of multiple extranodal involvement at presentation is quite an uncommon occurrence.
  • In this study, we report on a patient with an uncommon presentation of DLBL, and he had symptoms of left knee joint pain and hematemesis, characterized by bone and stomach involvement.
  • Computed tomography and fluorodeoxyglucose-positron emission tomography (FDG-PET) scanning revealed a rapid, extensive spread to the bones and soft tissues.
  • Subsequent histopathological examination verified the bony and gastric CD20-positive DLBL localization.
  • We diagnosed this case as DLBL of stage IV with an international prognostic index of 3, and classified him into the high intermediate risk group.
  • This patient was treated via chemotherapy with an R-CHOP regimen.
  • After achieving a partial response, the patient received autologous peripheral blood stem cell transplantation.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncologist. 2005 Oct;10(9):734-8 [16249354.001]
  • [Cites] Pathol Int. 2004 Nov;54(11):830-6 [15533225.001]
  • [Cites] Semin Oncol. 1999 Jun;26(3):338-45 [10375090.001]
  • [Cites] Semin Oncol. 1999 Jun;26(3):259-69 [10375083.001]
  • [Cites] J Clin Oncol. 1994 Aug;12(8):1673-84 [8040680.001]
  • [Cites] Oncology. 1992;49(6):484-8 [1465289.001]
  • [Cites] N Engl J Med. 1999 Nov 11;341(20):1520-9 [10559454.001]
  • [Cites] Oncology. 1990;47(4):334-8 [1694981.001]
  • [Cites] Curr Treat Options Oncol. 2004 Aug;5(4):307-13 [15233907.001]
  • [Cites] Br J Haematol. 2004 Jan;124(2):151-9 [14687024.001]
  • [Cites] Semin Hematol. 2003 Jul;40(3):244-56 [12876673.001]
  • [Cites] J Clin Oncol. 2001 Sep 15;19(18):3861-73 [11559724.001]
  • [Cites] Eur J Cancer. 1991;27(10):1201-8 [1835586.001]
  • (PMID = 19746186.001).
  • [ISSN] 1598-2998
  • [Journal-full-title] Cancer research and treatment : official journal of Korean Cancer Association
  • [ISO-abbreviation] Cancer Res Treat
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2739372
  • [Keywords] NOTNLM ; Bone / Diffuse large B-cell lymphoma / Extranodal / Stomach
  •  go-up   go-down


93. Miyahara T, Oyabul Y, Hayashi T, Shimizu S, Tanaka H, Matsuoka K: [A case of malignant lymphoma of the prostate]. Nihon Hinyokika Gakkai Zasshi; 2005 Sep;96(6):644-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of malignant lymphoma of the prostate].
  • We report a case of primary malignant lymphoma of the prostate.
  • A 76-year-old man was refer to our clinic with a chief complaint of dysuria.
  • Histological findings showed diffuse, large cell type malignant lymphoma.
  • His clinical stage was 1 A prostate (+) according to the Ann Abor classification.
  • The combination chemotherapy with THP-COP was performed for 3 courses, followed by irradiation at 30 Gy.
  • His prostate has showed no recurrence for 10 month after treatment.
  • Primary malignant lymphoma of the prostate is rare.
  • Preoperative diagnosis of malignant lymphoma of the prostate is difficult.
  • [MeSH-major] Lymphoma, B-Cell / therapy. Lymphoma, Large B-Cell, Diffuse / therapy. Prostatic Neoplasms / therapy. Transurethral Resection of Prostate
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Doxorubicin / analogs & derivatives. Drug Administration Schedule. Humans. Male. Prednisolone / administration & dosage. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16218408.001).
  • [ISSN] 0021-5287
  • [Journal-full-title] Nihon Hinyōkika Gakkai zasshi. The japanese journal of urology
  • [ISO-abbreviation] Nippon Hinyokika Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VEP-THP protocol
  •  go-up   go-down


94. Hughes M, Morrison A, Jackson R: Primary bladder lymphoma: management and outcome of 12 patients with a review of the literature. Leuk Lymphoma; 2005 Jun;46(6):873-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary bladder lymphoma: management and outcome of 12 patients with a review of the literature.
  • Primary bladder non-Hodgkin's lymphoma (NHL) is rare.
  • Using the Scotland and Newcastle lymphoma group database, 12 patients with primary bladder lymphoma were identified between 1980 and 2001, the largest single group of patients available to date.
  • Six cases were low-grade extranodal marginal zone lymphoma, 4 diffuse large B-cell lymphoma, one an ALK 1 positive anaplastic large cell lymphoma (ALKoma) and one a low-grade lymphoma unspecified.
  • Two patients (low-grade NHL) were treated with oral antibiotics (n=1) or diathermy (n=1) alone with complete resolution of disease.
  • One patient with high-grade NHL gained complete remission without conventional therapy.
  • Nine patients were treated with single or combined modality surgery, chemotherapy and/or radiotherapy.
  • A review of 88 additional cases in the literature support the findings that primary bladder lymphoma is associated with a good prognosis.
  • Patients with low-grade extranodal marginal zone lymphoma may respond well to simple therapies.
  • Patients with diffuse large B-cell lymphoma respond well to first-line chemotherapy regimens.
  • [MeSH-major] Lymphoma, B-Cell / diagnosis. Lymphoma, B-Cell / therapy. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / therapy. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / therapy. Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Medical Oncology / methods. Prognosis. Registries. Remission Induction. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16019532.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


95. Schmits R, Schmitz N, Pfreundschuh M, German High-Grade Non-Hodgkin's Lymphoma Study Group: The best treatment for diffuse large B-cell lymphoma: a German perspective. Oncology (Williston Park); 2005 Apr;19(4 Suppl 1):16-25
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The best treatment for diffuse large B-cell lymphoma: a German perspective.
  • While some improvement was achieved by adding etoposide and shortening the treatment intervals from 3 to 2 weeks (CHOEP-14), best results in young good-prognosis patients (age-adjusted International Prognostic Index [IPI] = 0,1) have been achieved with six cycles of CHOP (cyclophosphamide, doxorubicin HCl, vincristine [Oncovin], prednisone)-like chemotherapy in combination with the anti-CD20 antibody rituximab (Rituxan).
  • With this approach, 2-year event-free survival rates of > 90% and overall survival of > 95% can be achieved in a very favorable subgroup (patients without IPI risk factor and no bulky disease), while further improvement is warranted for the less favorable subgroup (event-free survival only 77%).
  • Ongoing studies will show whether dose-dense conventional or high-dose chemotherapy regimens requiring stem cell support in combination with rituximab will result in similar improvements of outcome as has been reported recently for young patients with good-prognosis aggressive lymphoma.
  • The ongoing RICOVER-60 (rituximab with CHOP over 60) trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL) evaluates whether the combination of both approaches (R-CHOP-14) can further improve the prognosis of elderly patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, B-Cell / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy
  • [MeSH-minor] Cyclophosphamide / administration & dosage. Disease Progression. Disease-Free Survival. Doxorubicin / administration & dosage. Germany. Humans. Prednisone / administration & dosage. Prognosis. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15934514.001).
  • [ISSN] 0890-9091
  • [Journal-full-title] Oncology (Williston Park, N.Y.)
  • [ISO-abbreviation] Oncology (Williston Park, N.Y.)
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone
  • [Number-of-references] 35
  •  go-up   go-down


96. Park YH, Kim SH, Choi SJ, Ryoo BY, Kang YK, Lee SS: Primary malignant lymphoma of the breast: clinicopathological study of nine cases. Leuk Lymphoma; 2004 Feb;45(2):327-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary malignant lymphoma of the breast: clinicopathological study of nine cases.
  • Primary lymphoma of the breast is rare, accounting for 1.7-2.2% of extranodal lymphomas and 0.38-0.7% of non-Hodgkin's lymphomas (NHL).
  • The aim of this study was to evaluate the clinicopathological features and treatment outcomes of patients with primary breast lymphomas (PBL).
  • Six cases involved the breast alone (stage IE), whereas 3 cases also involved the ipsilateral axillary lymph nodes (stage IIE).
  • Histopathologic studies revealed a diffuse large B cell lymphoma in 7 cases, marginal zone B cell lymphoma in 1 case, and small lymphocytic lymphoma in 1 case.
  • Immunohistochemical analysis revealed a B-cell phenotype in all cases.
  • There was no uniform approach to the treatment of PBL.
  • Modified radical mastectomy and chemotherapy was performed in 4 cases, modified radical mastectomy and chemoradiotherapy was performed in 1 case, chemoradiotherapy alone, modified radical mastectomy alone, chemotherapy alone, and radiotherapy alone were performed in 1 case each.
  • All cases achieved complete remission, but median overall survival was 12 months, showing very poor prognosis irrespective of the type of treatment modality.
  • [MeSH-major] Lymphoma, B-Cell / pathology. Neoplasms / pathology
  • [MeSH-minor] Adult. Breast. Female. Humans. Immunohistochemistry. Middle Aged. Neoplasm Metastasis. Phenotype. Prognosis. Retrospective Studies. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Primary malignant lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15101719.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


97. Kim IS, Kim DC, Kim HG, Eom HS, Kong SY, Shin HJ, Hwang SH, Lee EY, Kim S, Lee GW: DNA repair gene XRCC1 polymorphisms and haplotypes in diffuse large B-cell lymphoma in a Korean population. Cancer Genet Cytogenet; 2010 Jan 1;196(1):31-7